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ABSTRACT 
 
Validation of diagnostic assay performance is hampered where no gold standard 
exists.   Bayesian estimates of the sensitivity and specificity were applied to studies of two 
persistent bovine infections: bovine immunodeficiency virus (BIV), and bovine viral diarrhea 
virus (BVDV).  
BVDV pathogenesis is well described.  Losses of $20 million in 1992 alone led the 
Danish government to mandate eradication. Two enzyme-linked immunosorbent assay 
(ELISA) tests were developed; one antibody-based to detect exposure, one antigen-based to 
detect persistent infection. Bayesian estimates of the sensitivity and specificity were 96.6% 
and 99.2%, and 98.2% and 99.8% for the antibody and antigen ELISA, respectively.  
Maximum Likelihood estimates of the sensitivity and specificity were 96.3% and 100% and 
97.9% and 99.9% for the antibody and antigen ELISA, respectively. Estimates of diagnostic 
test performance by quarter are reported. 
A high prevalence of BIV has been reported in the southern U.S., but   BIV ‘s effect 
on production and present assay reliability is still undetermined. Using Bayesian estimation, 
the performance of an immunofluorescence (IFA) assay   (sensitivity = 60%, specificity = 
88%) and a polymerase chain reaction (PCR) (sensitivity = 80%, specificity = 86%) for BIV 
detection in two herds with varying estimated BIV prevalence (20%, 71%) was estimated. 
Although PCR was more sensitive for diagnosing BIV infection, substantial misclassification 
of infection is possible regardless of which assay was used. 
Past research into the pathogenesis of BIV is shrouded in misclassification errors. To 
evaluate the ability of BIV to shift immune responses to a type 2 cytokine response similar to 
HIV, we measured the effects of bovine herpes virus 1 (BHV1) vaccination on a cohort of 89 
 xi
lactating cows, all infected with bovine leukemia virus.  BIV negative animals had a more 
appropriate immune response with decreasing IgG1:IgG2 when compared with BIV positive 
animals.   Using Bayesian estimates of IFA performance, the effect of possible 
misclassification of BIV serostatus on study results was evaluated. 
Bayesian estimates are useful where no gold standard exists. More sensitive and 
specific diagnostic tests for BIV need to be developed. Methods for modeling 
epidemiological relationships that can adjust for misclassifcation errors are needed. 
 
 
 
 xii
CHAPTER ONE 
INTRODUCTION AND LITERATURE REVIEW 
1.1 Introduction 
Misclassification of infection status is a common problem with many diagnostic 
tests. Often there is not a reference test with 100% sensitivity and 100% specificity (gold 
standard). Such is the case with the two persistent bovine viral infections (bovine 
immunodeficiency virus (BIV) and bovine viral diarrhea virus (BVDV)) discussed here. 
After a brief review of misclassification as it applies to the two diseases discussed herein, a 
brief review of the pathogenesis of BVDV as it applies to the studied population in Denmark 
is given. Along with the much studied human immunodeficiency virus, BIV is a member of 
the retrovirus subfamily lentiviruses. As relatively little is known about the health effects and 
impact on immune function of BIV, a thorough discussion of HIV and immune response as it 
applies to this study is offered. In particular, as one of our BIV study populations was 100% 
infected with bovine leukemia virus (BLV), a review of the effects of HIV and HLTV co-
infection was necessary. Finally, a thorough review of current knowledge of immune 
responses in BIV is given along with a thorough review of BIV-associated literature.  
1.2 Misclassification as it Affects Diagnostic Test Performance  
The validation of diagnostic assay performance is hampered where no gold standard 
exists. However, it is possible to evaluate the accuracy of two diagnostic tests even if the 
error rates (false positive rates, false negative rates) for those tests are unknown.   When 
these two imperfect tests are applied simultaneously to the same individuals from two 
populations with different disease prevalences, the error rates of both tests (and the true 
prevalences of both populations) may be estimated using maximum likelihood estimation 
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(MLE) techniques(Hui and Walter, 1980).   When given two imperfect tests (no gold 
standard) and two populations with distinct prevalences, there are four misclassification 
probabilities to be estimated; the false positive rate for test 1, the false positive rate for test 2, 
the false negative rate for test 1, and the false negative rate for test 2 (Walter and Irwig, 
1988).  This approach requires the assumption that a test has identical false positive and 
negative rates for both populations.  Conditional independence of the errors of the tests is 
assumed, and two tests based on similar physiologic similar bases may have correlations that 
cause incorrect estimation of false negative and false positive rates (Vacek, 1985).   
Bayesian methods exist for the estimation of test parameters and disease prevalence. 
These methods are applicable to situations where there are one or more populations and one 
or more diagnostic tests, with no gold standard available.  Where two tests are available for 
one population, there will be five unknown parameters, a sensitivity and specificity for each 
test and the population prevalence, with 3 df.  With more parameters to estimate than degrees 
of freedom, constraints are required if maximum likelihood estimation is to be performed.  
Some proposed constraints include assuming a known sensitivity and specificity for one of 
the two tests or assuming known specificities for both tests.  The Bayesian approach 
eliminates the need for constraints by constructing prior distributions over all unknown 
quantities (Joseph et al., 1995).  Bayesian methods may also be used to determine the 
independence of sensitivity and specificity to population prevalence. The conditional 
independence between  two tests can be obtained using methods developed by Georgiadis et 
al., 2003. Bayesian estimates are useful where no gold standard exists.  Methods for 
modeling epidemiological relationships that can adjust for misclassifcation errors are needed. 
An exploration of determination of sample size for estimating binomial parameters 
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from data subject to misclassification was undertaken by Rahme et al. (2000). Sample sizes 
were found to be highly sensitive to uncertainty in misclassification errors. Although 
formulas exist for sample size calculation with and without adjustment for true sensitivity 
and specificity, the formulas do not take into account differences in prevalence and 
subsequent changes in sample sizes needed. Using a S-Plus (Insightful Corporation, Seattle, 
WA, 98109) algorithm, estimated sensitivity, specificity, and population prevalence are 
evaluated along with sample size to produce a posterior average coverage probability of 
prevalence. Various sample sizes can be evaluated to find a sample size that will produce the 
desired credible interval (95%). When sample size is fixed, as in a completed experiment, we 
can estimate our certainty about the prevalence estimate and thus have a rough estimate of 
the adequacy of the sample size used. 
1.3 Pathogenesis of Bovine Viral Diarrhea Virus (BVDV) in Denmark 
 
Infections with Bovine Viral Diarrhea/Mucosal Disease Virus (BVDV) cause a 
variety of diseases including reproductive disorders, abortion and malformation, 
thrombocytopenia, and mucosal disease. Currently, BVDV is classified in the genus 
pestivirus of the Flaviviridae family, along with the closely related border disease virus of 
sheep (BDV) and Classical Swine fever virus (CSFV), also referred to as Hog Cholera virus.   
BVDV exists in two biotypes, noncytopathic and cytopathic, characterized by their structural 
proteins.   Infection of the developing bovine fetus early in gestation with a noncytopathic 
biotype of BVDV may result in persistent infection and the birth of an apparently healthy 
calf.   Current diagnosis of BVDV infection is based on the clinical symptoms and viral 
isolation. Paired serum samples allow the detection of seroconversion in acute infections, 
while persistently infected animals are immunotolerant and generally lack antiviral antibody. 
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Although generally found in their respective host species, the pestiviruses of cattle, sheep and 
pigs are all capable of crossing the species barrier into the other species. The existence of 
pestiviruses in wild ruminants and boars may complicate control strategies (Weiss et al., 
1994). 
Prevalence studies around the world show that BVDV is widespread in most cattle 
raising countries. Significant differences in prevalence between areas may be the result of 
differences in cattle population structure and management practice. Some areas, such as 
Scandinavia, with greater dispersion of herds prefer not to vaccinate and instead to prevent 
spread by controlling intraherd movements. Direct contact with persistently infected (PI) 
animals is probably the most important method of transmission of infection. However, field 
studies have shown that some limited spread of infection also occurs in the absence of a PI 
animal, and may be due to contact with acutely infected animals or contact with other species 
infected with BVDV. Different methods of indirect transmission (e.g. contaminated needles, 
equipment) also have some importance in the dissemination of BVDV. If a PI animal is 
introduced directly into a dairy herd, most animals will be infected within a few months. If a 
herd becomes infected by means other than direct introduction of PI animals, then the 
infection may only spread to a few animals, and only breakout after PI animals are born.   
The clinical manifestations of acute BVDV-- reproductive disorders, birth of malformed, 
weak and undersized calves, unthrifty PI animals, and mucosal disease, often appear within 
certain periods. Clinical presentation, however, can vary between herd outbreaks depending 
on the virulence of the BVDV strain, methods used to house the cattle, and the variation in 
transmission patterns. Collecting a screening sample from a few young stock to measure 
antibodies and the determination of antibody titer in bulk milk will often give good indication 
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of presence of PI animals in herds not using BVDV vaccines. In herds using killed vaccine, 
determination of antibody titers among a few young unvaccinated stock can show the 
presence of PI animals.   Economic losses on a national level in the UK and Denmark have 
been calculated to be between $11 and $42 million per million calvings (Houe, 1995).  
When the Danish cattlemen decided to eliminate BVDV from Denmark and created a 
program to do so, they wanted tests based on Danish strains of BVDV for increased 
accuracy. The Danish Cattle Health Laboratory then created two ELISA assays, an antibody 
ELISA to detect exposure to BVDV, and an antigen ELISA to detect persistent infection. 
These tests were developed in reference to two existing tests commonly considered gold 
standards. Data from the validation and application of these assays was used to evaluate their 
performance and possibility of misclassification of disease status. 
  
1.4 Cytokine Response in Human Immunodeficiency Virus  
1.4.1  Lentiviruses 
        Lentiviruses  are exogenous, nononcogenic retroviruses which induce chronic, persistent 
disease in infected individuals that are distinguished by their ability to induce a persistent 
lifelong infection even with a strong host immune response, and are often characterized by 
long incubation periods  (months to years) before induction of disease. The host often 
appears clinically normal, and when disease is present is multicentric. Co-factors may be 
necessary for full disease expression: two primary sites of virus replication and pathogenesis 
are the immune system and the brain (Gonda et al., 1994). The chronic phase is the hallmark 
of most lentiviral infections. Chronic infection can result in immunodeficiency, severe 
neurological disease (either from the virus or combined viral and host reaction effect), other 
organ-specific involvement, or persistent infection with no long term effects on the host. 
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Secondary infection is a common sequelae to infection, and is often associated with 
immunosuppresion (Campbell and Robinson, 1998). There are eight members of the 
Lentivirus sub-family of retroviruses; human immunodeficiency virus (HIV), simian 
immunodeficiency virus (SIV), ovine visna,maedi and progressive pneumonia virus, feline 
immunodeficiency virus (FIV), caprine arthritis-encephalitis, equine infectious anemia virus 
(EIA), Jembrana disease virus (Barboni et al., 2001);  and bovine immunodeficiency virus 
(Brownlie et al., 1994). The immunodeficiency-inducing lentiviruses, FIV, SIV, and HIV, 
cause similar disease syndromes in their respective hosts. With HIV, an acute 
mononucleosis-like illness occurs several weeks following exposure and lasts for less than 
one month. This is generally followed by a long asymptomatic period lasting months to years 
and terminating with AIDS.  A high-level plasma and cell associated viremia is the hallmark 
of an acute episode. The hallmark immunologic lesion is CD4+ T cell depletion with one-
third of CD4+ T cell numbers lost during the initial viremic stage (Pedersen, 1995). 
HIV infection leads to unresponsiveness of T Helper T cells in response to T cell 
receptor (TCR) stimulation, and is associated with increased T cell death by apoptosis. Cells 
of the macrophage lineage play an important role in initial infection with HIV-1, and 
contribute to the pathogenesis of the disease throughout the course of infection (Kedzierska 
and Crowe, 2002). Both blood monocytes and tissue macrophages can be infected with HIV-
1 in vivo and in vitro, although the latter are more susceptible to infection.  Cells of the 
macrophage lineaage are infected predominantly with macrophage (M)-tropic strains, 
although infection with some T cell line (T)-tropic strains or dual-tropic isolates of HIV-1 
(exhibiting features of both M-tropic and T-tropic isolates) has also been reported. 
Monocytes, macrophages and dendritic cells play an important role in the initial infection and 
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contribute to its pathogenesis throughout the course of infection (Kedzierska et al., 2003). 
Myeloid cells express CD4 and chemokine receptors known for HIV-1 fusion and entry. The 
beta-chemokine receptor, CCR5, is the major co-receptor in conjunction with CD4 for 
macrophage (M)-tropic or (R5) isolates of HIV-1, whereas the alpha-chemokine receptor, 
CXCR4, facilitates entry of T-tropic or (X4) HIV-1 strains. Cells of myeloid lineage may be 
infected predominantly with R5- strains, although infection with dual-tropic isolates of HIV-
1 (exhibiting the capacity to use CCR-5 and/or CXCR-4 for entry) or some strains of X4- 
isolates has also been reported. The expression of chemokine receptors, HIV-1 infection and 
replication is under continuous regulation by a complex cytokine network produced by a 
variety of cells. The effects of cytokines/chemokines on HIV-1 replication in cells of myeloid 
lineage can be inhibitory (IFN-α, IFN-β, IFN-γ, GM-CSF, IL-10, IL-13 and IL-16 and beta-
chemokines), stimulatory (M-CSF, TNF-α, TNF-β, IL-1, IL-6), or both inhibitory and 
stimulatory (IL-4). After HIV-1 infection, monocyte/macrophages become resistant to 
cytopathic effects and persist as long-term stable reservoirs for HIV-1.   Cells of the 
macrophage lineage play an important role in the neuropathogenesis of HIV-1 infection and 
contribute to HIV-induced dementia via the production of proinflammatory cytokines and 
neurotoxins. Following HIV-1 infection, effector functions carried out by 
monocyte/macrophages are also impaired, and such defects contribute to the pathogenesis of 
AIDS by allowing reactivation and development of opportunistic infections.   
 1.4.2 T Helper 1 (TH1) and T Helper 2 (TH2) Cytokines 
Three patterns of cytokines have been identified in mouse, human, and bovine CD4 T 
cells: TH0, TH1, and TH2 cell subsets. TH cell subsets have specific cytokine profiles and 
responses to foreign antigens. T lymphocyte subsets were demonstrated in mouse strains 
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specifically bred to be resistant or susceptible to specific pathogens (Covert and Splitter, 
1995). TH1 cells secrete interleukin-2 (IL-2), interferon γ (IFN- γ), Tumor necrosis factor β 
(TNF-β) and are associated with cell-mediated immunity of delayed-type hypersensitivity 
reactions and against intracellular organisms. Murine TH1 cells stimulate IgG2a antibodies, 
which are effective for activating complement and opsonizing antigens (Romagnani et al., 
1994a). TH2 cells secrete IL-4, IL-5,  IL-10 and IL-13 are associated with humoral immunity. 
IL-4 stimulates IgE and IgG1 antibodies. IL-5 activates eosinophils, with IL-10, IL-13, and 
IL-4 inhibiting certain macrophage functions. The TH2 cells works on phagocyte-independent 
host defense, as occurs with parasitic infection (Mosmann, 1994).   TH0 cells may dominate 
in the early stages of some immune responses and produce IL-2, IFN-γ, TNF-β, IL-4, and IL-
6.  IL-10 in humans is produced by both TH1 and TH2 cells, unlike in mice, in which it is 
strictly a TH2 cytokine. TH2  human T cell clones produce IL-4 and IL-6 (Romagnani, 1991). 
According to Borish and Rosenwasser (1996), IL-2 production  may be produced not by just 
TH1 cells but also by TH2 lymphocytes. In fact, it has been reported that TH1 and TH2 cells 
both produce IL-2, IL-10, and IL-13 in addition to granulocyte macrophage colony 
stimulating factor and IL-3  (Borish and Rosenwasser, 1997). 
 HIV replicates in cells of the immune system, with CD4 expressing T lymphocytes 
as preferred targets. T cells secrete cytokines that play an important role in activating a 
variety of lymphoid cells including B cells, cytotoxic T cells, natural killer cells, 
macrophages, and additional cells participating in the immune response.  T cell populations 
are divided into TH1 and TH2 (type 1 and type 2). These cell populations have been identified 
in CD4 T cells.  CD4 TH1 cells produce IL-2, IFN-γ, TFN-α, TFN-β. CD4 TH2 cells produce 
IL-4, Il-5, Il-6 and Il-13.  TH1 and TH2 cells differ in the types of antibody response secreted 
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cytokines stimulated in B cells.  TH1 cells mediate delayed type hypersensitivity reactions 
and TH2 cells are more potent helpers of antibody production. Generally, viral and 
intracellular pathogens are controlled by TH1 and cell mediated immunity, with extracellular 
and bacterial pathogens controlled by T H2  and humoral immunity (Mosmann, 1994). 
However, this division is not always clear as INF-γ is considered a TH1 cytokine, but is also 
involved in determining the IgG isotype produced by B cells Other examples exist of TH1 
effects on humoral immunity and TH2 effects on cell-mediated immunity.  Both cell subsets 
produce cytokines that regulate development and activity of the opposite subset. IFN-γ is 
produced by TH1 cells and amplifies TH1 development, while inhibiting TH2 cell 
proliferation.  Il-10 and Il-4 are produced by TH2 cells and block the activation of TH1 cells. 
A number of cytokines can influence T Helper profiles.  Il-12 is produced primarily 
by macrophages and can bias the immune response towards a TH1 profile. Il-4 directs a TH2 
T cell response, and is the most powerful stimulus for TH2 differentiation with Il-12 and IFN-
γ favoring TH1 (D'Elios and Del Prete, 1998). Il-14, also known as high moloecular weight B 
cell growth factor, is produced by B cells and induces the rapid proliferation of B cells.  Il-16 
is produced by CD8 T cells, and binds to the CD4 receptor on CD4 T cells and may function 
in feedback communication between CD8 and CD4 cells.  Il-16 is chemotactic for CD4 T 
cells and induces Il-2 receptors on CD4 cells.  It induces transmembrane signaling events 
similar to the binding of gp120 of HIV on  the CD4 ligand.    Il-18 is INF-γ inducing factor 
and augments natural killer cell activity.  It may enhance T cell proliferation through an Il-2 
dependent pathway that augments TH1 cytokine production and cytotoxicity.   Microbial 
resistance may occur when TH1 responses are induced. TH1 cytokine response also occurs in 
viral infections where natural killer cells, cytolytic CD8 T cells, and neutralizing antibodies 
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provide the majority of host resistance.  As HIV-1 appears to preferentially infect TH2 cells, 
this suggests a mechanism for viral persistence in a TH1 deficient state.  Thus, cytokines that 
induce cellular activation and/or proliferation promote infection and replication in vitro, 
while inflammatory cytokines may effect pathogenesis by modulating the expression of 
monocyte chemokines and CD4+ T cell chemokine receptors (Orandle et al., 2001). 
Exposure of CD4+ T cells to HIV-1 envelope proteins may modify the responses 
evoked by additional stimuli in favor of a TH2- type dominant response (Hu et al., 1994) . 
Others have suggested that the "switch" is really preferential HIV replication in TH2 cells 
(Romagnani et al., 1994a).  Analysis of constitutive cytokine mRNA expression in lymphoid 
tissues from HIV-infected individuals does not confirm an in vivo Th1/Th2 switch nor does 
data available at the in vitro level provide clear evidence for a definite switch to the Th2 
responses. Experiments of in vitro infection with HIV of already established CD4+ T cell 
clones indicated that TH2 and TH0 cells supported HIV replication better than TH1 cells; early 
destruction of TH2 cells by direct or indirect HIV-mediated cell killing may occur.   In some 
HIV-infected individuals with low CD4+ T cell counts, a high prevalence of CD8+ T cells 
producing type 2 cytokines was found.  Enhanced production of type 2 cytokines may play 
some role in the pathogenesis of the disease (Romagnani et al., 1994b). Changes of TH1/TH2 
cytokine production by peripheral blood mononuclear cells (PBMC) that occur during the 
course of HIV infection were examined in a study by Klein et al., 1997. Mitogen-stimulated 
PBMC from 16 healthy donors, 18 HIV- 1-infected individuals without AIDS and 14 patients 
with AIDS were stained intracellularly with fluorescein-labelled MAb against interleukin 
(IL)-2, IL-4, IL-10 and  IFN-γ. Co-staining of CD4+ T-cell, CD8+ T-cell, natural killer (NK) 
cell, B-cell and monocytic markers was performed.   A reduced percentage of  TH1 cytokine-
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producing cells among CD4+ T cells from HIV-1-infected individuals was demonstrated. 
Also observed was a decrease of IFN-γ producing CD4+ T cells over the course of HIV 
infection, and a sharp reduction of IL-2 expressing cells among CD4+ T cells in patients with 
AIDS. The frequency of TH2 cytokine expressing cells among CD4+ T cells increased in 
HIV-infected individuals.  The decreased percentage of cells expressing IL-2 and IFN-γ in 
conjunction with an increased proportion of IL-4 and IL-10 producing cells among the CD4+ 
T cells in HIV-1 infected individuals demonstrated a TH1 to TH2 cytokine shift in the course 
of HIV infection on a single cell level. There was no evidence of a TH1 to TH0 cytokine shift 
(Klein et al., 1997). 
  In one study, the effect of HIV-1 envelope glycoprotein gp160 on secretion of 
cytokines IFN-γ/IL-2 and IL-4 was analyzed using freshly isolated unfractioned peripheral 
blood mononuclear cells (PBMC), CD4+ T cell lines, and PBMC depleted of CD8+ cells  as 
target cells. Pretreatment of these cells with HIV gp160 significantly reduced PHA-induced 
secretion of IFN-γ and IL-2, but augmented IL-4 production. This effect of gp160 was not 
observed when the target cells consisted of PBMC depleted of either CD4+ cells or of CD2+ 
cells. When gp160 was pretreated with soluble CD4-immunoglobulin chimeric molecules,  
the observed effects of gp160 did not occur, suggesting that CD4-gp120 interaction is 
required for modification of the cytokine secretion profile.   Exposure of CD4+ T cells to 
HIV-1 envelope proteins may modify the responses evoked by additional stimuli in favor of a 
TH2  response (Hu et al., 1994). 
 The balance between TH1 and TH2 is critical in determining the response to an 
infectious agent. One study examined the hypothesis that during HIV infection disease 
progression is characterized by a loss of TH1 activity and a shift to a TH2-type response, 
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resulting in loss of cytotoxic cell activity against infected host cells. The balance in three 
groups of individuals- HIV-negative volunteers,  HIV-infected patients not on a therapeutic 
regimen, and  patients managed with a mixture of plant sterols/sterolins, was examined. The 
results indicated that HIV-infected patients on no therapy exhibited a predominant TH2 
response (IL-4 secretion), whereas those on the sterol/sterolin mixture exhibited a beneficial 
TH1 response (IFN-γ) (Breytenbach et al., 2001). Pediatric HIV patients were found to 
produce more of the TH2 cytokine IL-4 and less of the TH1 cytokine IL-2 than healthy 
controls (Vigano et al., 1995). In a study of HIV-1 infected mothers, significantly stronger 
IFN-γ production relative to IL-10 was found among exposed uninfected infants when 
compared to infected infants. Infected infants had positively correlated levels of IFN-γ and 
IL-10 with no particular pattern of high or low production, consistent with the hypothesis that 
failure to establish a polarized type-1 response may increase risk of transmission. Infants 
from uninfected control mothers (n=11) had lowered levels of 1L-10 in cord blood 
leukocytes than infants of HIV-1 infected mothers (n=71)(Kuhn et al., 2001) . In another 
study where differences between cytokine levels in rapidly progressing (RP) versus 
seroreverting (SR) pediatric HIV patients were compared, RP patients produced less of the 
TH1 cytokines IL-2 and IFN-γ than SR patients. RP patients produced more IL-4 mRNA than 
SR patients (Katial et al., 1998). 
Two hallmarks of immunopathogenesis in the progression of HIV-infected 
individuals to AIDS are the loss of T helper cell function in response to antigens and the 
critical reduction in CD4+ T cell numbers. A study by Clerici and Shearer  (Clerici and 
Shearer, 1994) examined in vitro cytokine production by phenotype during the course of HIV 
infection. They reported decreased IL-2 production and increased IL-4 and IL-10 as a critical 
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step in HIV disease progression. Clerici (Clerici et al., 1994) also documented a  loss of T 
helper cell (TH) function in asymptomatic HIV-1 infected individuals occurring before the 
decline in CD4+ T cells. At least part of the loss in TH function results from changes in 
immunoregulatory cytokine profiles.    They observed that the TH2 IL-10-specific mRNA 
was marginally upregulated, and increased levels of IL-10 were produced by PBMC from 
HIV+ individuals compared with PBMC from uninfected individuals. Those individuals 
whose TH function was more severely compromised produced higher levels of IL-10. 
Additionally, defective antigen-specific TH function in vitro, including the response to HIV 
envelope synthetic peptides, could be reversed by anti-IL-10 antibody.    The antigen-specific 
TH responses of HIV-uninfected PBMC could be reduced with IL-10, and the reduction could 
be reversed by anti-IL-10. These results confirmed that the early loss of TH function in HIV+ 
individuals is due at least in part to cytokine-induced immune dysregulation and supported 
the hypothesis of a switch from a predominant type 1 state to a predominant type 2 condition 
in HIV infection.  A later study by Shearer et al, 1995, suggested that the loss of TH cell 
function and increased T cell death seen in vitro are correlated; and that in vivo HIV 
infection gives rise to inappropriate cytokines resulting in immune dysfunction and 
immunopathogenesis (Shearer et al., 1995). The predominance of immuno-inhibitory TH2 
cytokines in the cervical mucosa of HIV+ women is a potential cause of the impaired 
cytotoxic potential observed in CD8+ T lymphocytes and may contribute to the susceptibility 
of HIV-infected women to recurrent genital tract infections and cervical neoplasia (Olaitan et 
al., 1998).  
HIV isolation, rate of viral replication, phenotype, TH1 and TH2 cytokine production, 
and CD4 counts were cross-sectionally analyzed in 63 HIV seropositive (HIV+) individuals 
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to  examine correlations between  virologic and immunologic markers of protection and 
progression.  Lack of or low viral isolation was associated with the strongest TH1 cytokine 
production, the weakest TH2 cytokine production, and highest CD4 counts. Conversely, the 
isolation of highly replicating HIV strains was associated with the weakest TH1 cytokine 
production, the strongest TH2 cytokine production, and lowest CD4 counts. The IL-10/IL-2 
ratio best described disease progression (Clerici et al., 1996b). 
 Not all studies confirm the postulated TH1 to TH2 cytokine switch.  Graziosi 
(Graziosi et al., 1994) found that both cross-sectional and longitudinal analyses of 
constitutive cytokine expression of IL-2, IL-4, IL-10, and IFN-γ did not demonstrate a switch 
in phenotypes as disease progressed in sorted or unfractionated CD4+ cells from peripheral 
blood and lymph nodes, even after in vitro activation. However, increased expression of 
cytokines in lymph nodes from HIV+ patients was primarily observed in non-CD4  T cells 
(CD8 and other cells producing IFN-γ, and IL-10 from non T-cells). Maggi (Maggi et al., 
1994) did not see a bias toward TH2-like cytokine patterns as AIDS progressed, but did see 
an increase in TH0 clones. A study was based on cloning of CD45R0 (memory) T cells 
obtained from a single donor over time revealed a shift toward the TH0 secretion profile as 
infection progressed (Meyaard et al., 1994) HIV was also found to replicate preferentially in 
TH2 and TH0 clones in vitro.  TH cell mediated specific immune response is likely more 
complicated that TH1 and TH2. 
Ostrowski et al. 2003, investigated whether whole-blood culture cytokine production 
was associated with mortality in HIV-1-infected patients.  One hundred and seven HIV-1-
infected patients stratified according to the CDC criteria and 65 controls participated. The 24-
h phytohaemagglutinin and lipopolysaccharide-stimulated whole-blood culture production of 
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TNF-α, IFN-γ, IL receptor antagonist, IL-1β, IL-12, IL-10, IL-2 and soluble  IL-2 receptor α 
were studied.  Compared with controls, asymptomatic patients had increased production of 
IL-1β and IL-12 (TH1) and unchanged production of TNF-α, IFN-γ and IL-1 receptor 
antagonist; notably reduced production of IL-10 (TH2), IL-2 and soluble IL2-receptor α.  
HIV progression led to a progressive decline in whole-blood culture production of  TH1 and 
TH2 cytokines TNF-α, IFN-γ, IL-1receptor antagonist, IL-1β, IL-12, IL-10 and IL-2. Low 
production of these cytokines were all associated with increased mortality risk in the patients.  
Furthermore, low production of TNF-α, IL-1β, IL-12 and IL-10 independently predicted 
mortality.  Clinical significance of impaired cytokine production was associated with 
progressing HIV-1 infection. 
 Vecchiet et al., 2003, investigated  HIV-1 disease in untreated patients and in patients 
treated with Highly Active Antiretroviral Therapy (HAART). IL-4 and IFN-γ  in vitro 
production was determined in mononuclear cell cultures stimulated with different T 
lymphocyte mitogenic agents. Patients were classified by the number of CD4+ lymphocytes, 
and a progressive, but not significant, decrease in the baseline production of IFN-γ was seen 
with the progression of the immunodeficiency.  No significant differences in the baseline 
production of IL-4 or of  IFN-γ and IL-4 production in LPS-stimulated cultures was seen.  
Twelve patients were reassessed after one year and presented with a significant increase in 
IFN-γ production compared to the first assessment in the LPS-stimulated cultures. IL-4 
production showed a decreased in PHA-stimulated cultures, and the results were attributed to 
immunorestoring effects of HAART. IL-4 production was lower in the treated subjects 
compared to the naive ones in PHA-stimulated cultures. 
In a contradictory study by Sarih et al. (1996), no evidence of an in vivo switch from 
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the TH1 to TH2 phenotype was observed in HIV-infected patients. Spontaneous production of 
both IL-2 and IL-10 in PBMC after 48 h in culture was greater in HIV-infected subjects and 
increased with disease progression. IFN-γ production was greater in HIV-infected subjects, 
but there was no evident change with disease progression. IL-4 production was barely 
detectable or not detected in both HIV-infected and HIV- negative individuals.  
Breytenbach et al. (2001), studied the TH1--TH2 balance in HIV infected individuals 
during an immune response to an infectious organism. They proposed that during HIV 
infection, disease progression is characterized by a loss of TH1 activity, a shift to a more TH2 
response and loss of cytotoxic cell activity against infected host cells.  The TH1-TH2 balance 
in three groups of individuals, including, HIV-negative volunteers (n=10), a group of HIV-
infected patients on no therapy (n=10), a group of patients managed with a mixture of plant 
sterols/sterolins (n=9), was investigated.  HIV-infected patients on no therapy exhibited a 
pre-dominant TH2 response (IL-4 secretion), whereas those on the sterol/sterolin mixture 
exhibited a beneficial TH1 response (IFN-γ). In both patient groups, chronic activation 
appeared present in vivo.     
Romagnani et al. (1994a) suggested that TH1 and TH2 cells should be regarded as 
extremely polarized forms of the  heterogeneous TH cell-mediated effector response, instead 
as two functional subsets of CD4+ TH cells  In a study of IgE levels in HIV-infected 
individuals during the course of infection, they found 38% of HIV-infected patients had 
enhanced IgE synthesis in the early, intermediate, or advanced phase of infection and 
indicated a shift to TH2. The majority of patients’ serum IgE concentration remained low, 
arguing against a TH1/T H2 shift. Patients with high IgE serum levels at the time of 
serodiagnosis had a greater depletion of circulating CD4+ T cells over eight years. No 
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change in the production of TH2 cytokines (IL-4, IL-5, and IL-10) by bulk circulating 
mononuclear cells or CD4+ T-cell clones generated by stimulated single T cells from HIV-
infected patients was found when compared to HIV–negatives. This did not rule out an 
increase in TH0 cells, since TH0 cells would not support IgE synthesis.  TH1, TH2, and TH0 
clones from HIV-negative donors demonstrated differing ability to support viral replication 
after in vitro infection with HIV. TH1 clones did not support HIV replication, while all TH2 
and most TH0 clones did, suggesting HIV preferentially replicates in T cells producing TH2 
cytokines as opposed to a TH1/TH2 shift creating increased TH2 cytokines. 
Fakoya et al, (1997) conducted two separate studies of HIV patients and controls 
cytokine profiles including (i) a longitudinal study of HIV patients with high CD4 counts 
tested at three timepoints compared with controls, and (ii) a blinded cross-sectional study of 
controls and patients with high and low CD4 counts. Peripheral blood mononuclear cells 
(PBMC) from patients and controls were tested by ELISA for spontaneous and mitogen-
induced production of two TH1 (Il-2, IFN-γ) and two TH2 (IL-4, IL-10) cytokines. HIV 
infection led to the in vivo activation of TH2 cytokines in a small group of individuals with 
high CD4 numbers and was characterized by the spontaneous release of IL-4 and IL-10. The  
longitudinal data showed that high spontaneous IL-4 and IL-10 levels were a consistent 
feature of the patient group, but to be variable in a given individual. HIV infection was found 
to impair the ability of PBMC to respond to stimuli by IL-2, IL-4 and IL-10 in patients with 
both high and low CD4 cell counts. Interestingly, HIV infection led to an overproduction of 
IFN-γ in patients with high CD4 counts where patients with low CD4 produced normal levels 
of IFN-γ. This small study did not suggest polarization of the type 1/type 2 cytokine profile 
postulated in HIV patients. Instead, the data suggested more complex changes to type 1/type 
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2 cytokine patterns in HIV infection than originally proposed by the TH1/TH2 dichotomy. 
Another theory on TH1 and TH2 cytokines was proposed by Estaquier et al. (1995). 
Quantification of IL-2, IFN-γ, IL-4, IL-5, and IL-10 secretion by immunoassays, and of IFN-
γ, IL-4 and IL-10 messenger RNA expression by competitive  RT-PCR after in vitro 
stimulation of the T cell receptor (TCR),  revealed a similar TH1 cytokine profile in T cells 
from HIV-infected persons and from controls. These data indicated that the loss of CD4+ 
TH1 cell function in HIV-infected persons is related to a process of activation-induced death 
of CD4+ Th1 cells instead of a TH1/TH2 shift. Although TH2 cytokines levels were not 
elevated, apoptosis of CD4+ T cells, but not of CD8+ T cells, was prevented in vitro by 
antibodies to IL-10 or IL-4 (TH2 cytokines downregulating TH1 cell responses) or by   
recombinant IL-12, (TH1 cytokine upregulator).   CD4+ and CD8+ T cells from HIV-infected 
persons expressed high levels of a CD95 molecule, and were highly sensitive to antibody-
mediated CD95 ligation, which induced apoptosis in a percentage of T cells similar to that 
induced by TCR stimulation. As TCR-induced apoptosis, CD95-mediated apoptosis of CD4+ 
T cells, but not of CD8+ T cells, was prevented by the addition of recombinant IL-12. The 
authors concluded that apoptosis of CD4+ T cells from HIV-infected persons might involve 
an abnormal sensitivity to CD95 ligation, and to TCR stimulation in the presence of normal 
levels of TH2 cytokines.   
Douglas et al. (2003) studied cytokine production in healthy or HIV-infected 
adolescents. They analyzed cytokine mRNA and protein levels for  IFN-γ, IL-2, IL-4, TNF-α 
and protein levels of IL-6 in both stimulated and unstimulated  PBMC obtained from a large  
observational cohort study of HIV-seropositive and -seronegative adolescents. Cytokine 
results were correlated with viral load and CD4(+)-T-cell counts as critical markers of 
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disease progression.  Five hundred twenty subjects contributed blood samples.   In the subset 
of subjects with detectable cytokine values, differences in detected values were compared 
across subgroups defined by HIV serostatus and among HIV-seropositive subjects by three 
viral load classifications. The study sample was 65% HIV seropositive, 71% African-
American, and 75% female with a mean age of 17.4 years. HIV-seropositive subjects were 
relatively healthy with mean and median CD4(+)-T-cell counts of 534 and 499 cells/mm(3), 
respectively. Only 8.1% of subjects had CD4(+)-T-cell counts below 200 cells/mm(3), and 
25% had viral loads that were below the threshold of detection (<400 copies/ml). No 
differences in cytokines were detected in HIV-seropositive and HIV-seronegative 
adolescents, and there was no apparent relationship between the cytokine measurements and 
the viral load or CD4(+)-T-cell categorization.   The HIV-infected subjects were at an early 
stage in the course of their HIV-associated disease. They concluded that, early in the course 
of HIV-associated disease in adolescents, there was no detectable shift from TH1 to TH2 
cytokine production.  
1.4.3 Cytokine Profile in Non-Progressive HIV Infection 
The progression of HIV infection may be accompanied by a decline of in vitro 
production of TH1 cytokines interleukin-2 (IL-2), IL-12 and interferon gamma (IFN-γ), and 
an increase in the production of IL-4, IL-5, IL-6 and IL-10 (TH2  cytokines) by PBMC of 
HIV+ patients. As the disease progresses, an inability to elicit a delayed-type hypersensitivity 
reaction  (secondary to defective IL-2 production), hyper-IgE (secondary to increased IL-4 
production) and hypereosinophilia (secondary to increased IL-5 production) should occur. 
Strong TH1/weak TH2 cytokine  profiles were observed in HIV-seropositive patients with 
delayed or absent disease progression, whereas progression of HIV infection was 
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characterized by a weak TH1/strong TH2 cytokine  profile. PBMC of HIV-seropositive 
individuals were susceptible to antigen-induced cell death (AICD) after antigen recognition 
via T-cell receptor (TcR). While TcR-induced AICD is seen in CD4+ and CD8+ cells, 
apoptosis induced by recall antigens is preferentially observed in CD4+ cells. Since type 2 
cytokines augmented T-lymphocyte AICD, an increase in the concentration of type 2 
cytokines may well be the cause of the decline in CD4+ cells seen in HIV infection (Clerici 
et al., 1997). 
HIV + individuals have different patterns of disease progression. In a study 26 long-
term nonprogressors (LTNPs), 28 patients with progressive HIV infection (PI), and 24 HIV-
seronegative controls, IL-2 and IFN-γ (type 1 cytokines) production was reduced and IL-4 
and IL-10 (type 2 cytokines) production was increased in PI patients compared to both 
LTNPs and controls. Along with the increase in type 2 cytokines in PI patients, an increase in 
CD57+CD4+CD7-lymphocytes and in prevalence of HIV isolation was found. A dominant 
type 1 cytokine profile and reduced prevalence of virus isolation was associated with 
nonprogression of HIV infection (Clerici et al., 1996a). 
(Zanussi et al. (1996) studied the role of CD8+ lymphocytes in HIV+ LTNP.     The 
phenotypic profile and the cytokine production of CD8+ cells in a group of LTNP patients 
who had stable CD4+ cell counts (> 500/mm3) for at least 7 years were evaluated. CD8+ 
absolute numbers were similar to a control group composed of HIV-1+ patients who had a 
progressive decline in their CD4+ cell counts.  A clinical and immunologically stable 
condition was associated with the presence of a CD28+, CD95 strongly positive CD8+ 
population, while disease progression was marked by the CD28-CD95+CD8+ subset. 
Purified CD8+ cells from LTNP retained their ability to produce TH1 cytokines IL-2, and 
 20
IFN-γ  and to a lesser degree, IL-10 and IL-4. In contrast, CD8+ cells from progressors were 
unable to secrete IL-2 and IL-10.  LTNP CD8+ T cells maintain their capacity to produce IL-
2 and IL-10 in a TH0 pattern very similar to that observed in normal HIV healthy controls.   
 Type I and type II cytokine production of both CD4+ and CD8+ T cells activated by 
superantigen were investigated by Onlamoon et al. (2003) in 10 healthy donors and 39 HIV-1 
infected patients. Patients were divided into 3 groups based on their CD4 count (< 200, 200-
500, > 500 cells/µl). Whole blood from each subject was activated by staphylococcal 
enterotoxin B (SEB) and anti-CD28. Type I cytokine (IFN-γ) expression in CD4+ T cells co-
expressing CD69 were significantly increased in HIV infected patients, particularly in 
patients with CD4 counts in the two lowest groups when compared with the normal group 
(p< 0.05).  IL-2 production in the two lowest groups of CD4 count patients was significantly 
lower than the normal  (p < 0.05). For type II cytokines, there was no difference in all groups 
of subjects when IL-4 was determined. However, IL-5 production was significantly higher in 
patients with the lowest CD4 count than that in the normal group   (p < 0.005). CD8+ T cells 
also showed higher IFN-γ production in patients in the two lower CD4 count groups than the 
normal group (p < 0.005). In contrast, IL-2 production in CD8+ T cells was low in all HIV 
infected patients and significantly different compared to the control group (p < 0.05). For 
type II cytokines, only IL-4 production in patients with the lowest CD4 count was 
significantly reduced when compared to the other groups (p < 0.05).  Although HIV infection 
altered the production of both type I and type II cytokines, it did not induce a polarized type I 
or type II state in the course of HIV-1 progression in Thai patients. The study of cytokine 
response in BIV as measured by IgG1/IgG2 ratios was designed to determine if a type 2 shift 
occurred in BIV infected bovines. 
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1.4.4 Cytokine Response in Non-Human Primates 
Of the seven subgenera of lentiviruses now recognized, two share the characteristics 
with HIV of a T cell tropism and associated loss of CD4+ in the host (FIV< SIV).  Other 
animal lentiviruses grow best in macrophages and their infection generally reflects clinical 
sequelae of macrophage infection (Levy, 1996).  Chimpanzees are one of the few species 
susceptible to persistent HIV-1 infection. However, HIV- infected chimpanzees do not 
exhibit the marked immune system alterations seen in humans and remain relatively resistant 
to AIDS. In an effort to understand some of the mechanisms limiting lentivirus infection, 
Gougeon et al. (1997) compared apoptosis in infected humans’ and chimpanzees’ CD4 and 
CD8 T cells in relation to the expression of Bcl-2 and Fas molecules. The rate of apoptosis in 
CD4 and CD8 T cells from infected chimpanzees was comparable to that detected in 
noninfected chimpanzees.  CD45RO+ and HLA-DR+ subsets exhibiting a high propensity to 
undergo apoptosis in infected humans were not modified in infected chimpanzees.   
Resistance to apoptosis was associated with the predominance of CD3 T cells with a TH1 
phenotype.   
Immunological studies concerning changes in subsets of T cells, based on cytokine 
profile (TH0/TH1/TH2), showed that where rhesus macaques early post simian 
immunodeficiency virus (SIV) infection showed a dominant TH1 profile, this profile rapidly 
changes to TH0.  Mangabeys continuously demonstrated a TH2-like profile. Studies also 
showed a high frequency of in vivo-activated cells in the peripheral blood of SIV- infected 
rhesus macaques and mangabeys.  However, a similar level of in vivo-activated cells was 
found in seronegative mangabeys. Cells from SIV-infected mangabeys failed to show 
increased levels of apoptotic cells following incubation with immobilized anti-CD3, but 
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PBMC from rhesus macaques at varying time intervals showed increased levels of apoptotic 
cells, predominantly in CD8+ T cells   unrelated to levels of viremia. Sooty mangabeys 
maintain a high frequency of CD8+ T cells that regulate virus replication throughout their 
lifetime. Rhesus macaques only show a frequency of CD8+ T cells high enough to regulate 
virus replication shortly post infection, and this regulatory function is gradually lost prior to 
CD8+ cell loss and death (Villinger et al., 1996)  
  Benveniste et al. (1996) attempted to delineate the early events in the immune 
response to lentivirus infection by sequentially monitoring levels of pro-inflammatory (IL-1 
beta, IL-6, and TNF-alpha) and anti-inflammatory (IL-10) cytokine mRNAs in PBMCs of   
macaques during primary SIVmac infection. Eight monkeys were infected with cell-free 
SIVmac251. All monkeys seroconverted between days 16 and 21 post-infection (p.i). and 
had detectable viremia which peaked between days 12 and 16 p. i..  A marked increase in the 
expression of IL-6 mRNA was observed in all macaques during the first weeks following 
infection. A transient increase in the levels of expression of IL-1β, TNF-α, and IL-10 mRNA 
was also determined in six, six, and five of the eight monkeys, respectively.  
The influence of host cytokine response on viral load, disease progression, and 
neurologic lesions was investigated in (SIV)-infected macaques. Cytokine gene expression     
(IL-1β, IL-2, IL-6, IL-10, IFN-γ, and TFN-α) and viral loads were evaluated by 
semiquantitative RT-PCR in lymph nodes of 5 control and 28 terminal stage SIVmac251 
infected animals. Infected animals showed higher expression of IFN-γ, IL-6, and IL-10 
mRNAs. Levels of all cytokines were comparable between animals with rapid or 
slow/normal disease progression. However, among the 16 rapid progressors, the eight 
animals with SIV encephalitis had a unique cytokine profile (increased IL-2, IL-6, and IFN-
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γ) associated with higher viral loads than non-encephalitic rapid progressors. Perivascular 
infiltrates of macrophages in the CNS has been observed with SIV and HIV-1 infections.  
The monocyte/macrophage activating properties of IL-2 may activate brain microvascular 
endothelium, elevating cell adhesion molecules, and may contribute to nueropathogenesis via 
cellular activation mechanisms.  Additional host cytokine responses may also influence SIV 
neuropathogenesis independent of disease progression (Orandle et al., 2001). 
Inflammatory cytokines are believed to play an important role in the pathogenesis of 
human immunodeficiency virus type 1-associated encephalitis.   Inflammatory cytokine gene 
expression was evaluated in the brains of macaques infected with pathogenic SIV(mac251) 
by reverse transcriptase PCR. At the terminal stage of infection, TNF-α and IFN-β transcripts 
were coexpressed in the brains of four of five animals with SIV encephalitis (SIVE).  A 
direct relationship between neuropathology and altered cytokine gene expression was 
suggested.   TNF-alpha-expressing cells were frequently identified as CD68-positive 
macrophages within perivascular lesions.  Cytokines produced by activated inflammatory 
macrophages are an important element in the pathogenesis of SIVE  (Orandle et al., 2002). 
 To elucidate the initial pathogenic events of SIV in lymphoid organs, follow-up of 
viral load and cytokine mRNA production was performed in the rhesus macaque SIV 
mac251 model (Khatissian et al., 1996).  Lymph nodes (LN) obtained from animals 
sacrificed at early time points following intravenous inoculation with a high viral dose, 
showed that the production of cytokine mRNA in the LN (IFN-γ, IL-1-β, IL-2, IL-4, IL-
12p40, IL-6, IL-10, TNF-α and TNF-β) was correlated with viral replication and persisted 
during the two months p.i.. As a followup, LN  were sequentially analyzed in two groups of 
animals receiving  a high or a low viral dose. The initial higher local production of IFN-γ 
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mRNA in LN was associated with weak viremia, the capacity of the host to decrease 
productive infection in LN measured at one and two months p.i., and slow disease 
progression. 
1.4.5 HIV and HLTV Coinfection as a Model of BIV and BLV Coinfection 
Coinfections with HIV-1 and HTLV-I or HTLV-II have been associated with unique 
immunophenotypes and an increased risk for development of neurodegenerative conditions, 
possibly from an increased HTLV-I or II viral burden in dually infected individuals.   In 
humans, the Human T-cell Leukemia virus type 1 (HTLV-1),  an Oncovirus,   is the 
etiological agent of two diverse diseases: adult T-cell leukemia/lymphoma and the 
neurological disorder tropical spastic paraparesis/HTLV-1-associated myelopathy.  A 
genetically related virus, HTLV-2, has been identified and isolated. There has been no 
demonstration of a definitive etiological role for HTLV-2 in human disease to date.  Bovine 
leukaemia virus (BLV) has also been classified in the same family, Oncoviridae (Johnson et 
al., 2001). It has been theorized that coinfection with BIV and BLV may act in a similar 
fashion to HIV and HLTV coinfection. 
HTLV-I/II tax/rex messenger RNA and viral antigen expression in peripheral blood 
mononuclear cells (PBMCs) were measured  (Beilke et al., 1998) in 37 HTLV-I- or HTLV-
II-infected subjects with or without HIV-1 coinfection. Tax/rex messenger RNA was 
detected in 14 of 24 PBMC samples from dually infected subjects, compared with only 1 of 
13 PBMC samples from singly infected subjects (58% versus 7%; p < 0.003). The reverse 
transcription-polymerase chain reaction (RT-PCR) assay was correlated with HTLV-I/II viral 
antigen detection in PBMC cultures, but not with the HIV-1 viral load levels in plasma.   
A Retroviral Coinfection Clinic was established in New Orleans, Louisiana, at 
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Charity Hospital Medical Center of Louisiana to study patients dually infected with human 
immunodeficiency virus (HIV) and human T lymphotropic virus (HTLV-I, HTLV-II). Eight 
patients were evaluated.  Multiple neuromuscular diseases were observed, including tropical 
spastic paraparesis, polymyositis, and polyneuropathies. Only one patient developed AIDS. 
HIV-1 infected patients with HTLV-I, but not HTLV- II, coinfection have maintained stable 
CD4 counts, despite the fact that quantitative HIV DNA PCR suggests a relatively high copy 
number. HTLV-I/II antigens were detected in lymphocyte cultures from four patients, and 
lymphoblastoid cell lines have been established from two. These results support the 
contention that upregulated HTLV-I/II virus expression and disease manifestations occur 
during coinfection with HIV, sometimes in association with normal CD4 counts(Beilke et al., 
1994). 
Domingues et al. (1995) conducted a prospective clinical and epidemiologic 
evaluation of 45 cases of human T lymphotropic virus type I (HTLV-1)-associated with 
myelopathy/tropical spastic paraparesis in Sao Paulo, Brazil. All of the enrolled patients had 
progressive chronic myelopathy and high titers of HTLV-I and HTLV-II antibodies, as 
determined by enzyme immunoassay and western blot. In 24 cases, PCR was performed so 
that HTLV-I could be distinguished from HLTV-II.   All patients whose serum was tested by 
PCR were infected with the HTLV-I virus. 
To determine whether coinfection with HTLV-II influences the course of HIV-1 
infection, Visconti et al. (1993) evaluated the progression of disease from asymptomatic HIV 
infection (CDC group II) to persistent generalized lymphadenopathy (CDC group III) to 
AIDS-related complex (CDC group IVA) to full-blown AIDS (CDC group IVC) to death 
from AIDS in two groups of HIV-seropositive intravenous drug users (IVDUs). The first 
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group consisted of 123 patients infected with HIV-1 only, and the second comprised 22 
patients with HTLV-II/HIV- 1 coinfection. Immunological and clinical follow-up indicated a 
greater likelihood of developing persistent generalized lymphadenopathy among individuals 
infected with HIV-1 alone than among those coinfected with HTLV-II. No statistical 
difference was detected between the two groups in the depletion of CD4+ cells, the temporal 
decrease of the CD4/CD8 ratio, or progression to AIDS or to death from AIDS. These 
findings suggest that HTLV-II may have no effect on the clinical evolution of HIV infection 
in IVDUs, perhaps due to the lack of pathogenicity of the HTLV-II coinfecting strain( s) 
and/or other still unclear biological or immunological cofactors.  In a study of 963 HIV-
infected patients in Martinique, medical files were used to retrieve information about age, 
sex, circumstances of diagnosis, HTLV-I status, and HIV clinical grade at first examination 
according to CDC criteria. Complete information was available for 774 patients. At the first 
clinical examination, the clinical grade of 65 coinfected patients was more severe than that of 
the monoinfected patients (OR = 2.60, p < 0.01), but after adjustment for age and sex, the 
odds ratio reduced  to 1.57. This study did not invalidate the hypothesis of a faster 
progression toward AIDS of coinfected than of singly infected patients (Chavance et al., 
1995). 
Popovic et al. (1984) studied infection with HLTV-1 and HLTV-II (but not HIV) in 
two functionally different types of human T-cell clones, one with helper function and two 
with specific activity.  Both types of human T cells showed alterations in specific function 
after infection with either of the HTLV subgroups. Before HTLV infection, the T-cell clone 
with helper function proliferated and provided help to B cells only in the presence of both a 
specific soluble antigen and histocompatible antigen-presenting cells. After HTLV infection, 
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these cells responded with increased proliferation and indiscriminant stimulation of 
polyclonal immunoglobulin production by B cells. Infection of the normal cytotoxic T-cell 
clones led to a decrease or loss of the cytotoxic function.   
1.5 Cytokine Response in Bovine Immunodeficiency Virus 
BIV is a retrovirus in the Lentivirinae subfamily. Like other retroviruses, it induces 
cell syncytia formation. Its action may take years and requires one or more cofactors for 
clinical effects of the virus.   BIV contains gag, pol, and env genes which are similar to 
primate lentiviruses.     Diagnosis is difficult and may involve IFA, ELISA, Western blot, or 
viral isolation.  The bovine immune system differs from other mammalian species in 
development of the B cell lineage and the humoral response. Cattle do not have sIgD, and 
have a unique distribution of Ig isotypes in secretions. A predominant TH1 response in vivo 
would be expected to upregulate IgG2 as IFN-γ likely controls IgG2 production at the 
transcriptional level.   In the mouse, TH1 cells encourage IgG2a production in vivo (Estes, 
1996).  TH0, TH1, TH2, cell subsets exist in the bovine. Brown et al. (1998) determined that 
cattle have cytokine mediated regulation of TH cell responses differing from those observed 
in mice.  The majority of over 60 parasite antigen-specific TH cell clones coexpressed IL-4 
and IFN-γ and polarized cytokine profiles were rarely observed.  IL-2 expression was not 
restricted to IFN-γ producing cells norIL-10 to  IL-4 producing cells. Bovine type 1 and type 
2 responses do not appear coordinated; TH1 and TH2 responses may not typify the immune 
response to most pathogens.  Major regulatory cytokines (IL-4, IL-10, IL-12) do not 
selectively exert negative (IL-4, IL-10) or positive (IL-12) effects on TH1-like cells in the 
mouse. Instead, IL-10 is produced by TH1 and TH2 CD4+ cells like humans and unlike mice. 
Polarization of an immune response towards a type1 or type 2 response can occur in vivo 
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against a specific antigen, particularly by intra-macrophage pathogens that induce IL-12 and 
then IFN-γ as in a type 1 response. A polarized type 2 response is seen with IL-4 and IL-5 
induction by allergens.  Covert and Splitter (1995) developed a reverse transcriptase 
polymerase chain reaction (RT-PCR) assay to monitor gene expression of bovine T 
lymphocyte cytokines and examine T cell mediated immunity against pathogens. Cytokine 
transcription of β-actin, IL-1α, IL-1β, IL-2, IL-4, IL-6, IL-10, tumor TNFα, TNFβ, and IFN-γ  
was detected from concanavalin A activated PBMC and CD4+ purified T lymphocytes.  
Cytokine mRNA profiles of bovine CON-A-activated CD4+ T cells showed products of TH1 
and TH2 human T cell clones (IL-2, IFN-γ, TFN-β, IL-4, IL-6).  In this case, the bovine cells 
could have been TH0 clones or a mix of TH subsets. IL-1α and IL-1β were produced from 
bovine CD4+ with IL-1α production similar to that seen in murine TH2 while IL-1β was not 
produced by murine TH1 or TH2 clones.  
  The biological effects mediated by bovine IL-12 in cattle were examined by Collins 
et al. (1999).   Using bovine respiratory syncytial virus (BRSV) and ovalbumin (OVA) the 
effects of IL-12 on the responses of PMBC to antigens was studied in vitro. The presence of 
IL-12 markedly influenced the level of IFN-γ secreted by these cells. IL-12 induced IFN-γ 
production in the absence of antigenic stimulation- IFN-γ production was accelerated and 
augmented in response to IL-12 and antigen.  CD4+ T cells comprised the largest 
contributors to IFN-γ production with WC1 + γδ T cells appearing not to contribute to   
production. When tested on lymphoblasts rather than resting T-cells, IL-12 also enhanced 
proliferation. In contrast IL-4 and, to greater extent, IL-10 inhibited the response (Collins et 
al., 1998). 
Using antigen- receptor cross-linkage or mitogen (pokeweed mitogen) costimulation, 
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Estes (1996) demonstrated that recombinant bovine IL-4 (rboIL-4)  upregulated the 
expression of IgM, IgG1 and IgE in vitro. Upregulation of IgG1 and IgE production by 
rboIL-4 was inhibited in a dose-dependent manner by the addition of rboIFN-γ to the 
cultures.   They also found that TGF-β did not solely upregulate IgA production from 
noncommitted precursors (sIgM+) in coculture with mitogen or with formalin fixed 
Staphylococcus cowan Strain I (SAC), but did have positive effects on IgA production in the 
presence of both IL-2 and IL-10. Different modes of T-independent costimulation by 
classical B cell activators did not result in differential IgG subisotype or IgE production by 
bovine B cells in the presence of cytokines.  T cell – B cell interactions studies focus on the 
CD40 molecule present on B cells and the CD40 ligand on T lymphocytes. CD40 cross-
linking is the first step in the interaction between T and B lymphocytes and influences B cell 
activation and isotype production. Polyclonal B cell activators are needed for cytokines to 
effect class switching in resting B cells.  Individual cytokines appear to regulate isotype 
expression in cattle. 
1.6 Cytokine Response in Bovine Leukemia Virus  
BLV is an exogenous type C retrovirus associated with the development of malignant 
lymphoma in cattle. BLV infects B lymphocytes, and has about 50% nucleotide sequence 
similarity to HTLV types II and I. B cells (CD5) are the primary host of BLV infection 
unlike HTLV, which is found in T cells.  HLTV activates IL-2 and IL-2 receptor genes, thus 
promoting T-cell proliferation.  In BLV infection, abnormal regulation of B cell development 
results in sustained nonmalignant polyclonal expansion of CD5+ B cells.  BLV and HLTV-1 
have a common genomic organization  and are associated with pre-neoplastic lymphocyte 
deregulation and lymphoid neoplasia. Two well characterized proteins Tax and Rex regulate 
 30
expression and replication of BLV and are essential in viral infectivity. HLTV-1 transforms 
CD4+ T cells, but preferentially infects activated CD4+  T cells, and in vivo can integrate 
CD8+ T cells, granulocytes, monocytes, and microglial cells in primary cultures. BLV 
transforms B cells. It can preferentially infect B cells and also can infect CD4+, CD8+, 
monocytes and granulocytes.   
Vertical transmission, in utero, or through colostrum and milk, accounts for a 
relatively small proportion of infections in BLV (Hopkins and DiGiacomo, 1997). Iatrogenic 
horizontal transmission, through procedures permitting the transfer of blood between cattle, 
is a major route of transmission in most settings. Contact transmission from a mixture of 
natural sources of blood, exudates, and tissues occurs as well. The prevalence of BLV 
infection is US herds is at least 50%, but lymphosarcoma only occurs in 10% of infected 
animals, and most are asymptomatic (Pyeon et al., 1996). Enzootic bovine leukosis is a 
contagious disease induced by BLV and characterized by a persistent lymphocytosis (PL) 
that can culminate in B cell lymphoma.    BLV infects between 10 - 30% of dairy cows in the 
U.S.  Most infected cows are asymptomatic (aleukemic) (AL).  Approximately 30-70% of 
BLV carrriers will develop PL while less than 10% develop malignant lymphosarcoma.  The 
influence of BLV infection on bovine health and productivity is uncertain.   BLV- and BLV+ 
AL animals did not differ in response to mitogen stimulation; BLV+ AL had fewer T lymphs 
(CD4+ and CD8+). The effects of BLV on the phenotypic and functional characteristics of 
PBMC were investigated. Whole blood differentials showed that persistently lymphocytotic 
(BLV+PL) dairy cattle had more lymphocytes and fewer neutrophils than the aleukemic 
seropositive (BLV+AL) or seronegative (BLV-) animals. Flow cytometric analyses of 
peripheral blood mononuclear cells indicated that the BLV+PL animals had more B 
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lymphocytes and decreased CD2+ cells when compared with the BLV- group. Mononuclear 
cells from the BLV+AL animals also had fewer CD2+ cells, but no differences in B 
lymphocytes count when compared with BLV- cattle.  Lymphocytes from BLV+PL animals 
had lower proliferative responses to concanavalin A and pokeweed mitogen when compared 
with cells from the BLV- or BLV+AL groups. The level of spontaneous blastogenesis in the 
absence of mitogenic stimulation was high for lymphocytes obtained from BLV+AL cattle. 
Cultures of lymphocytes obtained from BLV+PL animals produced greater amounts of  IL-2 
than BLV+AL and BLV- groups, although no differences were observed in the expression of 
IL-2 receptors. The development of uncontrolled lymphocytosis in BLV-infected cattle may 
result from an altered responsiveness to IL- 2-regulated B-lymphocyte proliferation (Sordillo 
et al., 1994). 
BLV shows a shift in cytokine profiles from TH1 to TH2 as disease progresses in 
serologically positive animals to PL.  As BLV progresses and reaches persistent 
lymphocytosis with tumor formation, TH1 cytokines decrease and Il-10 (produced by 
monocyte/macrophages) becomes a prominent regulatory cytokine.  Il-10 inhibits other 
cytokines expression, especially TH1 cytokines, and reduces expression of major 
histocompatibiltiy complex class II molecules (mainly on macrophages) to inhibit antigen 
presentation.  This may cause reduced Il-2, Il-6, and IFN-γ production.  Il-10 also induces 
programmed cell death in TH1 cells.  Early in BLV infection TH1 cells may be activated, and 
later these activated TH1 cells undergo programmed cell death, reducing Il-2 and IFN-γ 
(Splitter, 1997). Late-stage BLV infected animals demonstrated considerably more IL-
10mRNA expression from PMBC than BLV negative or early-stage infected animals (Pyeon 
et al., 1996).   As the disease progressed, the type 1 cytokines, Il-2 and IFN-γ, decreased. 
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Another study of cytokine profiles in bovine leukemia virus was undertaken by Amills et al. 
(2002), where the contribution of CD4+ cells to IFN-γ, IL-2, IL-4, and IL-10 mRNA 
expression in BLV-infected cattle was evaluated. Encoding mRNA levels were measured in 
fresh and activated PBMCs and purified CD4+ T cells using semiquantitative reverse 
transcription-polymerase chain reaction RT-PCR) assay. Cells were collected from 
seronegative (BLV-), seropositive without persistent lymphocytosis (PL-), and seropositive 
with persistent lymphocytosis (PL+) animals. All of the cytokines, with the exception of IL-
10, had a significant reduction in mRNA expression in PBMC of PL+ cows when compared 
to negative controls. Reduced IL-2 and IL-4 mRNA expression was also detected in fresh 
CD4+ T cells from PL+ cows. It was determined that the differences seen in CD4+ T cells 
were not due to changes in the frequency of cells transcribing IL-2 and IL-4 mRNA, but to 
changes of mRNA levels expressed by individual cells. No significant difference in mRNA 
expression was observed between the two groups of BLV infected cattle. The authors 
concluded that as BLV progresses to PL, both TH1 and TH2 cytokines expression is reduced 
in CD4+ cells. 
Peripheral blood lymphocytes from bovine leukemia virus (BLV)-negative and BLV-
infected cows were evaluated for expression of B and T lymphocyte subset-specific 
molecules and co-expression of the interleukin-2 receptor alpha (IL-2Rα) molecule. Results 
demonstrated enhanced mitogen-induced expression of the IL-2Rα molecule on B 
lymphocytes from BLV+ lymphocytotic cows.  Lymphocytotic cows were characterized by 
sustained elevations in CD5+ B lymphocytes and showed significantly elevated numbers of 
CD3+, CD4+, and CD8+ T lymphocytes. These results suggested that B lymphocytes from 
BLV+ lymphocytotic cows were more sensitive to activation signals and up-regulation of the 
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IL-2 signaling pathway than lymphocytes from BLV-free cows, and that T lymphocytes may 
be involved in the aberrant regulatory pathways underlying BLV-induced persistent B 
lymphocytosis (Stone et al., 1994). 
 In a study of the effect of BLV on the immune system of experimentally infected 
calves, lower levels of secretory IgM and a decrease in T lymphocytes (mainly CD4) in 
peripheral blood were demonstrated (Trainin et al., 1995).  BLV-Infected animals showed 
diminished responsiveness to newly encountered antigens.  Higher levels of cytokines were  
found in the sera of BLV-infected cows compared to noninfected animals. 
 IL-10 produced by TH2 helper T cells, B cells, and macrophages inhibited cytokine 
production by TH1 cells and enhanced B-cell proliferation and differentiation. Pyeon et al.  
(1996) demonstrated that PBMC from BLV-infected animals in the late stages of disease 
expressed considerably more IL-10 mRNA than animals not infected or  in the early stages of 
disease. In contrast, TH1 cytokines IL-2 and IFN-γ decreased with disease progression.   IL-
10 was observed to be expressed principally by monocytes/macrophages in PL animals, 
indicating that B cell proliferation does not cause the IL-10 expression seen in BLV disease 
progression.  Keefe et al. (1997b) examined the effect of BLV on cytokine production. 
Mesenteric and supra-mammary lymph nodes were obtained from nine cattle. Three were 
non-infected controls, three were BLV-positive AL, and three were BLV-positive PL. 
Mononuclear cells were perfused from the organs and total RNA extracted and cDNA levels 
were normalized to enable a semi-quantitative assessment of cytokine gene transcripts. IL-2, 
IL-10 and IFN-γ message was detected in the T-cell fractions of all of the BLV- infected 
animals, but not in the non-infected controls. The potential role of aberrant cytokine 
production in the pathogenesis of bovine leukemia virus (BLV) was also studied  (Keefe et 
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al., 1997), analyzing cytokine mRNA expression in pokeweed-stimulated PBMCs of cows in 
different phases of disease progression. Using a semi-quantitative RT-PCR assay,  IL-2, -4, -
6, -10, -12, IFN-γ and actin were detected using cDNA derived from phorbol-stimulated 
PMBC. Using a PCR specific for BLV tax, agar gel immunodiffusion and white blood cell 
counts, BLV-negative, BLV-positive AL, and BLV-positive PL cattle were identified. 
Peripheral blood lymphocytes cultured in vitro for 24 h in pokeweed mitogen to facilitate 
non-specific T- and B- cell activation were analyzed for cytokine production using the RT-
PCR assay. Consistently elevated levels of IL-2 and IL-12 in AL and PL cattle in were 
detected, while IFN-γ was elevated in the AL but not the PL cattle (probably from 
significantly lower numbers of T-cells in PL cattle). Il-4 and IL-10 levels were 
indistinguishable between all 3 groups. 
 Since infection with BLV results in deregulation of the host immune system at both 
humoral and cellular levels, Meirom et al. (1997) investigated  the role that cytokines play in 
the pathogenesis and immune response of BLV infected animals.  They found that the levels 
of IL-6 in the sera of BLV+ PL+ were significantly higher than  BLV+ PL- or  BLV- cows. 
Spontaneous production of IL-6 in peripheral blood mononuclear cells (PBMC) was also 
higher in BLV+PL+ cows.  PBMC derived from BLV+PL+ cows secreted higher levels of 
IL-6 and TNF alpha than those derived from BLV+PL-  and BLV- ones after in vitro 
exposure to the BLV gp51 antigen, bacterial endotoxins (LPS) and ConA. Similar results 
were obtained when supernatants from stimulated monocytes, macrophages, B and T 
lymphocytes were tested. Exogenous IL-6 and TNF alpha strongly suppressed viral antigen 
expression in BLV infected cells in vitro. Elevated production of IL-6 and TNF-α may well 
play a role as contributing factors to the latency of clinical expression in BLV infection. 
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Isaacson et al. (1998) observed that a group of cattle experimentally infected with 
bovine leukemia virus (BLV) had enhanced antibody responses to recall antigens. None of 
the cattle in this group were classified as PL, but they did have significantly increased 
numbers of circulating T and B cells.   Freshly isolated PBMC from BLV-infected cattle 
were found to contain a significantly higher percentage of B cells that expressed MHC II 
molecules (p<0.01). In addition, an increased proportion of CD4+ T cells from BLV-infected 
cattle expressed increased MHC II molecules on both CD4+ (p<0.01) and CD8+ (p<0.05) T 
cells from BLV-infected cattle after 68 h in vitro, even in the absence of exogenous mitogen.  
An increased percentage of B cells from BLV-infected cattle expressed CD25 after 20 h of 
culture, either in the presence (p<0.05) or absence (p<0.01) of Con A. Thus, in addition to 
causing alterations in absolute numbers of circulating lymphocytes, BLV infection appears to 
cause a functional activation of both B and T cells, even in AL cattle.  BLV-induced 
alterations in lymphocyte activation status may contribute to the enhancement of antibody 
responses in vivo. 
    In a study of BLV effects on cytokines, Pyeon and Splitter (1998) discussed the  
effects of IL-12  on various cells including T cells, NK cells, and B cells.  IL-12 has 
proinflammatory and immunoregulatory effects on TH cell responses inducing T-cell 
differentiation and proliferation and cytokine production in mature TH1 cells.  IL-12 inhibits 
type 2 cytokine production.  The cytokine profile shift from type 1 to type 2 may result 
directly from cytokines produced by viral infection or viral load.  Type 1 cytokines activate T 
cells which may be eliminated by programmed cell death, exhausting the type 1 immune 
response.  No BLV antigen preferentially stimulating type 2 cytokine production is known.  
However, evidence exists that other viruses including HIV have naturally occurring variants 
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that antagonize cytotoxic T-cell responses.  Some mutant viral antigens can alter binding 
affinity of peptides to MHC molecules or alter T-cell receptor recognition.  This may occur 
with BLV; infection persists for years, and could allow accumulation of proteins with altered 
peptides that differ in affinity to MHC molecules or T-cell receptors.  Infected animals with 
minimal antigenic variation might have high affinity to cellular receptors causing type 1 
cytokines to predominate.  After variants with low-affinity peptides are generated, the T-cell 
response might alter to production of type 2 cytokines as disease progresses to persistent 
lymphocytosis. 
The expression of IL-2, IL-4, IL-10, and IFN-γ mRNA in stimulated  PBMC from PL 
BLV-infected cows, AL BLV-infected cows, and uninfected cows was measured (Trueblood 
et al., 1998). IL-2 and IL-10 mRNA expression and IL-2 functional activity were 
significantly increased when PBMC from PL cows were stimulated with ConA. During 
persistent lymphocytosis, peak IL-2 and IL-10 mRNA expression was delayed and elevated 
expression was prolonged.  Isolated B lymphocytes from PL cows did not have consistently 
inducible detectable changes from human recombinant IL-10 (rhIL-10).   RhIL-2 increased 
viral protein (p24) and IL-2 receptor expression were seen in isolated B lymphocytes from 
PL cows. RhIL-2 and supernatant from ConA-stimulated T lymphocytes enhanced B-
lymphocyte proliferation, but the stimulation could be completely inhibited with a polyclonal 
anti-rhIL-2 antibody.  Spontaneous proliferation of PBMC was inhibited by anti-rhIL-2 and 
anti-BLV antibody from PL cows. Spontaneous lymphoproliferation characteristic of BLV-
induced persistent lymphocytosis is IL-2 dependent and antigen dependent. Increased T-
lymphocyte expression of IL-2 in BLV-infected cows contributes to development and/or 
maintenance of persistent B lymphocytosis. 
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1.7. Initial Reports on BIV  
BIV is a nonacute pathogenic lentivirus of cattle associated with chronic immune and 
central nervous system lesions. It is the most complex of the nonprimate lentiviruses and 
strongly resembles the primate lentiviruses HIV-1 and SIV. BIV was first described in the 
USA in 1969 from a cow (R29) with a wasting condition from field work by Dr. Cameron 
Seger, a veterinarian at the Louisiana State University Agricultural Cener, and his 
collaborator, Dr. Martin Van Der Maaten from the National Animal Disease Center. Dr. Van 
Der Maaten  isolated and initially characterized the virus. The initial case, an 8-year-old 
pregnant Holstein, had elevated white cell counts, and a deteriorating condition resulting in 
her death after delivery. On necropsy, enlarged lymph nodes were found with a generalized 
follicular hyperplasia of lymph nodes and perivascular cuffing in the brain. The virus induced 
syncytia formation in cell culture and was designated bovine visna virus. It was the third 
distinct lentivirus discovered after equine infectious anemia, and ovine lentivirus. It has been 
designated as BIV since Gonda  found it structurally, immunologically and genetically 
resembled human and simian immunodeficiency viruses (Gonda et al., 1994).    In calves 
inoculated with the R29 isolate the virus could be recovered 8 to 12 weeks later. Calves 
showed a lymphoproliferative reaction that resulted in significant enlargement of lymph 
nodes and a mild lymphocytosis.  R29 has been passaged many times and has been adapted 
to grow in a canine thymus cell line. Some R29 stocks may be contaminated with Bovine 
viral diarrhea virus (Brownlie et al., 1994). 
BIV is now known to be an RNA lentivirus of the family Retroviridae with 
worldwide distribution. There are three major structural proteins, gag, pol, and env.   The 
BIV Gag precursor can be processed into three major proteins BIV codes gag, pol, and env 
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structural genes and also encodes vif, tat, rev, vpw, vpy, and tmx. This precursor is involved 
in virus particle assembly and is further processed into the matrix (MA), capsid (CA), and 
nucleocapsid (NC) functional domains in the mature virus. Gag determinants are also found 
in the gag-pol polyprotein precursor(Lu et al., 2002).   Nonstructural/accesory genes and the 
long terminal repeat (LTR) of lentiviruses play an important role in regulating virus gene 
expression and pathogenesis (Fong et al., 1995). 
Lentivirus disease has been described as primary and secondary. Primary disease is 
found in all tissues and is associated with increased viral replication in macrophage 
populations in affected tissues.  Secondary disease is associated with viral replication in 
CD4+ lymphocytes and immune suppresssion and seen only in primate and feline lentivirus 
infections (Carpenter et al., 1992). Specific viral receptors by which many lentivirsues target 
cells for infection are still largely unresolved.  In ungulates, the viruses show a tropism for 
cells of the monocyte/macrophages lineage, while in species where lentiviral infection causes 
immunodeficiency virus, there is also a tropism for T lymphocytes.  BIV has been isolated 
from PBMC, lymph nodes, liver, and spleen.  Examples of BIV being associated with 
immune defects include a decrease in lymphocyte blastogenesis response to mitogens and 
infection and dysfunction of monocytes but not T-cells. While there seems to have no effect 
on leukocytes populations, a significant depletion in CD4+ cell staining within various lymph 
nodes at the time of peak viremia has been observed (Heaton et al., 1995). In brief, SIV has 
been associated with immunodeficiency, neuropathologic changes, wasting, and 
opportunistic infections. Human immunodeficiency virus has the same associations plus 
Kaposi’s syndrome. Characteristics of ovine lentivirus include progressive lethal pneumonia, 
chronic encephalomyelitis, spasticity, paralysis, lymphadenopathy, mastitis, generalized 
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wasting, and opportunistic infections. Similar symptoms without pneumonia plus progressive 
arthritis are characteristics of caprine arthritis encephalitis virus. Equine infectious anemia 
virus presents a  different picture with fever, persistent viremia, hemolytic anemia, 
lymphoproliferation, immune-complex glomerulonephritis, and  CNS lesions. Feline 
immunodeficiency virus shows symptoms similar to HIV with immunodeficiency-like 
syndrome, generalized lymphadenopathy, leukopenia, fever, anemia, emaciation, 
opportunistic infections. 
Bovine immunodeficiency virus  and Jembrana disease virus (JDV) are closely 
related bovine lentiviruses.  Jembrana disease has clinical signs of fever, lethargy, anorexia, 
and enlargement of superficial lymph nodes. There was a 17% mortality in Bali cattle 
experimentally infected with Jembrana disease and persistence of the virus for at least two 
years after infection. Leukopenia, thrombocytopenia, increased blood urea and decreased 
plasma protein were found. Major pathological findings included lymphoproliferation, 
lymphocytic infiltration into most organs, and generalized hemorrhaging.   Jembrana disease 
does not cause acute clinical disease in European cattle (Bos taurus).  Recently a monoclonal 
antibody (MAb; MAb 10H1) against the BIV Gag protein identified a differential epitope 
located at the 6.4-kDa N terminus of a 29-kDa Gag capsid protein (Lu et al., 2002). 
1.8 BIV Transmission 
BIV shows wide tropism for CD3+,CD4+ , CD8+, and B cells, monocytes, and WC1 
cells, including γδ T cells and null cells. Lentiviruses are typically spread through sexual 
contact, contaminated blood, or from mother to offspring either in utero or via contaminated 
milk or colostrum. There is evidence for in utero and postnatal transmission of SIV from 
infected female monkeys.  Maedi/visna virus in sheep and caprine arthritis-encephalitis virus 
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in goats are both efficiently transmitted via colostrum and/or milk.  EIA has also been 
reported to be transmitted in utero and by milk, but inoculation is more important.  Insect 
transmission has been documented.  In a study of FIV transmission, 4 queens were inoculated 
with FIV immediately postpartum; and all four developed FIV infection as determined by the 
presence of provirus in PBMC at 2 weeks post infection and the development of FIV-specific 
antibodies.  Sixteen kittens were delivered from the four females and were evaluated for FIV 
infection every 2 to 3 weeks starting from birth. Ten of sixteen kittens developed FIV as 
determined by FIV provirus in PBMC and by antibody detection.  Kittens developing 
infection had higher proportions of CD4+ and Pan-T+ lymphocyte subsets at birth. The 
CD4+/CD8+ ratio did not differ (Sellon et al., 1994).   BIV transmission may be horizontal 
and may be environmentally influenced by blood sucking insects as in EIA and BLV (Coats 
et al., 1994).  BIV was found in bull serum as evidenced by PCR of a 235-base pair highly 
conserved domain of the BIV pol gene.  Nine of 11 bulls had the target sequence in seminal 
leukocyte DNA.  BIV has been detected in bovine mammary leukocytes.  Pooled colostrum 
and milk may lead to widespread transmission.   Twenty cows sired by semen of positive 
bulls were 45% seropositive for BIV (Nash et al., 1995). Vertical transmission of BIV has 
been documented (Scholl et al., 2000). BIV is transmitted experimentally by intravenous 
inoculation of infected whole blood and cell-free and cell-associated virus. BIV is more 
prevalent in dairy than beef herds; and it is postulated that practice management techniques 
unique to dairy herds might contribute to disease spread, in particular, shared palpation 
gloves and needles, and colostrums pooling. Cell-associated BIV and cell- free BIV were 
subjected to increasing temperatures, including pasteurization conditions (Moore et al., 
1996). To determine the effect of heat treatment on BIV viability, reverse transcriptase 
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activity and infectivity of the heat-treated virus were assessed. BIV was inactivated by 
heating to 47ْ C for 30 min and by low - and high-temperature pasteurization conditions. 
(Venables et al., 1997) determined that BIV in milk was inactivated by pasteurization. Three 
groups of three calves were inoculated with virus (BIV isolate FL112), milk seeded with 
virus, or milk seeded with virus that had been pasteurized before inoculation. Seroconversion 
to BIV was monitored for 12 months by IFA. The presence of BIV proviral DNA in 
peripheral blood was determined by nested PCR. The animals were euthanized and virus 
isolation and PCR was attempted on PMBC, prescapular lymph nodes and spleen. 
Transmission of BIV was confirmed in the groups that were inoculated with the virus and 
with the virus in milk, but no evidence of its transmission was demonstrated in the group that 
received the pasteurized milk. 
1.9 Chronological Highlights in BIV Research 
 In 1987, Gonda characterized and molecularly cloned BIV. Studies of experimental 
inoculations and natural infection have continued since viral isolation. In 1990, Whetstone 
found humoral antibodies (primarily to p26) and virus in experimentally infected calves. 
Using IFA and Western immunoblot assays, antibodies could be detected from 2 weeks to 
2.5 years postinoculation. Antibodies were also found in sera from naturally infected cattle 
(Whetstone et al., 1990). In a follow up study, a cocultivation method was used to establish a 
cytocidal bovine immunodeficiency-like virus (BIV) infection in primary fetal bovine lung 
(FBL) cell cultures.   Pelleted virus preparations from FBL-BIV cell cultures were used to 
produce an antigen for Western blot. Sheep and goats were inoculated with BIV and serum 
antibody responses were monitored up to 1 year afterwards. Sera from experimentally 
infected cattle, sheep, and goats reacted in Western blot assay with BIV viral induced 
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polypeptides. Antibodies to p 26 were detected as early as 2 weeks postinoculation in all 
three species. The last antibodies detected were to gp 110; detection was by 4 to 6 weeks 
postinoculation in cattle, and by 9 months in sheep and goats. Antibodies to BIV proteins 
were still evident in cattle sera 2.5 years postinoculation, 1 year postinoculation for the 
smaller ruminants (Whetstone et al., 1991).  
  An early study of the impact of BIV infection on the bovine immune system was 
carried out by Martin et al (1991). The study evaluated the lymphocyte transformation 
responses of male Holstein calves inoculated with BIV strain R-29 to three mitogens at two 
and six months postinoculation.  By six months, the response to all three mitogens was 
diminished compared to control animals and remained depressed 10 months  postinoculation. 
These results demonstrated functional impairment of lymphocytes early in the course of BIV 
infection and prior to the onset of clinical disease. T cell depletion was not observed as a loss 
of CD4+ cells did not occur. However, a slight decrease in CD8+  cells was seen. Co-factors 
such as BLV may have contributed to disease progression in vivo. 
Kashanchi et al. (1991) infected embryonic bovine lung cells with BIV and were able 
to detect infection at 24 h. They optimized the detection of BIV RT, but found no active 
infection of human cells by BIV when PCR or RT was used. Also in 1991, the prevalence of 
BIV in the Netherlands was examined using Western blot based on serum of a calf after 
experimental BIV infection. When 957 randomly collected cattle sera from The Netherlands 
were tested by indirect immunofluorescence and confirmed using Western blot and/ or 
radioimmunoprecipitation, 1.4% appeared seropositive  (Horzinek et al., 1991). 
Encephalitis, lymphoid tissue depletion and secondary infections occurred over a 5-
yr-period in Holstein cows infected with BIV (Snider, III et al., 1996).   The encephalitis was 
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characterized by meningeal, perivascular, and parenchymal infiltration with lymphocytes, 
occasional plasma cells and macrophages with  perivascular edema. Affected areas had no 
recognizable distribution pattern and included the cerebrum, cerebellum, and spinal cord.  
The lymphoid depletion was primarily an absence of follicular development in nodes 
draining regions with secondary infections. A primary depletion of T cells was suggested by 
a scarcity of lymphocytes in thymic-dependent regions of lymph nodes.  Secondary 
infections included mastitis and pododermatitis, with many cows having non-responsive 
abscesses, cellulitis and myositis attributed to injection site infections. A large number of the 
cattle had parturition difficulties such as dystocia, obturator paralysis, and metritis.   Four of 
59 cattle had lymphosarcoma. The herd size throughout the year was 75-85 in  the milking 
herd.  Cows were bled annually to measure antibodies to BIV and BLV using ELISA and 
WB technology.   In the spring of 1991, 103/134 (77%) animals were dually infected. 
 The early pathogenic effects of BIV were studied in by Carpenter et al. (1992) in 
calves experimentally inoculated with BIV. All of the animals inoculated with BIV R29- 
infected cells seroconverted by 6 weeks postinoculation, and BIV was recoverable from each 
animal at 2 weeks postinoculation.   Levels of BIV replication in vivo appeared to be low, 
since during peak periods of viral replication in vivo, less than 0. 03% of peripheral blood 
mononuclear cells expressed detectable levels of viral RNA.  Inoculated calves had 
significantly higher numbers of circulating lymphocytes, and follicular hyperplasia was 
observed.  The histopathological changes occurred early in infection and were similar to 
changes found after infection with  HIV-1 and FIV. Clinical changes could not completely be 
ascribed to BIV and  might have been due to BVDV. 
The first isolation of BIV in Australia was in 1992(Forman et al., 1992). Sixty serum 
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samples were collected from two dairy herds in Victoria and another 60 from four dairy 
herds in Queensland, Australia.  These herds were found to have antibody to bovine 
lentivirus on both  ELISA and western blot.  A prevalence of antibody to the virus between 
7-17% was found, indicating the presence of a bovine lentivirus in Australia. 
 A study that demonstrated that BIV could be activated by bovine herpesvirus type 1 
(BHV-1), a pathogen frequently associated with cattle diseases, bears directly on this 
dissertation and the measurement of BIV infected cows response to BHV-1 vaccination. 
Activation of BIV expression was detected as increased BIV reverse transcriptase activity, 
increased  number of syncytia induced by BIV, and increased steady state level of BIV-
specific RNA upon BHV-1 super-infection. Additional  quantitative transactivation studies 
using the BIV-LTR (long terminal repeat) were conducted.  When the transfected cells were 
infected by BHV-1, there was an increase in chloramphenicol acetyl transferase gene (CAT)  
expression, indicating transactivation of the BIV-LTR by BHV-1.   Results showed that 
BHV-1 infection resulted in  binding to the NF-kappa B-like sequence on the BIV-LTR,  
suggesting that transactivation of BIV by BHV-1 may be mediated by a bovine NF- kappa B-
like protein that binds to the target sequence in the BIV promoter region (Geng et al., 1992). 
BIVs interaction with other viruses was examined in a Canadian study (Jacobs et al., 
1992). In the study, cattle (n=39) were examined for bovine syncytial virus (BSV) and BLV 
too. BIV antibodies were detected by Western blot.  Twelve had anti-BSV antibodies, 5 had 
antibodies to both BSV and BIV, and 4 had both BSV and BLV antibodies.  Only 1 animal 
had antibodies to both BIV and BLV. No sole BIV infection was found. A previous study 
found BLV to be the most common retroviral infection of dairy cows, and that BIV was most 
often found in association with BLV(Jacobs et al., 1992). 
 45
 In a 1992 study at Hokkaido University, three calves were experimentally inoculated 
with BIV.  Inoculated calves produced a specific antibody that could be detected from 3 to 5 
weeks up to 1 year  postinoculation.  Using syncytia assay, virus was isolated from PMBC 3 
to 4 weeks postinoculation to the terminus of the study.    BIV could be isolated from 
monocytes, but not from T cells, and monocytes could be infected with BIV in vitro. Various 
monocyte functions of these BIV-infected calves and age-matched uninfected calves were 
tested: superoxide anion release, phagocytic activity, and chemotactic responsiveness of 
monocytes were depressed in BIV-infected calves compared with control calves. A slight 
delay in the humoral immune response against mouse serum protein was also evident. During 
the one year observation period, no significant clinical symptoms could be observed. One 
calf was euthanized at 15 months postinoculation.; BIV was  isolated from PBMC as well as 
from cells of the spleen, liver, and lymph nodes (Onuma et al., 1992)     
Characterization of the BIV gag gene encoding a 53- kDa precursor (Pr53gag) was 
reported in (Battles et al., 1992). The BIV MA, CA, and NC gag proteins were identified as 
p16, p26, and p13, respectively. In addition to BIV Pr53gag, the major gag precursor, two 
other gag-related precursors of 170 and 49 kDa were identified.  Several alternative gag 
cleavage products were also observed.   The monospecific antisera to human 
immunodeficiency virus type 1 CA (p24) and NC (p7) proteins showed cross- reactivity to 
and aided in the identification of analogous BIV proteins. Based on the data, a scheme for the 
processing of BIV Gag precursors was created. 
In 1993, Archambault et al. (1993) reviewed the progress shown in studies on BIV 
from 1990-1991 and up to mid-1992. At that time, the genomic sequences of BIV had been 
analyzed in detail with several subgenomic RNA identified. Nucleic acid molecular probes, 
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PCR amplification and a Western blotting were used for experimental diagnosis of BIV.  
Antibodies to p26 antigen were always demonstrated in naturally and experimentally infected 
animals. The experimental infection of sheep, goats and rabbits was confirmed. They 
reported no pathognomonic clinical signs in cattle and sheep for at least 3 and 4 years, 
respectively.    
 In 1993, Flaming et al. (1993) studied the effect of BIV infection on the bovine 
immune system in three groups of cattle. Groups were evaluated at various stages of 
postinoculation, 0- 2 months  (Group 1), 4-5 months  (Group 2), and 19-27 months 
postinoculation (Group 3). BIV infected animals were inoculated with the R-29 isolate of 
BIV by various methods. Most inoculated animals seroconverted to BIV as determined by 
Western immunoblot and demonstrated virus. BIV infection was associated with an increase 
in the lymphocyte blastogenic response and  decreased neutrophil antibody dependent cell 
mediated cytotoxicity in Groups 2 and 3. Neutrophil iodination was decreased only in Group 
3. All animals were clinically normal during the evaluation periods.  
In 1993, identification of transactivation-response sequences in the long terminal 
repeat of bovine immunodeficiency-like virus was perfomed by Carpenter et al. (1993). 
Additional work on a PCR for bovine immunodeficiency-like virus was done (Nadin-Davis 
et al., 1993). Two pairs of oligonucleotide primers directed to regions of the gag and pol 
genes generated the expected PCR products from molecular BIV clones and from DNA of 
BIV-infected cell cultures. Uninfected cultures did not generate PCR products.  
An Escherichia coli recombinant fusion protein containing the major core protein of 
BIV was used to immunize mice for generation of monoclonal antibodies to BIV p26. Eight 
hybridomas specific for BIV p26 were identified; and two antibodies, designated 104 and 
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142, were further characterized and isotyped as IgG1. The antibodies reacted specifically 
with both BIV p26 and the recombinant fusion protein in Western immunoblot analyses.   
Immunoperoxidase assays were used to determine if either antibodiy 104 or 142 could detect 
BIV replication in cell culture. Both antibodies reacted with BIV-induced syncytia and BIV-
infected cells. The antibodies were also used successfully in a focal immunoassay for 
quantitation of BIV- infected cells (Wannemuehler et al., 1993).   
In a study to associate BIV with clinical disease, the deaths of over 30 adult cattle  
from a single herd in 1990-1991 were investigated.. A variety of clinical signs were reported 
including masititis, pneumonia, chronic pododermatitis, lymphadenopathy, and 
lymphosarcoma. In many of these cattle, brain lesions characterized by slight to moderate 
lymphocytic meningitis and lymphocytic perivascular were found.   Many animals in the 
herd were dually infected with  BIV and BLV (Snider, III et al., 1993).  
In 1993, two new isolates BIV were found in Florida (Suarez et al., 1993).  These 
were the first new isolates since the original R29. The isolates were derived from buffy coat 
cells cocultivated in vitro with fetal bovine lung cell cultures.  The new isolates differed from 
R29 by having higher cocultivation rates, longer incubation times between passage, 
decreased number of nuclei per syncytium with greater granularity and slower lysis of the 
syncytia. When compared to a molecular clone of BIV R29 (BIV R29-127), homology of pol 
gene product showed a 92.6 and 93.6% agreement with the published nucleotide sequence of 
BIV R29-127.  
A 1994 review article on BIV was prompted by a report in the British press of a 
Cheshire herd with wasting disease from BIV (Connor, 1994). Seroprevalence in healthy 
cattle in Britain was estimated to be 1 to 5% but individual herds with chronic undiagnosed 
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disease were postulated to have an incidence of 30 to 50%.  The article postulated a 
difference in European and American BIV isolates and suggested further study was 
warranted  (Brownlie et al., 1994). 
BIV was also reported in Germany in 1994. Serum samples from 380 cattle were 
analyzed for  BIV antibodies by focus immunoassay (cell- ELISA) and immunofluorescence 
assay (IFA). All specimens originated from dairy farms in the eastern part of Germany: the 
cattle were clinically healthy and free of BLV and BVDV antibodies. The seroprevalence of 
BIV antibodies was 6.6%, as determined by cell-ELISA. Comparison of IFA and cell-ELISA 
showed that all IFA positive sera were also positive in cell-ELISA, but some IFA negative 
sera were cell-ELISA positive.  This was the first report of BIV infection in German cattle; 
no association with clinical disease was reported (Muluneh, 1994). 
In a further attempt to create a screening test for BIV, TrpE fusion protein was used 
to identify nine different recombinant clones spanning various regions of the BIV envelope 
gene open reading frame.  These clones span the entire external glycoprotein as well as the 
transmembrane glycoprotein region. These proteins were expressed at various levels, as 
fusions to the TrpE protein in E. coli.   A recombinant env protein representing the 
extracellular domain of the env protein was detected by BIV-infected bovine sera; and a 134 
amino acid peptide located at the amino terminus of the transmembrane glycoprotein and 
specifically recognized by all BIV-infected calf sera tested was identified (Chen et al., 1994). 
A key report on BIV in 1994 reported a cumulative BIV seroprevalaence of 50% found 
 in Mississippi animals with  BIV seroprevalence increasing with  age (Coats et al., 1994). 
  Peripheral blood leukocytes of age-matched BIV seropositive and seronegative 
animals did not differ in total leukocyte populations or leukocyte populations at time zero or 
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one year later.  Sera was cryopreserved and screened for BIV using an ELISA. The antigen 
evaluated was a recombinant BIV gag protein from the National Cancer Institute with a 
molecular weight of 53 Kda and antigenically analogous to the native viral protein.  One 
dairy herd had a 64% incidence of BIV with a high incidence of lymphosarcoma, 
lymphadenopathy, and persistent health problems.  Seventy-four% of this herd was 
seropositive for BLV. In addition, a 21% seroprevalence of BIV was reported in a Colorado 
dairy herd, 40% and 64% in beef and dairy herds from Louisiana, respectively (Coats et al., 
1994). 
 A 1994 review article on the molecular biology and virus-host interactions provided a 
historical review, discussion on clinical and pathological features, possible modes of 
transmission, molecular biology, and host – virus interactions. Some of the problems 
enountered in determining the significance of BIV natural infection include high turnover 
rate of cattle in herds from production demands and the unknown effect of disease 
progression with BLV coinfection (a common situation in many BIV positives) (Gonda et al., 
1994).  
A review of BIV diagnosis, prevalence and pathogenesis was compiled by Suarez et 
al. (1994).  BIV structural proteins gag, pol, env and  nonstructural regulatory proteins (tat, 
rev) were described, with  the tat protein function’s to upregulate BIV's LTR expression.  
The rev regulatory protein is localized in the nucleus like HIV and thought to be important in 
viral regulation.   Western immunoblot was reported as a highly specific and sensitive test 
able to detect the presence of viral polypeptide-specific antibodies with results that are 
reliable, but the test is cumbersome.  Sole use of the major core p26 gag protein in the 
Western blot decreased sensitivity in experimentally inoculated cattle.  ELISA testing was 
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highly sensitive but false positives were common.  IFA was difficult to interpret and 
cumbersome.  Nested PCR detected BIV early in infection before viral isolation was 
possible, and later in infection when antibodies and virus fell below detectable levels.   
In a study of BIV infection in three experimentally infected calves, Baron et al. 
(1995), found the virus to be transcriptionally active in experimental infection.    Two primer 
pairs located in the gag and pol regions of the viral genome detected the viral genomic DNA 
by PCR, as well as the unspliced genomic viral RNA transcript, by RT-PCR.  Using reverse 
transcription followed by nested PCR, an mRNA transcript of the regulatory trans-activator 
tat gene was found in PBMC. Virus was sequentially rescued from unstimulated PBMCs in 
cell culture, from 4 weeks until 15 months following the infection. 
Jembrana disease virus, the cause of an acute, severe disease in Bali (Bos javanicus) 
cattle in Indonesia was shown to have 74% nucleotide sequence identity with BIV.  The 
pathogenesis of Jembrana disease differs markedly from that reported for BIV 
infection(Chadwick et al., 1995). 
Serological (Western blot) detection of bovine immunodeficiency- like virus (BIV) in 
Holstein dairy herds was reported in Costa Rica for the first time in 1995.  The virus was 
isolated  from a seropositive bovine by cocultivation of PBMC with embryonic rabbit 
epithelial (EREp) cells. The isolated strain was named BIVCR1 and reacted similarly in 
Western blot as the reference strain BIV R29. An association between BIV and BLV 
infections was suggested. 
The development and persistence of virus-specific antibodies were investigated by 
Isaacson et al. (1995) in eight cattle experimentally infected with the BIV R29 virus.  By 4 
weeks postinfection antibodies reactive to BIV gag- and env-encoded recombinant fusion 
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proteins were detectable by immunoblotting in all animals. By 40 weeks postinfection, seven 
of eight cattle had dramatically decreased gag-specific antibodies: and anti-gag reactivity 
remained very low or undetectable through 190 weeks postinfection while virus was still 
recoverable from PBMC.   Antibodies to a recombinant BIV env protein were readily 
detectable throughout the study in all eight cattle. Interestingly, the single animal that 
maintained detectable anti-gag reactivity throughout the study was repeatedly negative for 
virus recovery beyond 17 weeks postinfection. All animals remained clinically normal for 
over 4 years postinfection, with no evidence of consistent changes in mononuclear cell 
subsets. These findings suggest that diagnostic testing would be better focused on env 
protein. 
The effects of BIV on monocyte function were examined in experimentally infected 
cattle and in monocytes infected in vitro. Infection with the R29 isolate of BIV appeared to 
have relatively little effect on monocyte function in cattle during the first 2 years 
postinfection. For the first 4 to 8 months postinfection, monocyte phagocytosis of 
Staphylococcus aureus tended to be lower (P = 0.06) in BIV infected calves than in control 
animals. After 8 months PI, however, phagocytosis became equal between the two groups. 
Monocytes from BIV infected cattle responded to in vitro treatment with IFN-γ similarly to 
monocytes from control cattle.  Experimental infection with BIV R29 had minimal effects on 
monocyte function. This may have been the result of a low virus burden in vivo or because 
BIV is unable to affect monocyte function.  Monocytes from control, uninfected cattle were 
treated with BIV virus in vitro. Treatment of normal monocytes with cell-free virus 
significantly increased phagocytosis  in a dose-dependent manner.  The authors concluded 
that normal function of peripheral blood monocytes in the BIV R29 infected animals may be 
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due to a low virus burden rather than an inability of BIV to affect monocyte function (Rovid 
et al., 1995). 
Bovine paraplegic syndrome (BPS) is a debilitating cattle disease of unknown origin 
that is characterized by leukocytosis, lymphocytopenia and monocytopenia that has a 
postulated association with BIV (Walder et al., 1995).  Clinical signs include difficulty in 
locomotion and hypoalgesia  in the hind quarters, posterior paralysis and death within 72 to 
96 hours after recumbency.  Serum samples (n = 1,278) were collected from both healthy and 
BPS-prevalent cattle herds in Venezuela, and organ extracts were prepared from euthanized 
animals (n = 11) suspected of having BPS. Sera were analyzed for reactivity to recombinant 
BIV and BLV gag precursor proteins by immunoblot procedures. Serum reactivity to BIV 
ranged from 12-66% between groups of BPS prevalent herds. The percentage of samples 
reactive to BLV antigen was much lower (2-17%).  
Suarez et al. (1995) compared methods of BIV detection and developed nested PCR 
for BIV.   Some of the first serologic tests for BIV detection were the protein immunoblot 
assay in which pelleted virus was used as the antigen and the indirect fluorescent antibody 
(IFA). Virus isolation was also used, but was difficult and unreliable. A more accurate test 
for BIV detection was necessary. The nested PCR test was designed to decrease false-
negatives and false-positives. The use of 2 sets of primers (pol, env) based on different areas 
of the BIV genome, the use of multiple primer pairs and the use of multiple samples 
decreased the possibility of a false-negative. Primers were designed to amplify 2 separate 
regions of the pol and env segments of the BIV genome. Two calves were experimentally 
infected, one with an isolate derived from R29 and one from a field isolate FL491. Nested 
PCR detected BIV infection by 3 days after experimental inoculation, earlier than both virus 
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isolation and protein immunoblot. Infected cattle were identified 9 to 15 months after 
inoculation by PCR even when virus isolation and serology was negative.   
BIV infection has been reported in Costa Rica, with most BLV-infected animals 
seropositive for BIV. Experiments were designed to evaluate the effect of BLV on mitogen-
stimulated  PBMC from naturally infected cattle (Hidalgo and Bonilla, 1996).   Dually-
infected cattle (BIV-BLV) had reduced lymphoproliferative responses to the mitogen Con A.  
Leukocytosis and lymphocytosis were both observed and cows with lymphosarcomas were 
severely affected.   Due to the high rate of dual infections observed in Costa Rica, these 
results were not seen as sufficient to clarify if BLV or BIV was responsible for the 
suppressive activity or if they acted synergistically. 
A serological survey for BIV infection was performed in cattle on 3 different farms in 
Hokkaido, Japan, where a relatively high seroprevalence of BLV exists. About half of 120 
cattle tested were seropositive for BLV, while 7. 5% of the cattle were seropositive for BIV. 
Though increased numbers of leukocytes were frequently observed in BLV-seropositive 
cows, no such changes were observed in BIV-positive BLV-negative cows. No correlation 
was demonstrated between BIV- and BLV-seroprevalence.  Calves inoculated with BIV 
developed a mild lymphocytosis and a moderate lymphoproliferative reaction in the small 
subcutaneous lymph nodes (Hirai et al., 1996).  
Nested PCR detected BIV in the organs of two experimentally infected cows 
maintained without clinical symptoms of BIV infection for 28 months (Tajima et al., 1997).  
Virus and provirus were continuously detected from peripheral blood leukocytes.  Provirus 
was found in the liver, lung, and spleen of both cows, and in the brain of one animal.  Virus 
was also detected in the liver and lung of one cow, and the spleen of both animals.  
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   The first serologic detection of antibodies to bovine immunodeficiency virus (BIV) 
in France was reported in 1996 (Polack et al., 1996). Serum samples from dairy and beef 
cattle from southwestern and western France were tested using a western blot assay with a 
recombinant 53 kDa gag precursor derived from the Louisiana BIV R29 isolate.  A study was 
performed on the oldest animals from 37 different herds that were under serologic follow up 
for previous BLV infection. Overall, 398 selected bovine sera were assayed and 15 serum 
samples from 8 herds reacted with the recombinant 53 kDa BIV R29 gag protein.  Reactions 
obtained with French sera were weaker than with positive Louisiana sera, possibly indicating 
the occurrence of distinct French and Louisiana BIV variants. 
In 1996, Rovid et al. (1996) reported that an 11-month-old Holstein calf 
experimentally infected with BIV ( but BLV-) developed T-cell lymphosarcoma 5 months 
postinoculation, concurrent with a progressive monocytosis.  CD2+, CD4-, CD8- T cells 
tumors were found in the thymus, multiple lymph nodes, and brain. Infectious BIV was 
recovered from splenic tissue and blood mononuclear cells.   Neutrophil and monocyte 
functions were normal; however, lymphocyte blastogenesis was enhanced before the 
development of lymphosarcoma. Follicular hyperplasia in lymphoid tissues was also 
observed.  BIV infected cattle have lower neutrophil antibody-dependent cell-mediated 
cytotoxicity 2-4 years post infection. In a study by Flaming et al. (1997) BIV infection was 
not associated with any long-term significant changes in lymphocyte blastogenesis or 
mononuclear cells.  BIV infections could be associated with decreased neutrophil iodination 
and lymphocyte blastogenesis.  Co-infection with BIV and BLV did not consistently cause a 
different response than either virus considered separately.   
Supernatants from BIV-infected cells have been previously shown to affect monocyte 
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random migration, chemotaxis, phagocytosis, and antibody- dependent cell-mediated 
cytotoxicity (ADCC) in vitro.  Rovid and Roth (1997) demonstrated that BIV Gag (core) 
proteins can enhance monocyte random migration, chemotaxis, and phagocytosis.   A 
recombinant Gag protein, consisting primarily of BIV p26, also enhanced monocyte random 
and chemotactic migration.   Direct treatment with affinity-purified BIV Gag proteins or a 
recombinant Gag protein appeared to significantly affect the function of normal monocytes 
in vitro.   
Since R29 is believed to be attenuated and no longer associated with increases in 
mononuclear cell number or lymphatic enlargement in experimentally infected cattle, 
Whetstone et al. (1997) examined host cell tropism and changes in host peripheral blood 
lymphocyte populations using the field isolate FL112. This isolate is known to cause a 
transient, mononuclear cell lymphocytosis in experimentally infected cattle. After inoculation 
with BIV FL112, data from flow cytometry showed that BIV caused a B-cell lymphocytosis 
with no consistent, significant changes in other mononuclear cell populations, including 
CD3+, CD4+, and CD8+ cells. Cell sorting and PCR amplification demonstrated  proviral 
DNA was present in CD3+, CD4+, CD8+, and B- cells, monocytes, and WC1 cells (γ/δ T 
cells, null cells) by 3 to 6 days postinoculation and also at 2.5 years postinoculation. 
A western blot assay using purified recombinant BIV gag protein was developed   for 
detection of BIV antibodies in bovine serum samples (Zhang et al., 1997). The test was 
standardized with known BIV virus positive and negative bovine serum samples and the 
monoclonal antibody to gag protein. Both naturally and experimentally infected cattle sera 
demonstrated positive test results. The result of western blot assay was compared with PCR 
test results in 134 blood samples collected from Kansas. Twenty-six samples (18.7%) tested 
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positive for bovine immunodeficiency virus DNA with polymerase chain reaction and 25 
(17.9%) were positive for the antibody to gag protein by western blot analysis. Of 26 cattle 
testing positive using PCR, 24 were antibody-positive by western blot assay, thus 
establishing a strong correlation between the two tests. The sensitivity and specificity of 
western blot relative to polymerase chain reaction were 0.92 and 0.99, respectively. In 
another study, Zhang et al. (1997a ) detected proviral DNA from BIV in the tissues and cells 
of neural tissues and some lymphoid tissues in BIV-infected calves.  It was also found in 
lung, heart, esophagus, and pancreas.   Zhang et al.(1997b) also designed a study to evaluate 
the effect of BIV infection on immune function and across the possible interaction between 
BIV and other bovine viruses in calves. Increased lymphocyte proliferation to BIV gag 
protein was demonstrated 2-6 weeks after BIV inoculation (P < 0.05).  A decreased 
CD4/CD8 ratio (P < 0.05) occurred during weeks 2 to 7, suggesting a possible immune 
dysfunction in BIV-infected calves. When the calves were inoculated with bovine 
herpesvirus type 1 (BHV-1), the antibody response to BHV-1 in BIV-infected calves was 
delayed; and the antibody titers were significantly lower (P < 0. 05). Injection of bovine viral 
diarrhea virus vaccine also elicited a lower neutralizing antibody response in BIV- infected 
calves, all indicating that immune suppression occurred in BIV-infected calves. 
In 1998, Cavirani et al. (1998) reported the first serological detection of antibodies to 
BIV in Italy.  A stratified-random sampling of dairy cattle reared in the Parma area had sera 
from 3166 cows belonging to 272.  Of the animals tested, 2.5% of individual animals, and 
5.8% of herds were positive.  When bulls from 2 artificial insemination centers were tested, 
5.1% were positive for BIV-R29 by IFA.   Cows selected for the study were 6 - 10 years of 
age, for presumed greater clinical consequences of BIV infection.  No differences were 
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demonstrated in total and differential leukocyte counts between BIV positives and negatives.   
 Jacobs et al. (1998) found the rate of BIV infection among a sample of 100 bulls from 
Ontario stud farms to be 9.6% using serology, and 12.6% when tested by PCR for the 
presence of BIV provirus in peripheral blood leukocytes. Previously, the frequency of BIV 
infection among the general dairy cow population in Ontario was estimated at 5.5% and was 
based on serological analysis. Apparently, serological testing detected only 77% of BIV-
infected bulls. PCR was thought to be the best method to identify BIV- infected individuals. 
More recently, Gonzalez et al. (2001) examined the large cattle industry in western Canada 
for the presence of BIV.   Genomic DNA, derived from semen and buffy coat samples, was 
analyzed by nested polymerase chain reaction (PCR) using specific primers for the gag, pol, 
and env genes of BIV.  BIV sequences were not amplified in any of 317 buffy coat and 50 
semen samples collected from different sources in Alberta (1980-1999). In the 367 DNA 
samples examined, there was no evidence of BIV infection, suggesting that the prevalence of 
BIV infection was very low. 
Zhang et al. (1998) developed an ELISA for rapid detection of BIV antibodies using 
the gag coding region cloned into an expression vector expressed from E. coli.   A BIV 
monoclonal antibody to gag protein was used as a control.  ELISA and western blot were 
found to be equally specific, but ELISA was quicker and easier. 
A 120-amino-acid polypeptide selected from the transmembrane protein region (tTM) 
and the major capsid protein p26 of bovine immunodeficiency-like virus (BIV) were 
expressed as fusion proteins from recombinant baculoviruses by Abed et al. (1999).  One 
hundred and five bovine serum samples were tested for the presence of anti-BIV antibodies 
by the recombinant protein-based Western blot and a reference Western blot assay. There 
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was a 100% concordance when the p26 fusion protein was used in the Western blot. 
However, the Western blot using the tTM fusion protein as its test antigen identified four 
BIV-positive bovine sera which had tested negative in both the p26 recombinant-protein-
based and the reference Western blot assays.   The results of this study showed that the 
recombinant p26 and tTM proteins are useful as test antigens for the serodetection of BIV-
infection in animals. 
Munro et al. (1998) used the Florida strain 112 of BIV, to infect three groups of three 
calves. Group A received the virus as a subcutaneous injection, group B received virus 
suspended in milk, and group C received virus pasteurized in milk before inoculation.  
Necropsies were performed 12 months post immunization.  Subtle ataxia was found in two 
group A calves in the form of shifting leg lameness, and there was palpable enlargement of 
prescapular lymph nodes was found in one animal from group B.  Enlarged hemal lymph 
nodes were palpated in groups A&B, and histopathological examination showed hyperplastic 
changes in the lymph nodes.  The two clinically ataxic animals from group A had 
hyperplastic lymph nodes and a non-suppurative meningo-encephalitis. The 
lymphoproliferation with R29 has lessened from multiple culture passages and considerable 
variation in lymphoid hyperplasia now occurs with experimental R29 infection. The new 
strains (FL112, FL191) have caused transient mononuclear cell increase early in infection 
and induced mild to significant follicular hyperplasisa and non-suppurative pervascular 
cuffing in the cerebrum.   No evidence of replication of BIV in germinal centers was found, 
suggesting that lymphoid hyperplasia was not caused by local antigen production.  It was 
postulated that immune dysfunction associated with interference of cytokine regulatory 
pathways might be a contributor to lymphoid hyperplasia.   
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 Isaacson et al. (1998a) examined immune responses in cattle 3-5 years after 
experimental inoculation with BIV R29 and/or BLV.  Antigen specific antibody and 
lymphocyte proliferative response were measured following vaccination with tetanus toxiod 
(TT) and BHV-1.  Lymphocytes from BIV-infected cattle had significantly reduced 
proliferative responses to Con A. BIV infection had little effect on TT-specific antibody 
responses in vivo.  In contrast, BLV-infected cattle had increased secondary antibody 
responses to vaccination with TT as well as enhancement of antibody responses to BHV-1.  
Coinfection with BIV did not alter response to BLV.   Lymphocytes from BLV-infected 
cattle had slightly increased proliferative responses to Con A, but no consistent alterations in 
response to allo-MHC, TT, or BHV-1.    
BIV testing of 266 sera, from 20 dairy and 26 Korean native beef farms revealed a 
prevalence of 35% and 33% of dairy and beef  respectively (Cho et al., 1999). Nested PCR 
was used to confirm that seropositive cows had provirus in PBMC. There were relatively few 
dual infections with BLV with an incidence of 5-13% in dairy cattle and 0-15% in beef 
cattle.   BIV seroprevalence in dairy cows ranged from 15-56% and 19-67% in beef cattle 
when divided into districts.  Seropositive farms for BIV by district ranged from 50-83% for 
dairy farms and 56-100% for beef farms..   Seroporevalence of BLV by district ranged from 
15 -67% in dairy cattle and 0-66% in beef cattle, while 5-13% were dually infected.  A 
greater percentage of BIV positive cows were BLV seronegative.   
The development of the antibody response to peptides of the transmembrane 
glycoprotein of BIV was followed by over a period of 50 weeks in six cattle experimentally 
infected with the BIVFL112  isolate (Scobie et al., 1999). The TM glycoprotein of the envelope 
of BIV was used, as it was thought to be a suitable target for antiviral antibodies since the 
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TM proteins of all lentiviruses have common structural features and contain 
immunodominant B-cell epitopes. The assay was specific for BIV, detecting antibody in 
bovine to sera to BIVFL112 or BIVR29, but not to six other common viruses of cattle.  Antibody 
was present in the sera of all cattle inoculated with BIVFL112 within 4 weeks of infection, 
peaked between 10-30 weeks, and persisted in most cattle during the 50 weeks of 
observation.  Peptides were synthesized using the available sequence of TM glycoprotein of 
BIVR29. A cyclic and linear form was developed.  Two of the three cattle inoculated with 
BIVR29  reacted with the peptide EIA.  Control cattle had no response.  Cattle positive to 
other common bovine viruses did not react.   Antibody response to the linear peptide peaked 
during the period of 10-30 weeks after infection but persisted after 50 weeks.  This timing 
corresponded with presence of proviral DNA in peripheral blood and seroconversion to BIV 
(determined by IFA).  The linear and cyclic peptide had 87% similarity. Antibodies to p26 
the major BIV capsid protein, persisted for more than 2 years after inoculation of 
experimentally infected cattle, while anti-p26 antibodies were detected 2 weeks after 
infection and peaked at 6-9 weeks. Fifty percent (2/4) of the cattle tested had no detectable 
antibody 19-38 months post-infection as determined by WB and IFA.  Using gag and env, a 
strong antibody response to both was detected 5 weeks after infection with R29.  All cattle 
reacted to env for over 4 years after infection with BIV but lost response to gag after about 6 
months. 
In a study to document the presence of BIV in semen, Gradil et al. (1999) inoculated 
five 18-24-month-old bulls were inoculated with either a cell suspension containing bovine 
immunodeficiency virus (BIV-FL112; 3 bulls) or a BIV-free cell suspension (2 bulls). Blood 
and semen specimens were collected once a week for 14 weeks, and seroconversion was 
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confirmed by IFA testing. The presence of BIV in blood and semen was determined by virus 
isolation and/or PCR assays. Antibodies to BIV were detected in the 3 experimentally 
infected bulls as early as day post inoculation (DPI) 17, and levels peaked at DPI 37-58.   
PCR detected virus PBMC in all three of the experimentally infected bulls from DPI 9 until 
the termination of the experiment at DPI 98.  Additionally, 30 bulls from artificial 
insemination  centers were evaluated for BIV infection by PCR with negative results.  
Recently BIV has been found in Pakistan and Cambodia. A survey of antibodies to  
BIV and BLV  was conducted by with samples from water buffalo and cattle populations in 
Pakistan (Meas et al., 2003). A total of 370 water buffaloes and 76 cattle were tested, and 
10.3% and 15.8%, respectively, were found positive for anti-BIV p26 antibodies determined 
by Western blotting, while 0.8% of water buffaloes and no cattle were positive for anti-BLV 
antibodies.   In Cambodia, (Meas et al., 2000) studied the prevalence  of antibodies to  BIV 
and BLV in draught animals in five provinces in Cambodia,. A total of 544 cattle and 42 
buffaloes were tested, including Haryana, Brahman, mixed-breed, local breed cattle and 
muscle water buffaloes; and 26.3 and 16.7%, respectively, were found positive for anti-BIV 
p26 antibodies determined by Western blotting. There were 5.3% positive for anti-BLV 
antibodies among the cattle, but no reactors among buffaloes and no dual infection for both 
BIV and BLV.   The first seroepidemiological study of  BIV and BLV infections was 
conducted in four different cattle herds in Turkey by (Meas et al., 2003). A total of 300 blood 
samples were analyzed, and 12.3% were found to be positive for anti-BIV p26 antibodies by 
Western blot analysis and 1.6% positive for anti-BLV gp51 antibodies by immunodiffusion. 
In all of the above studies by Meas et al., BIV infection was confirmed with the detection of 
BIV-provirus DNA using nested PCR.   
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Antibodies directed against two bovine lentiviruses, Jembrana disease virus (JDV) 
and  BIV, were detected in Balinese cattle sera by (Barboni et al., 2001) using two new  
ELISAs. The arrays were based on the combination of capsid (CA) protein and 
transmembrane (TM) peptides derived from JDV or BIV sequences. Twenty-eight (36%) of 
the 77 sera tested on the JDV ELISA showed anti-JDV antibodies with an unequal 
distribution of seropositive animals throughout the different districts of Bali.The ELISA was 
a more sensitive technique for the detection of seropositive animals. Nine of the 49 JDV 
seronegative animals showed anti-BIV antibodies when tested on BIV-specific ELISA. This 
was the first report of BIV in Bali. 
Another first report of BIV infection in a country was by Meas et al. (2002a). They 
were the first to perform a cross-sectional study to assess antibodies to BIV and BLV in six 
different herds in Brazil.  Out of a total of 238 sera analyzed, 11.7% were found positive for 
anti-BIV p26 antibodies using Western blot analysis, while 2.1 % were positive for anti-BLV 
gp51 antibodies using immunodiffusion test. Amino acid sequences of Brazilian pol gene 
products showed 98-100% homology to the American strain BIV R29, while homogeneity to 
the Japanese BIV isolates were 97 to 99%. Divergence between Brazilian BIV isolates from 
0 to 4%.   
Scobie et al., (1999) estimated the prevalence of BIV in Great Britain by randomly 
testing sera from 971 adult cattle from 49 herds; 50% were from beef and 50% were from 
dairy herds.  Sera were tested for antibodies to the transmembrane protein of BIV using a 
highly-specific enzyme immunoassay. The resulting seroprevalence was 5.9% in dairy cattle, 
and 5.0%  in beef cattle.  No statistically significance difference was found between 
individual locations, and there was no evidence of prevalence increasing with age. 
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In 2000, an ELISA was established for rapid detection of specific BIV antibodies in 
cattle using recombinant Gag protein as antigen.   A total of 139 cattle serum samples from 
diagnostic laboratories at Kansas State University and LSU were compared by ELISA and 
immunoblot assays for detection of BIV-specific antibodies.  Twenty-six (19%) sera samples 
were positive using immunoblot, 23 (17%)  positive by ELISA. The sensitivity and 
specificity of the ELISA, relative to immunoblot, was 0.88 and 0.93.  Recombinant-protein-
based ELISA eliminated the use of native viral protein.which is difficult to produce, and the 
prokaryotic expression system has a high level of protein expression which improves the 
specificity. No reactivity was seen in animals infected with BVDV and BLV.  Ten BIV 
positive and negative serum samples tested for BIV antibodies with WB and ELISA were 
identified correctly.  When field samples were used, discrepancies occurred. There were 8 
ELISA positive samples that were WB negative and 3 ELISA negative samples that were 
WB positive.   The 8 positives were weakly positive, and the three negative ELISA were near 
the negative cut off point. The presence of other closely related retrovirus antibodies in field 
serum samples might have interfered with the BIV test, resulting  in false-positives. The 
World Health Organization recommends using 3  specific tests for HIV testing; WB, ELISA, 
and PCR. The use of three tests was necessary here to confirm indeterminate ELISA profiles 
(Zheng et al., 2000). 
Bielanski et al. (2001)  conducted experiments to determine if BIV was likely to be 
transmitted via embryo transfer.  Twelve single embryos collected from experimentally BIV 
infected donors were transferred to BIV-negative recipients resulting in the birth of 7 BIV 
negative calves. The recipients also remained BIV-negative throughout the experiment, and 
demonstrated that it is possible to produce transferable stage embryos from donors infected 
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with BIV, and that such embryos are unlikely to transmit this agent either to the recipients or 
the resulting offspring. 
Recent studies have confirmed vertical transmission of BIV. Vertical transmission of   
BIV was investigated   in five dairy cattle herds in Hokkaido, where 17.0% of cattle were  
BIV seropositive and 9.9% of dams were co-infected with both BIV and BLV (Meas et al., 
2002).  Offspring born from dams infected with both BLV and BIV (9 cases) were examined 
for the presence of BLV and BIV by PCR and syncytial assay before and after feeding 
colostrum.  After birth, all calves were separated immediately from their dams. In the case of 
offspring born from dams co-infected with BLV and BIV, calves were BIV positive before 
colostrum feeding at 1 day after birth, indicating in utero transmission of BIV.   These results 
suggested that BIV can be transmitted to offspring in utero. Another study (Moody et al., 
2002) explored whether BIV is vertically transmitted in naturally infected dairy cattle.  
Twenty-two dam/calf pairs from a Mississippi Agriculture and Forestry Experiment Station 
dairy were studied with blood samples collected following delivery of calves;  PCR of 
leukocyte DNA was used, targeting the pol gene region of the BIV provirus.  Southern 
blotting and hybridization were used to confirm BIV specificity.  BIV provirus was detected 
in 14 of 22 calves (64%) demonstrating vertical transmission. Six PCR-positive calves were 
born to PCR-negative ( but serologically positive) mothers with five PCR-positive cows 
producing PCR-negative calves.   Eight calves were disqualified because of the possibility of 
colostrum ingestion.  Transplacental transmission of BIV was identified in 6 of 22 calves 
(27%). 
 During a one month period, 16 cows were removed from a dairy herd with endemic 
BIV infection and euthanized due to one or more disease conditions. The duration of clinical 
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disease  ranged from 3 to 40 weeks. With the BIV ELISA, 11 (69%) were positive, 4 (25%) 
were negative, and one (6%) juvenile was not tested.   Four animals were positive for non-
cytopathic BVDV and one was  positive for cytopathic BVDV.  Five of 16 (31%) were 
negative for BIV provirus in all of the tissues examined; four of five (80%) PCR negative 
cows were positive by ELISA for serum BIV antibody (Snider, III et al., 2003b). The 
clinical, serological, and pathological abnormalities observed in Holstein cows naturally 
infected with BIV and other infections were progressive and most commonly associated with 
weight loss, lymphoid system deficiency and behavioral changes. Clinical evidence of 
meningoencephalitis presented with dullness, stupor, and occasional head or nose pressing 
postures. BIV provirus was detected in the central nervous system and lymphoid tissues. 
Multiple concurrent infections developed in retrovirally infected cows undergoing normal 
stresses.   (Snider, III et al., 2003a) also found BIV in cows associated with morphologic 
evidence of lymphoid organ deficiency in Holstein cows housed under normal management 
practices. During clinical disease there was marked weight loss and wasting with frequent 
and sever concurrent infections. Lymphoid follicular hyperplasia and dysplasia in lynph 
nodes, and hypertrophy and hyperplasia in hemal lymph nodes were characteristics of the 
lymphoid tissues. Lymphoid pathology included atrophy of lymphoid cell compartments with 
depletion of lymphocytes and lymphocytic lymphoid folliculitis.   Nodal tissues lesions 
resembled those observed in feline, simian, and human lentiviral disease. Unresolving 
multiple bacterial infections were correlated with immune system deficiency. Further study 
of clinical effects of BIV infection as well as clinical effects of dual infection with BLV are 
warranted. Disruption in cytokine profiles and humoral immunity as seen in HIV infection 
may indicate potential for BIV to contribute to decreased production or clinical disease.   
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CHAPTER TWO 
EVALUATION OF ELISA BASED DIAGNOSTIC TESTS USED IN THE DANISH 
BVDV ERADICATION PROGRAM 
 
2.1 Introduction 
Bovine viral diarrhea virus (BVDV), can present as an endemic disease with a small 
number of persistently infected (PI) animals serving as the main source of transmission 
(Houe, 1999). It is a single-stranded RNA virus, and a member of the Pestivirus genus of the 
family Flaviviridae. BVDV is separated into two biotypes, cytopathic (CP) or noncytopathic 
(NCP), characterized by the presence or absence of visible cytopathic effects in infected cell 
cultures.  PI cattle have only NCP biotypes (Houe and Palfi, 1993). In Denmark, many herds 
without PI animals contained a high proportion of antibody carriers among the older cow 
population (Houe et al., 1993). Calves born to a PI dam always become persistently infected; 
however, calves born to a previously exposed but not persistently infected dam may also be 
born persistently infected. Acutely infected animals will shed virus, but only in small 
amounts for approximately 2 weeks.  PI animals older than two months of age are almost 
always negative for antibodies to BVDV, but have a constant high level of virus in blood, 
milk, saliva, feces, and urine (Sandvik, 1999). Many European countries have BVDV 
eradication or control programs. Sweden was one of the first countries to begin eradication in 
1993 with a prevalence of approximately 65% of all herds having infected cattle. By 2001, 
87% of herds were BVDV-free. Because the cattle population in Sweden was widely 
dispersed and contact between herds could be controlled, it was and has remained a country 
where BVDV vaccination is not used.  Regardless of the vaccination practices, the first step 
in any countrywide eradication program is identification and removal of persistently infected 
animals; vaccination as a method of control depends on the density of the cattle population, 
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the seroprevalence of BVD, and the means of funding (government or cattle industry). In 
high density areas with high seroprevalence, infection control can minimize economic loss 
by reducing the number of PI animals and decreasing new infection (Greiser-Wilke et al., 
2003). Cattle are believed to have a lifelong humoral immune response following BIV 
infection. Known responses include antibodies to virus-encoded proteins including surface 
glycoprotein gp53 and highly immunogenic non-structural catalytic serine protease NS2-3. 
Similar responses are observed after modified live BVD virus vaccine. With natural 
infection, a rapid seroconversion occurs, and stable virus neutralization titers persist for three 
or more years (Graham et al., 2003). As Denmark does not vaccinate against BVD, the 
presence of antibodies to BVD are indicative of exposure (Houe et al., 1995) 
Two approaches exist for detection of BVDV, one is to detect exposure, the other to 
detect PI animals. Antibodies to BVDV can be detected in serum or milk and represent 
exposure to virus. Detection of BVDV antigen indicates PI. The traditional test for detection 
of BVDV antibodies has been the virus neutralization test (VNT). Since the early 1990s, 
several ELISAs to detect antibody have been developed. Tests have been directed against 
monoclonal antibody (e.g.non-structural protein NS2-3) or pooled monoclonals. Most have 
been serum based. A few have been designed for whole blood or pooled or individual milk 
samples. For a more thorough review see (Beaudeau et al., 2001). For screening non-
vaccinated milk herds, bulk tank milk ELISA testing is the most economical procedure, as it 
can detect recent exposure and may indicate PI animals in the herd. For BVDV antigen 
detection, indicative of PI animals, recently reverse transcriptase-polymerase chain reaction 
(RT-PCR) has been used to detect BVDV antigen in bulk milk samples for PI detection. It 
requires the isolation of somatic cells from milk samples. Tissue Culture Isolation Technique 
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(TCIT) has been the standard for detection of BVDV antigen in PI animals; antigen ELISAs 
have been developed for individual serum testing (Greiser-Wilke et al., 2003). 
In 1994, the Danish farmers’ organization decided to initiate an eradication program 
for BVD.  Prior to that, pilot studies had demonstrated the reliability of two new diagnostic 
tests, the antigen ELISA to detect presence of BVDV and the antibody ELISA to detect 
exposure to BVDV.  Before the start of eradication, the annual risk of infection was 34% for 
non-infected animals, and bulk tank milk testing of all Danish dairy herds indicated 39% of 
herds had persistently infected animals. Annual national losses in 1992 were estimated to be 
US$ 20 million  (Houe, 1999). Because young PI animals can be virus negative (due to 
blocking with maternal antibodies), and because of the need to identify recently acquired 
infections, 3 calves, 8 to 12 months of age (ideally between 8 and 10 months) were tested for 
antibody and antigen as part of yearly herd tests in herds that failed or did not provide a bulk 
milk test  (Rønsholt et al., 1996b). In 1999, 9% of dairy and 5% of beef herds still had PI 
animals, and previously BVDV-free herds were re-infected. Re-introduction occurred 
through purchase of pregnant cows, common grazing, and PI animals in nearby fields. New 
regulations on animal movements, and pasturing were implemented (Greiser-Wilke et al., 
2003).  By August 2000, the number of dairy herds registered as infected was down to 4% 
with 2% of beef herds registered as infected. Only 1% of dairy herds had undetermined status 
(not tested within the past 12 months) compared to 12% of beef herds. (K.B. Larsen, personal 
communication).   
The purpose of this study was to estimate more precisely the diagnostic accuracy of 
two tests for detection of exposure to and infection with BVDV, namely the antibody ELISA 
and the antigen ELISA developed by the Danish Cattle Health Laboratory (DAHL).  The 
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antibody ELISA was a blocking ELISA based on polyclonal antibodies from two 
antigenically different BVDV strains. The antigen ELISA was based on polyvalent 
hyperimmune sera from swine and rabbits and used the sandwich principle for antigen 
detection (Rønsholt et al., 1996a).These tests were necessary as part of an eradication 
program that would permit detection and removal of viremic animals from unvaccinated 
populations.  In addition, prevalence of BVD in the tested population was estimated as well. 
The original standardization data of the two ELISAs (antibody to virus neutralization (VNT) 
and antigen to tissue culture (TCIT) were used to estimate each test’s performance in a two 
test and two population setting by ML estimation described by (Hui and Walter, 1980) for 
two tests in two populations.  Bayesian analysis using Gibbs sampling was also applied and 
conditional dependence of antibody ELISA to VNT and antigen ELISA to TCIT was 
evaluated. 
  Bayesian methods also exist for the estimation of test parameters and disease 
prevalence for one or more tests applied to one or more populations. These methods were 
used to estimate individual test performance in a single population, using simultaneous 
inferences about the population prevalence and test sensitivity and specificity gathered using 
the Gibbs sampler.   The Bayesian approach does not require normal distribution 
approximations to derive confidence interval(Joseph et al., 1995). Using data available, the 
performance of each individual test was estimated for each quarter year between 1 January 
1995 and 1 October 2000. Sub-samples of the entire population were examined to determine 
the effect of sample size on assay performance and assay performance in specific populations 
including the sentinel population of 8 to 12 month old calves and separate evaluation of test 
performance in beef and dairy cattle populations. 
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 As the test discussed here were to be used for the eradication of BVDV in Denmark, 
accurate estimations of their sensitivity and specificity was necessary. Original estimation of 
ELISA tests parameters was done with the corresponding reference test (VNT or TCIT) 
considered a gold standard. These estimates had to be confirmed to assure the diagnostic tests 
would not produce a large amount of false negatives leaving infected animals in the herd, nor 
false positives with large numbers of healthy animals destroyed. Bayesian techniques were 
used to estimate test performance in two test and two populations and in one test and one 
populations. 
2.2 Materials and Methods 
2.2.1 Validation of ELISA Tests Created by DAHL   
The Danish Cattle Health Laboratory developed two ELISAs (one antigen, one 
antibody) for detection of persistent infection with or exposure to BVD.  These assays were 
tested in 1992 and 1993, and employed in 1994 when control and eradication of BVD in 
Denmark was begun.  BVD became a notifiable disease in Denmark with mandatory testing 
and removal of PI animals.   VNT and TCIT are considered the established reference test 
methods for antibody and antigen detection, respectively. Their accuracy may be influenced 
by various factors including the susceptibility to infection of the cell cultures, the cell culture 
medium, the test protocol, as well as test materials. The complications involved in using 
these two “gold standards” for large population testing suggested the need for a faster, less 
complex test such as an ELISA (Sandvik, 1999). The BVD antibody blocking ELISA was 
used on serum/plasma to control infection status of individuals or herds, and on bulk tank 
milk to control the infection status of dairy herds. The BVD antigen ELISA was used on the 
leukocyte fraction from stabilized blood samples in the control of PI.  The BVDV antigen 
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ELISA had a sensitivity of 97.9% and specificity of 99.7% relative to TCIT when tested on 
4161 blood samples from Danish cattle. The BVDV antibody ELISA had a sensitivity of 
96.5% and specificity of 97.5% relative to the VNT when tested on 3718 sera.   
2.2.2 Description of Data Set 
The data set used for this study consisted of all test results of diagnostic assays for 
BVDV processed through the DAHL from January 1, 1995 to October 1, 2000.  Data 
available at the individual animal level included current herd, animal, breed, date of birth, 
sex, date of blood sample, results of antigen and/or antibody ELISA blood testing, and at the 
herd level, date and result of milk testing. The data set was comprised of 1,200,000 
individual bovines from 40,000 herds. Dairy herds represented approximately 30% of herds 
tested. In September 2000 there were 9,760 dairy and 22,486 beef herds registered in 
Denmark. 
2.2.3 Maximum Likelihood Estimation of Test Sensitivity and Specificity  
For comparison with posterior error distributions for parameters estimated by 
Bayesian estimation, data from the original validation (Rønsholt et al., 1996a) of the antigen 
ELISA to TCIT and of the antibody ELISA to VNT were used (Table 2.1). Original 
estimates of assay performance assuming VNT and TCIT as gold standards are reported in 
Table 2.2. Estimates of sensitivity and specificity were determined for each test using the 
methods of Hui and Walter (1980) for two tests and two populations (Table 2.3) 
2.2.4. Bayesian Estimation of Test Sensitivity and Specificity   
Each test parameter was transformed into a beta prior density by matching the starting 
point estimate to the mean of the beta distribution, given by α/(α+ β) and matching one 
quarter of the total range with the standard deviation of the beta distribution and solving for 
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α and β. The standard deviation of the beta distribution is (αβ/((α +β)2(α + β + 1)))1/2.   
Priors for Bayesian analysis were loosely based on MLE results and are as follows; [Antigen 
Elisa (population 1 prevalence 0.19 ± 0.04, population 2 prevalence 0.01 ± 0.01, TCIT 
sensitivity 0.93 ± 0.02, TCIT specificity 0.99 ± 0.01, Antigen ELISA sensitivity 0.98 ± 0.01) 
Antigen ELISA specificity 0.99 ± 0.01]; Antibody Elisa (population 1 prevalence 0.70 ± 
0.02, population 2 prevalence 0.55 ± 0.04, VNT sensitivity 0.97 ± 0.02, VNT specificity 0.99 
± 0.01, Antibody ELISA sensitivity 0.96 ± 0.02, Antibody ELISA specificity 0.99 ± 0.01. 
Non-informative priors were used to evaluate the effect of prior belief about diagnostic test 
performance and population prevalence on parameter estimation. The conditional 
independence of the ELISA antibody to virus neutralization and the ELISA antigen to tissue 
culture were evaluated, and conditional correlation Bayesian model estimates were obtained 
using methods developed by (Georgiadis et al., 2003) and compared to those obtained in the 
simpler Bayesian model (Table 2.3). For the relationship between VNT and ELISA, both 
negative and positive correlation 95% credible intervals embraced zero, so the original 
Bayesian estimation would be acceptable. For the comparison of TCIT and ELISA, the 
positive correlation 95% credible interval embraced zero. 
Table 2.1 
Test comparison Danish Ag ELISA compared with the tissue culture isolation technique 
(TCIT) and Danish Ab ELISA compared with the virus neutralization test (VNT) by separate 
populationsa
 TCIT1   TCIT2  
Ag ELISA Positive Negative Ag ELISA Positive Negative
Positive 94 7 Positive 47 6
Negative 3 452 Negative 0 3352
 
 VNT1   VNT2  
Ab ELISA Positive Negative Ab ELISA Positive Negative
Positive 2483 72 Positive 500 11
Negative 96 1067 Negative 18 432
adata from Rønsholt et al.,1996. 
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Table 2.2 Original estimation of test performance from Rønsholt, L., Nylin, B., and Bitsch, 
V.,    1996a.    
Original  validation Parameter Point estimate 
Antigen ELISA 
Sensitivity 0.979 
Antigen ELISA 
Specificity 0.997 
Antibody ELISA 
Sensitivity 0.965 
Antibody ELISA 
Specifity 0.975 
 
Table 2.3 Two-test Two-population Bayesian parameter estimates with 95% credible 
intervals contrasted with Parameter estimates from Bayesian estimation with adjustment for 
test correlation, and from Maximum Likelihood estimation with 95% confidence intervals  
Bayesian 
 estimation Conditional Correlation MLE Parameter Point 
estimate 95% CI
a Point 
estimate 95% CI
a    Point 
estimate 95% CI
b
Antigen ELISA 
Sensitivity 0.982  0.964, 0.994 0.971  0.924, 0.996 0.979 0.919, 1.000
c
Antigen ELISA 
Specificity 0.998  0.996, 0.999  0.993  0.987, 0.998 0.999  0.997, 1.000
c
Antibody ELISA 
Sensitivity 0.966  0.959, 0.973  0.962  0.947, 0.972 0.963 0.945, 0.981 
Antibody ELISA 
Specifity 0.992  0.982, 0.998 0.989  0.962, 0.999 1.000  0.971, 1.000
c
aBayesian credible interval 
bConfidence interval 
cgenerated confidence interval  included values above 1.0  
The negative correlation 95% CI did not embrace zero, but was less than 10%, so the 
original Bayesian estimates were again used. A comparison of the credible intervals of the 
two Bayesian estimates illustrates the smaller credible intervals with the original Bayesian 
estimate as it uses information about both test, and not just the reference test.  
2.2.5 Bayesian Estimation by Individual Test and Quarter   
 
Bayesian techniques were used to estimate both the individual diagnostic test overall 
performance and quarterly test performance and prevalence among tested animals.  The two 
test and two population data from the initial assay validation (Rønsholt et al., 1996a) and ML 
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estimation results were used to create priors for input into the Bayesian estimation. Herd 
prevalence, negative predictive value (NPV), positive predictive value (PPV), and ELISA 
sensitivity and specificity in quarterly increments were estimated independently for each test 
using Bayesian estimation  (Joseph et al., 1995).   The unknown number of true positives in 
each cell of the two 2 x 2 tables served as the latent data (Table 2.1).  Each posterior 
distribution of prevalence, NPV, PPV, sensitivity, and specificity, given actual cell counts 
and latent data, was the product of independent beta posteriors for each parameter. 
Subsequently, prior point-estimates for Bayesian estimation of quarterly specific 
diagnostic test performance were selected based on the Bayesian two-test two-population and 
ML estimations using reference test data.  Priors used were an antibody ELISA sensitivity of 
0.975 and specificity of 0.99, and antigen ELISA sensitivity of 0.975 and specificity of 0.99.   
The range of values used as a starting point for each diagnostic test parameter was ± 0.025 
for sensitivities and ± 0.01 for specificities. Relaxed priors were used for prevalence 
estimates and were 0.5 ± 0.5 for the antibody ELISA and 0.1  ± 0.1 for the antigen ELISA.   
The same analysis was also performed using the same priors for prevalence and sensitivity, 
but with relaxed priors for specificity (0.975  ± .025).   
Test performance in small samples evaluated included a 1/100 random sampling of 
each quarter’s entries, and the entire sentinel population of 8 to 12 month old animals. In 
addition, a comparison of estimate of test performance in beef versus dairy cattle was 
performed. 
Adequacy of small sample sizes was evaluated by estimating the coverage 
probabilities for prevalence; a coverage probability of 95% or higher would indicate an 
adequate sample size. Estimates of prevalence, sensitivity, and specificity, from the Bayesian 
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one test one population quarterly ELISA antibody 1/100 random subsample estimates using 
relaxed priors, sample sizes for each individual estimate, and an assumed credible interval 
width of 0.1 for the prevalence estimate were used to examine the effect of sample size on 
prevalence estimates. (Rahme et al., 2000). Estimates of sensitivity and specificity in 10 
herds of  ≤100 head and test based antibody prevalence of 0-98% were also examined. 
2.3.  Results 
2.3.1 Maximum likelihood Estimates of Overall Test Performance 
Maximum likelihood estimation gave point estimates of antibody ELISA sensitivity 
of 96.3% and of antibody ELISA specificity of 100.0%.  For the antigen ELISA, the point 
estimate of sensitivity was 97.9% and specificity was 99.9%. When 95% confidence intervals 
were calculated for these point estimates, all but the antibody ELISA sensitivity upper limits 
ranged outside 100%. Results are reported in Table 2.3. 
2.3.2 Bayesian Estimates of Overall Test Performance 
The Bayesian point estimates and 95% credible intervals are reported in Table 2.3. 
These correspond closely to the original estimates of antibody ELISA sensitivity and 
specificity (96.5%, 97.5%) and antigen ELISA sensitivity and specificity (97.9%, 99.7%) 
resulting from the original comparison of each ELISA to its corresponding reference test 
performed during test development (Rønsholt et al., 1996a).   Both ML and Bayesian 
estimation suggested that the specificity of both ELISAs were higher than the original 
estimation when VNT and TCIT were considered gold standards. Bayesian point estimation 
of Antibody ELISA sensitivity was 0.97 and 0.99 for specificity. Antigen ELISA estimates 
were 0.98 and 0.998 respectively. These estimates were used as prior information  for quarter 
specific prevalence estimates. 
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2.3.3 Quarter Specific Prevalence Estimates 
It must be noted that prevalence estimates are not indicative of the entire Danish 
bovine population but of the sizeable percentage included in this national testing program. 
Prevalence was estimated by actual test results and compared to Bayesian one test one 
population methods. Prevalence estimates based upon the antibody ELISA (Figure 2.1) are 
significantly higher than the antigen ELISA (Figure 2.2) as the antibody ELISA is used to 
detect animals with exposure to BVDV while the antigen ELISA detects persistently infected 
animals, a much smaller percentage of animals tested. The decrease in number of animals 
exposed to BVDV as determined by presence of BVDV antibody (Figure 2.1) over the 
course of the BVDV eradication program is obvious. From January 1995 to October 2000 the 
estimated prevalence of exposure based upon the antibody ELISA in the tested population 
decreased from 60.3% to 20.3%. The Bayesian estimates of prevalence did not vary from the 
actual test results regardless of which set of priors was used. The estimated prevalence of 
persistently infected animals in the tested population based upon the antigen ELISA 
decreased from 2.41% to 0.00% (Figure 2.2). Bayesian estimation of prevalence of 
persistently infected animals gave estimates not completely consistent with actual test results 
as Bayesian estimates of prevalence of persistent infection did not always include the test 
based prevalence in its 95% credible interval nor did they include 0.00.   
2.3.4 Quarter Specific Sensitivity and Specificity Estimates 
Use of the Bayesian one test one population method allowed for estimation of 
individual test sensitivity and specificity on a quarterly basis. The effect of decreasing 
population prevalence on sensitivity and specificity was evaluated with little variation 
observed.  Using restricted priors of sensitivity 0.975 ± 0.025 and specificity of 0.99 ± 0.01, 
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estimated antibody ELISA sensitivity (Figure 2.3) was consistent across all quarters, and 
tightly centered around 0.977 with an average credible interval width of 0.048.   
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Figure 2.1 Prevalence of  BVDV exposure as determined by antibody ELISA 
Using relaxed priors (sensitivity 0.975 ± 0.025, specificity 0.975 ± 0.025, not shown) 
did not alter the estimates and estimated antibody ELISA specificity (Figure 2.4) was tightly 
centered around 0.991 with an average credible interval width of 0.019.  Using relaxed priors 
(sensitivity 0.975 ± 0.025, specificity 0.975 ± 0.025, not shown) gave a lower, but consistent, 
estimated specificity of 0.977 with an average credible interval width of 0.046. However, 
restricted priors are appropriate for use here, since we have good prior information.  
Using restricted priors, sensitivity 0.975 ± 0.025 and specificity 0.99 ± 0.01, estimated 
antigen ELISA sensitivity (Figure 2.5) was consistent across all quarters, and tightly centered 
around 0.976 with an average credible interval width of 0.049.  Using relaxed priors 
(sensitivity 0.975 ± 0.025, specificity 0.975 ± 0.025, not shown) did not alter the estimates as 
the average sensitivity was 0.977 with an average credible interval width of 0.049. Using 
restricted priors, estimated antigen ELISA specificity (Figure 2.6) was centered around 0.996 
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with an average credible interval width of 0.007. However, unlike all previous estimations, 
the width of the 95% credible interval was not consistent between quarters as the average 
credible interval width for 1995 was over 5 times that of 2000. 
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Figure 2.2 Prevalence of  BVDV persistent infection as determined by antigen ELISA 
Using relaxed priors (sensitivity 0.975 ± 0.025, specificity 0.975 ± 0.025, not shown) 
gave a lower estimated specificity consistent across all quarters as the average sensitivity was 
0.994 with an average credible interval width of 0.008. The relaxed prior gave a slightly 
lower (0.2%) estimate of specificity; yet the two CIs overlapped. 
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Figure 2.3 Bayesian estimation of the sensitivity of the antibody ELISA with restricted priors 
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Figure 2.4 Bayesian estimates of the specificity of the antibody ELISA with restricted priors 
2.3.5 Quarter Specific Negative and Positive Predictive Values 
The use of the Bayesian one test one population method allowed for the estimation of 
negative and positive predictive values for each diagnostic test per quarter.  The effect of 
decreasing population prevalence on predictive values was also evaluated.   The restrictive 
priors (sensitivity 0.975 ± 0.025, specificity 0.99 ± 0.01) showed a PPV for the antibody 
ELISA of 0.994 at the beginning of eradication, dropping to a low of 0.940 in the first quarter 
of 1999, but returning to 0.968 by the third quarter of 2000 (Figure 2.7). As the population 
prevalence decreased, the 95% CI for the PPV greatly increased, indicating more uncertainty 
about the estimates. Similar behavior was observed when test performance was evaluated in 
subgroups such as beef animals, dairy animals, and young stock (not shown).   
When more relaxed priors were used (sensitivity 0.975 ± 0.025, specificity 0.975 ± 
0.025, not shown), the range of the PPV increased although the trend remained similar. The 
NPV of the antibody ELISA (Figure 2.8) behaved as expected, increasing from a beginning 
value of 0.965 to 0.994 by the third quarter of 2000.  The 95% credible interval was much 
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wider at the start of eradication. Similar behavior was observed when subgroup test 
performance was evaluated.  
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Figure 2.5 Bayesian estimates of the sensitivity of the antigen ELISA with restricted priors 
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Figure 2.6 Bayesian estimates of the specificity of the antigen ELISA with restricted priors 
When the predictive values of the antigen ELISA were examined, the PPV of the 
antigen ELISA behaved similarly for both set of priors. A lower PPV was estimated for the 
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1st quarter 95 when relaxed priors were used (0.60 with a 95% credible interval of 0.30 – 
0.86, not shown) compared with 0.73 (0.49 – 0.91) when the more restrictive priors were 
used (Figure 2.9).   
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Figure 2.7 Bayesian Estimates of the Positive Predictive Value of the Antibody ELISA with 
Restricted Priors 
 
The trend over time in the PPV for the antigen ELISA was surprising; it actually 
increased as estimated prevalence decreased to 0.93 (0.83 – 0.98) when relaxed priors were 
used and to 0.97 (0.92 – 0.99) for the more restrictive priors.  This was surprising, as PPV is 
expected to decrease with decreasing prevalence  (Martin et al., 1987).  However, it must be 
noted that the beginning prevalence in January 1995 for persistent infection was less than 3% 
of the population sampled. The NPV of the antigen ELISA (Figure 2.10) remained near 
100% for the entire period 1 Jan 95 to 1 Oct 2000, regardless of which set of priors was used. 
2.3.6 Applications for Small Sample Sizes 
The effect of sample size on Bayesian estimation of antibody ELISA test parameters 
was examined using the relaxed priors for specificity and prevalence.  A random sub-sample 
of approximately 1/100 of each quarter’s total entries was used to evaluate the effect of 
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sample size on estimation of sensitivity and specificity.  The sensitivity of the antibody 
ELISA in the sub-sampled population was completely consistent with the entire population 
estimate across all quarters with an average of 0.977 and 95% credible interval width of 
0.048 (Figure 2.11). 
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Figure 2.8 Bayesian Estimates of the Negative Predictive Value of the Antibody ELISA 
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Figure 2.9 Bayesian Estimates of the Positive Predictive Value of the Antigen ELISA with 
restricted priors 
 
The antibody ELISA sub-sample specificity estimates from relaxed priors (sensitivity 
0.975 ± 0.025, specificity 0.975 ± 0.025, Figure 2.12) gave a lower estimated specificity that 
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was also consistent across all quarters with the relaxed prior estimates for the total 
population, as the average specificity was 0.977 with an average credible interval width of 
0.048.  In addition, estimates of sensitivity and specificity using relaxed priors in 10 herds of 
100 or fewer head and test based antibody prevalence of 0-98% were examined. 
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Figure 2.10 Bayesian Estimates of the Negative Predictive Value of the Antibody ELISA 
with Restricted Priors 
 
Despite the wide variation in prevalence, sensitivity and specificity were consistent 
with the entire population relaxed samples. Mean sensitivity of the small herd sample was 
97.73±0.12 with credible interval width 4.68±0.34. Mean specificity was 97.73±0.15 with 
credible interval width 4.71±0.33. Point estimates and credible intervals differed from whole 
population estimates by less than 1%. 
2.3.7 Performance of Tests in Specific Populations  
The antibody ELISA sub-sample specificity estimates from relaxed priors (sensitivity 
0.975 ± 0.025, specificity 0.975 ± 0.025, Figure 2.12) gave a lower estimated specificity that 
was also consistent across all quarters with the relaxed prior estimates for the total 
population, as the average specificity was 0.977 with an average credible interval width of 
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0.048.  In addition, estimates of sensitivity and specificity using relaxed priors in 10 herds of 
100 or fewer head and test based antibody prevalence of 0-98% were examined. 
Diagnostic test sensitivity and specificity was estimated for the antibody ELISA test 
in the specific population of 8 to 12 month old animals (sentinel population) by quarter. This  
population was used for herd status determination in the absence or failure of a bulk milk 
test, so it was of interest to see if the diagnostic tests were behaving consistently in this test 
population.  Using restricted priors, antibody ELISA sensitivity (Figure 2.13) and antibody 
ELISA specificity (Figure 2.14) estimates in the sentinel population were consistent with 
estimates for the entire population. The sensitivity and specificity of the antibody ELISA in 
the sub-sampled population was identical with the entire population estimate across all 
quarters with an average sensitivity of 0.977 and 95% CI width of 0.048. The antibody 
ELISA specificity had a point estimate of 0.991 and 95% CI width of 0.019.  
         Diagnostic test sensitivity and specificity was estimated for the ELISA antibody test 
in both beef and dairy populations by quarter from the 1st quarter of 1995 to the 3rd quarter of 
2000.  The Bayesian estimation of ELISA antibody sensitivity in beef and dairy herds, 
(Figure 2.17) was consistent with an average of 0.977 and 95% credible interval width of 
0.048, among both types of cattle, and identical with earlier whole population estimations.  
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Figure 2.11 Bayesian estimation of Antibody ELISA sensitivity for population subsample 
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Figure 2.12 Bayesian estimation of Antibody ELISA specificity for population subsample 
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Figure 2.13 Estimated sensitivity of Antibody ELISA in sentinel population 
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Figure 2.14 Estimated specificity of Antibody ELISA in sentinel population 
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Figure 2.15 Estimated sensitivity of Antigen ELISA in sentinel population 
Bayesian Estimation of Antigen ELISA  specificity 
in 8 to 10 month old calves 
94
95
96
97
98
99
100
1st
 qt
r 9
5
3rd
 qt
r 9
5
1st
 qt
r 9
6
3rd
 qt
r 9
6
1st
 qt
r 9
7
3rd
 qt
r 9
7
1st
 qt
r 9
8
3rd
 qt
r 9
8
1st
 qt
r 9
9
3rd
 qt
r 9
9
1st
 qt
r 0
0
3rd
 qt
r 0
0
 
 
Figure 2.16 Estimated specificity of Antigen ELISA in sentinel population 
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Figure 2.17 Estimated sensitivity of Antibody ELISA in beef and dairy cattle 
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The Bayesian estimation of ELISA antibody specificity in both beef and dairy herds, 
(Figure 2.18) was completely consistent across all quarters with an average of 0.991 and 95% 
credible interval width of 0.019 and identical with earlier entire population estimates.  
2.3.8 Adequacy of Sample Size 
 Because the database was so large, an opportunity was present to examine the effect 
of sample size on the Bayesian estimation of population prevalence. Using the one 
population one test estimates of antibody sensitivity and specificity and relaxed priors, the 
adequacy of small sample sizes was evaluated by estimating the coverage probabilities for 
prevalence; a coverage probability of 95% or higher would indicate an adequate sample size 
(Rahme et al., 2000). Sample sizes ranged from 8-642.As seen in Figure 2.20, samples of 180 
or greater consistently generated coverage probabilities of 95% or higher. This indicated a 
95% chance that the true prevalence actually fell within  ± 0.05 of the estimated prevalence, 
since a 0.1 credible interval width for the prevalence was fixed.  Smaller sample sizes were 
found towards the end of eradication, with five samples smaller than 100. The worst case 
scenario found was a sample size of eight that generated a 52% credible interval, or an 
approximate ½ chance that the prevalence estimated would actually be found within ± 0.05 
of the prevalence point estimate.  This is not surprising, as actual Bayesian estimate of 
prevalence for this sample generated a very large 95% CI of width 0.48. Linear regression 
(SAS 8.0, The SAS Institute Inc., Cary, NC, USA) was used to evaluate the relationship of 
sample size to average credible coverage. Although there was a significant relationship 
(p<0.02), an r2 of 0.3695 suggests that other factors contributed to the relationship. Since the 
average credible coverage is generated through Bayesian methods, it is not surprising that a 
high correlation did not result.  
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Bayesian Estimation of Prevalence in beef and dairy cattle
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Figure 2.19 Estimation of prevalence in beef and dairy populations  
2.4. Discussion 
Data presented here represents animals tested by the Danish Cattle Health Laboratory 
and is not completely representative of the population, as at any given time, a percentage of 
herds remain untested. A greater percentage of beef herds remained untested at any given 
time, probably due to the ease of testing dairy herds via bulk milk. Positive animals not tested 
in beef herds and the relative close contact between dairy herds may account for the higher 
prevalence of exposure found in dairy animals. 
A similar antibody ELISA (“Ceditest”) (Kramps et al., 1999)was developed in the 
Netherlands using two monoclonal antibodies directed to highly conserved epitopes on the 
non-structural peptide NS3 of pestiviruses. Using the VNT as the gold standard, 1,000 field 
samples were performed resulting in a specificity of 99% and sensitivity of 98% for the 
Dutch ELISA relative to VNT. This compares to a specificity of 97.5% and sensitivity of 
96.5% for the Danish ELISA relative to the VNT.  Agreement between the Danish ELISA 
and the Dutch ELISA was ≥ 0.92 (Kramps et al., 1999). This is not unexpected, as the Danish 
ELISA was optimized for Danish strains of BVDV and the field samples were from the 
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Netherlands. Using ML estimation methods proposed by Hui and Walter 1980), comparison 
of the test results of the two ELISAs on 484 Danish plasma samples and 467 Dutch plasma 
samples resulted in an estimated sensitivity and specificity of 98.7% for the Danish antibody 
ELISA. This was only slightly inconsistent with the ML estimation of the Danish antibody 
ELISA sensitivity (but not the specificity) (94.5-98.1%, 97.1-100%, 95% confidence 
intervals respectively) estimate resulting from comparison of the ELISA to the VNT during 
its initial testing (see 3.1). It was also inconsistent with the Bayesian estimation for the 
Danish antibody ELISA sensitivity, but not the specificity estimation  (95.9-97.3%, 98.2-
99.8%, 95% credible intervals) from the two test two population Bayesian estimation (3.2). 
Actual sensitivity of the Danish antibody ELISA might be higher than earlier estimates. 
A study to estimate the performance of a BVDV antibody ELISA bulk-tank milk test 
using Bayesian methods found low prevalence resulted in a lack of power to assess 
sensitivity (Valle et al., 2000). However, for the Danish ELISAs we had data from the initial 
testing that allowed us to use two—population--two test Bayesian and MLE methods to 
derive more accurate prior information. Data from the testing of the Dutch “Ceditest” 
(Kramps et al., 1999) to provide alternate estimation of the Ab ELISA performance.  
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Figure 2.20 Relationship of sample size to accuracy of Bayesian prevalence estimates 
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2.5. Conclusions 
The Danish BVD eradication program has drastically decreased the prevalence of 
persistently infected cattle.  Both the Danish antigen ELISA and antibody ELISA are 
effective tools in identifying persistent infection and exposure respectively in unvaccinated 
cattle such as the Danish bovine population. It is common in test development to base test 
performance on correspondence with “gold standard” reference tests.  With Bayesian 
estimation, conditional independence of tests can be evaluated, and estimation of new test 
performance without the assumption of 100% sensitivity and specificity of reference tests can 
be performed.  Bayesian estimation of test performance in one--test one--population 
situations appeared robust in sample sizes as low as 91. However, Bayesian estimates will 
always be dependent upon prior information and care should be taken in its development. 
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CHAPTER THREE 
ESTIMATION OF SENSITIVITY AND SPECIFICITY OF TWO DIAGNOSTICS 
TESTS FOR BOVINE IMMUNODEFICIENCY VIRUS USING  BAYESIAN 
TECHNIQUES 
 
3.1 Introduction  
 Bovine immunodeficiency virus (BIV), along with human immunodeficiency virus  
(HIV), is a lentiviral member of the family Retroviridae.  BIV is structurally, genetically, and 
immunologically similar to HIV.  Both of these protein-encapsulated RNA viruses replicate 
within host white blood cells using a reverse-transcribed DNA form.  The DNA provirus 
form is transported to the host-cell nucleus where it integrates into host chromosomes and 
can persist for the life of the cell (Gonda, 1992).  Unlike HIV, BIV has not been associated 
with a severe acquired immunodeficiency syndrome.  However, epidemiological research 
into subclinical and secondary effects of BIV infection has been hampered by, among other 
constraints, limited availability of validated assays. 
  BIV was first isolated from a Louisiana dairy cow in the 1960's (Van Der Maaten et 
al., 1972). The distribution of infection is worldwide; infection prevalences range from as 
high as 50% in Mississippi dairy herds (St. Cyr Coats et al., 1994) to as low as 5% in other 
areas of the United States (Black, 1989). Beef herds appear to have lower prevalences  (5% 
and <1%) compared to dairy herds (30% and 50%)  (Amborski et al., 1989).  In Louisiana, 
rates of 40% in beef and 60% in dairy herds were reported by Gonda (1994). Variations in 
infection prevalence might be influenced by the disparity of assays used for BIV detection, 
because St. Cyr Coats et al. (1994) used an enzyme-linked immunosorbent assay (ELISA), 
and Black(1989) and Amborski  et al. (1989) used  IFA on Madin, Darby bovine kidney 
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(MDBK) and bovine fetal spleen (BFS) cells respectively.  
There currently is no gold standard  (a completely accurate test) to detect infection 
with or exposure to BIV.  Culture of the virus is difficult, and antibody to the p26 gag 
antigen used in western-blot tests can be undetectable when antibody levels are diminished, 
as in long-term infection. Loss of detectable antibody also affects ELISA and IFA 
performance. There is no  commercially available IFA test for BIV.  A previously available 
commercial test was used to detect anti-BIV antibodies in bovine serum.   IFA is time 
consuming and interpretation is subjective because of irregularly occurring background 
fluorescence especially in field samples from cattle with natural exposure to Bovine Viral 
Diarrhea Virus (Suarez et al., 1994). Whetstone et al. (1991) demonstrated a lack of 
sensitivity when IFA assay was used to detect BIV experimentally infected animals with 
infections of over two years duration.  
Nested-set polymerase chain reaction-based assay (PCR) detects provirus in white 
blood cells, and also requires time for sample preparation and reaction. Existing assays vary 
in the segment of the BIV genome they detect. Nested-set PCR is advantageous in that it can 
detect BIV early after infection before specific antibodies are present, before virus can be 
isolated, and late in infection when antibodies and virus cannot be recovered (Suarez et al., 
1994). Although PCR typically is very sensitive, Suarez and Whetstone (1997) demonstrated 
variability (from 0 to 10 out of 12) in the classification of infection status of samples from 
experimentally infected bovines.  
It is possible to evaluate the error probabilities of two diagnostic tests even if a gold 
standard is unavailable.  An excellent review of methods for estimating sensitivity and 
specificity of diagnostic tests, as well as prevalence when the true infection status is 
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unknown, was recently compiled (Enøe et al., 2000).  When two imperfect tests are applied 
simultaneously to the same individuals from two populations with different disease 
prevalences, the sensitivity, specificity and  prevalences of both populations can be estimated 
using  Maximum Likelihood Estimation (MLE)  (Hui and Walter, 1980).  Each population 
contributes 3 degrees of freedom (df) from the three independent cells in its 2x2 table (one 
cell must remained fixed to maintain an accurate population count); thus, there are 6 df total 
and no constraints are required when two populations are present (Walter and Irwig, 1988).  
This approach assumes that a test has identical sensitivity and specificity across populations 
conditional on the true disease status.   
 Bayesian methods also exist for the estimating test parameters and disease prevalence 
for one or more tests applied to one or more populations. Simultaneous inferences about the 
population prevalence and test sensitivity and specificity are gathered with the Gibbs 
sampler.   The Bayesian approach, unlike MLE, does not require Normal-distribution 
approximations to derive confidence intervals (Joseph et al., 1995). Bayesian methods can 
also be used to determine whether sensitivity and specificity are independent of population 
prevalence. 
Our purpose was to estimate the validity of two available assays for BIV: a commercially 
available IFA and an in-house nested-set PCR assay, neither of which has been validated in 
naturally infected populations.    
3.2 Materials and Methods 
3.2.1 Populations and Sampling  
 Herd A was a commercial dairy herd located in Tangipahoa Parish, Louisiana,USA; 
Herd B was the Louisiana State University (LSU) Dairy herd located on the LSU Dairy 
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Research and Teaching Farm, Baton Rouge, Louisiana, USA.  Animals tested were the 
cohort of cows in lactation at the time of sampling in Herd B and the dry cows of Herd A. 
Whole blood was collected by ventral coccygeal venipuncture into sterile vacutainer tubes 
with and without EDTA anticoagulant.  Blood was cooled on ice during transit until 
separation into serum (for IFA) and buffy coat (for PCR) could be performed. Samples were 
collected from Herd A in August of 1999 and Herd B samples were stored samples collected 
over the last 6 months of 1995.  Samples were frozen in Sarstedt 1.7 ml tubes at –70° C prior 
to assaying.   
3.2.2 Serum Antibody IFA 
An IFA was used to detect anti-BIV antibodies in bovine serum samples.  Test sera 
were diluted 1:20 in 0.01 M phosphate buffered saline, pH 7.2 (PBS) containing 10% goat 
serum. Serum dilution was per slide manufacturer’s direction, was necessary to decrease 
background fluorescence occurring in some samples and replicated  methods used both in a 
prior study of BIV transplacental transmission (Scholl, et al., 2000) and in our ongoing BIV 
research. Ten well commercial IFA substrate slides  (VMRD, Inc., Pullman, WA, USA) were 
equilibrated to room temperature and 50 µl of diluted test serum was placed in one well; 
seven animals were tested on each slide. Each slide was incubated with a positive and 
negative control of 1:20 diluted negative serum and positive serum provided by VMRD. An 
additional negative control of 50 µl of PBS was also included on each slide.   The slides were 
incubated in a humidified chamber at 37° C for 30 min, flushed with PBS, then soaked, for 
10 min in PBS, and blotted.  Fifty  µl  of a 1:200 dilution of fluorescein isothiocyanate-
labeled goat anti-bovine IgG (VMRD, Inc.) was added to each well and the slides were 
incubated for 25 min, and then washed as before.  The slides were dried, and a coverslip 
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mounted with one drop of VMRD FA mounting fluid applied. Slides were examined for 
fluorescence immediately using a Zeiss fluorescent microscope at 400x.  All slides were read 
by a single individual with no knowledge of the PCR status of the samples and in a manner 
consistent with established laboratory protocols.  Positive fluorescence brighter than the 
negative serum control and centralized around syncytial nuclei indicated the presence of anti-
BIV antibody in the test serum (Orr et al., 1999). 
3.2.3 Antigen PCR 
A modification of the nested-set polymerase chain reaction (PCR) described by 
Suarez et al., (1995) was used to detect proviral BIV in white blood cells.    While Suarez 
used primers based on both the pol and env segments of the BIV genome, the PCR used here 
was restricted to the pol segment and was less labor intensive. Briefly, after extraction, each 
50-µl reaction buffer contained 0.5µg of sample DNA, 3 mM MgCl, 20 pmol of each primer, 
and 1.25 units of Taq polymerase. The primers used were derived from the pol portion of the 
BIV genome and were P01 and P36 for the outside and P02 and P37 for the inside.  The 
cycling conditions for the outside were 1 cycle of 94° C for 2 minutes, 51° C for 15 seconds, 
and 72° C for 2 minutes; 30 cycles of 94° C for 45 seconds, 51° C for 1 minute, and 72° C 
for 2 minute; 1 cycle of 72° C for 10 minutes and 1 minute hold.   The cycling conditions for 
the inside were identical to the outside cycling conditions except for an annealing 
temperature of 61° C instead of 51° C.  For confirmation that a positive test had amplified the 
correct portion of the pol gene, 20 µl of the PCR product was electrophoresed at 90 volts for 
50 minutes on a 1.4% agarose gel.  The gel was stained with ethidium bromide, 
photographed under UV light and compared with a known standard to assure accuracy of 
primers. 
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3.2.4 Bayesian Estimation of Individual Test Sensitivity and Specificity and Population 
Prevalence 
 
 To estimate prior error distributions for Bayesian estimation, we used a review of the 
current literature (Baron et al., 1998; Suarez et al., 1994; Suarez and Whetstone, 1997;and 
Zhang et al., 1997) and expert opinion on the performance of the IFA and PCR.   We then 
chose these prior point-estimates:  IFA sensitivity = 65% and specificity = 75%, and PCR 
sensitivity =75% and specificity  = 85%.  Because proviral BIV can be detected by PCR over 
a longer interval than the BIV specific antibody detected by IFA (Suarez et al., 1994) and 
because PCR had greater sensitivity in lentiviral detection than serologic testing  (Gradil et 
al., 1999), animals initially were classified positive or negative based solely on PCR test 
results.  The prevalence prior point-estimates used for Bayesian analysis were the PCR - 
based prevalences of 24% for Herd A and 69% for Herd B.   
  The range of values used as a starting point for each accuracy parameter was ± 0.15 
and for each prevalence was ± 0.10. Arbitrary ranges were chosen to reflect an unknown 
degree of uncertainty in the accuracy of these estimations. Each test parameter was 
transformed into a beta prior density by matching the starting point estimate to the mean of 
the beta distribution, mean =  α/(α+ β) and equating one quarter of the total range to  the 
standard deviation of the beta distribution and solving for α and β. The standard deviation of 
the beta distribution is:  αβ/ ((α +β)2(α + β + 1))1/2.  Herd prevalence and IFA and PCR 
sensitivity and specificity were first estimated independently for each herd by Bayesian 
estimation using two test and one population methods(Joseph et al., 1995).  A modification 
of Joseph’s method then was used to evaluate both populations and tests simultaneously 
using the Law of Total Probability as described in Singer {Singer, 1998 1067 /id} and 
applied in Enøe et al. (2000).   The unknown number of true positives in each cell of the two 
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2 x 2 tables served as the latent data to represent misclassified data. In other words, an animal 
testing positive on both tests could still be negative and thus misclassified, and an animal 
testing positive on one test and negative on the other is misclassified since it is truly either 
positive or negative.  The number of animals misclassified is estimable using the above 
methods.  Each posterior distribution of sensitivity, specificity, and prevalence, given 
observed cell counts and latent data, was the product of independent beta posteriors for each 
parameter. The results were produced as independent posterior distributions of sensitivity, 
specificity and prevalence from which mean and credible intervals were derived. A 95% 
credible interval (CI) may be interpreted as a 95% possibility that the actual parameter mean 
lies within the reported range, in contrast to the frequentist interpretation of a 95% 
confidence interval as an interval that contains the true value of the parameter for 95% of 
unlimited repetitions (Rothman and Greenland, 1998).   
 The observed cell counts in the 2 x 2 tables of original tests results by individual 
population (Table 3.1) were perturbed and additional Bayesian estimations of test parameters 
and herd prevalence were performed on the perturbed tables. These additional estimates 
served as a analysis of the sensitivity of the Bayesian estimates to additional misclassification 
(Enøe et al., 2000) within the context of our sample size. Specifically, close to 10% of the 
PCR apparent positive animals were reclassified as to IFA outcome. This amount of 
“reclassification’ was arbitrarily selected as representative of a moderate amount of 
misclassification in the observed data. Because perturbation resulted in cell values of zero, 
the effect of possible zero cell values  was evaluated as well (Table 3.4). Non-informative 
priors (letting start values of sensitivity, specificity and prevalence range from 0 to 100%) 
were also used in the sensitivity analysis to observe the effect of disregarding expert 
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information on the final estimations (Table 3.3).   
Bayesian methods were used to obtain estimates from each of the two separate 
populations evaluated independently (two tests, one population, Table 3.2) and to obtain 
estimates of the two tests’ performance in two populations evaluated simultaneously (Table 
3.3). This novel approach compared obtained estimates of sensitivity and specificity from 
independent and simultaneous Bayesian evaluation to confirm the assumption that each test 
behaves consistently in different populations.  
Table 3.1 Cross-classification of indirect-fluorescent antibody assay (IFA) and polymerase 
chain-reaction assay (PCR) results for bovine immunodeficiency virus infection in dairy 
cattle in a commercial dairy herd with low prevalence (Herd A) and an university herd with 
high prevalence (Herd B)a
 Herd A Herd B 
 IFA+ IFA- IFA+ IFA-
PCR+ 3 8 13 11 
PCR- 1 34 3 8 
adata from Orr, LSU,1999 
 
Conditional independence of the errors of the tests was assumed, but tests based on a 
similar physiological basis might have correlated errors that cause incorrect estimation of 
sensitivity and specificity (Vacek, 1985).  One might expect that diagnostic assays based on 
different principles such as an antibody and an antigen assay would have independent errors. 
However, it seemed prudent to confirm that the tests’ sensitivities and specificities were 
indeed independent conditional on disease status. Gardner et al. (2000) points out that 
dependence of test sensitivities does not imply a dependence of test specificities. Actual test 
conditional independence of the PCR and IFA was evaluated using a Bayesian based S-Plus 
algorithm developed by Georgiadis et.al. (2003). This algorithm determines the amount of 
positive and negative correlation (if any) between two tests. 
 109
Table 3.2 Individual herda Bayesian estimates (and 95% credible intervals) of polymerase 
chain reaction (PCR) and indirect fluorescent-antibody (IFA) assay performance for bovine 
immunodeficiency virus infection in a commercial dairy herd with low prevalence (Herd A) 
and an university herd with high prevalence (Herd B) 
Herd A 
n=46 
Herd B 
n=35 Parameter 
Estimate 95% CIb Estimate 95% CIb
Prevalence 0.15 0.06, 0.29 0.73 0.56, 0.86 
IFA Sensitivity 0.63 0.47, 0.77 0.61 0.49, 0.73 
IFA Specificity 0.87 0.78, 0.94 0.77 0.62, 0.89 
PCR Sensitivity 0.77 0.61, 0.89 0.80 0.67, 0.90 
PCR Specificity 0.85 0.74, 0.94 0.84 0.65, 0.96 
a Gibbs sampler-based estimation from separate examination of each population 
b CI = Bayesian credible interval  
 
This method estimates the sensitivity and specificity of two possibly correlated diagnostic 
tests in the absence of a gold standard more accurately than a model that assumes test 
independence, especially if moderate dependence exists. Because conditional dependence 
was not found, it was possible to use results from the first Bayesian estimation.   
3.3 Results 
3.3.1 Apparent BIV Prevalence 
 Forty-six animals from Herd A and 35 from Herd B were sampled.  The simple 
observed 2 x 2 tables suggested two populations with different prevalence (see Table 3.1). 
The PCR-prevalences (which served as the prior information for Bayesian analysis) were 
24% for Herd A and 69% for Herd B.     
3.3.2 Bayesian Estimates 
 Using the prior information detailed in section 2.4 and 3.1, data from each 
herd were analyzed independently  (Table 3.2).  The estimates again suggested that the 
prevalence of BIV infection differed greatly between herds, but that the individual test 
sensitivities and specificities were consistent across the herds.  The greatest difference was 
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for IFA specificity, but the 95% credible intervals still showed considerable overlap. 
Bayesian techniques also were used to estimate population prevalence and test sensitivity and 
specificity simultaneously using the same priors used in examining each herd separately 
(Table 3.3, under Informative priors). The resulting estimates were consistent with the single-
herd Bayesian estimates, but the credible intervals were narrower as a percentage of the point 
estimates, reflecting additional data density.   
Table 3.3 Parameter estimates from two-population Bayesian estimation  contrasted with 
parameter estimates from estimation with non-informative priors with credible intervals 
Informative priors Non-informative priors 
Parameter Point 
estimate 95% CI 
Point 
estimate 95% CI 
Prevalence Herd 
A 0. 20 0.13,  0.29 0.15 0.01,  0.37 
Prevalence Herd 
B 0.71 0.61,  0.79 0.81 0.51,  1.00 
IFA Sensitivity 0.60 0.48,  0.72 0.53 0.33,  0.81 
IFA Specificity 0.88 0.78,  0.94 0.98 0.87,  1.00 
PCR Sensitivity 0.80 0.69,  0.90 0.81 0.61,  0.98 
PCR Specificity 0.86 0.74,  0.95 0.86 0.68,  1.00 
 
For example, the credible interval width for Herd A prevalence estimated  simultaneously 
was 56% of that from the individual  herd estimate, while the credible interval width for the 
prevalence of Herd B estimated simultaneously was 60% of that from the individual herd 
estimate.  Use of two populations provided more prior information on test performance, 
hence the narrowing of the credible intervals. 
Bayesian techniques also were used to estimate population prevalence and test 
sensitivity and specificity simultaneously using the same priors used in examining each herd 
separately (Table 3.3, under Informative priors). The resulting estimates were consistent with 
the single-herd Bayesian estimates, but the credible intervals were narrower as a percentage 
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of the point estimates, reflecting the  additional data density.  For example, the credible 
interval width for Herd A prevalence  estimated  simultaneously was 56% of that from the 
individual  herd estimate, while the credible interval width for the prevalence of Herd B 
estimated simultaneously was 60% of that from the individual herd estimate. 
Table 3.4 Two-population Bayesian parameter estimates from perturbed data tables with zero 
values with credible inervalsa  
Herd A reclassifiedb Herd B reclassifiedc Herds A and B reclassifieddParameter Point 
estimate 95% CI 
Point 
estimate 95% CI 
Point 
estimate 95% CI 
Prevalence Herd A 0.21 0.14,  0.30 0.20 0.13,  0.29 0.21 0.14,  0.30 
Prevalence Herd B 0.71 0.61,  0.79 0.71 0.61,  0.79 0.71 0.62,  0.79 
IFA Sensitivity 0.61 0.48,  0.72 0.61 0.49,  0.73 0.61 0.49,  0.73 
IFA Specificity 0.88 0.79,  0.94 0.89 0.80,  0.95 0.89 0.81,  0.95 
PCR Sensitivity 0.81 0.69,  0.90 0.85 0.74,  0.93 0.85 0.74,  0.95 
PCR Specificity 0.86 0.74,  0.95 0.86 0.74,  0.95 0.86 0.74,  0.95 
aOriginal data distribution (Table 1): 3, 8, 1, 34, 13, 11, 3, 8 
bHerd A PCR+/IFA+ changed from 3 to 4, PCR -/IFA+ changed from 1 to 0 
cHerd B PCR+IFA+ changed from 13 to 16, PCR-/IFA+ changed from 3 to 0 
dHerd A and B changed simultaneously by the same amounts 
 With data drawn from two populations (Table 3.3), the estimated specificity of the 
IFA was 0.88 (0.78-0.94), similar to the results of the single herd estimation for Herd A 
(Table 3.2), but less consistent with the single herd estimation for Herd B. There was 
substantial overlap of the credible intervals of the Herd B single-herd IFA specificity 
estimates and the corresponding interval obtained when estimated in both herds 
simultaneously, yet the latter interval excluded the single-herd IFA specificity point estimate 
for Herd B individual estimation. 
The two tests were evaluated for conditional independence using Georgiadis’ method 
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(Georgiadis, et al., 2003) and were judged independent with no evidence of correlation 
conditional on test outcome. Actual positive ( ρD) and negative ( ρDbar)  test correlations were 
not significantly different from zero with ρD 95%  probability interval (-0.4, 0.37) and   
ρDbar  95% probability interval (-0.07,0.79).  The estimates resulting from the estimation for 
conditional correlation were within the same range as the two-population Bayesian model 
estimates assuming conditional independence (Table 3.5). When test correlation 95% 
probability interval encompasses zero as demonstrated here, the results from the conditional 
independence model may be used.   
Table 3.5  Parameter estimates from two-population (simultaneous) Bayesian  with 
conditional correlation  (informative priors) with Credible Intervals 
Conditional Correlation 
Parameter 
Point estimate 95% CIa
Prevalence Herd 
A 0. 21 0.14,  0.31 
Prevalence Herd 
B 0.71 0.62,  0.80 
IFA Sensitivity 0.51 0.33,  0.81 
IFA Specificity 0.93 0.87,  1.00 
PCR Sensitivity 0.80 0.61,  0.98 
PCR Specificity 0.87 0.77,  0.96 
 
Data perturbation used as a representation of the possible effects of additional 
misclassification (Table 3.4), had an inconsequential impact on all joint estimates and 
credible intervals. Data was perturbed to reflect the possibility that PCR-/IFA+ animals were 
actually positive by shifting all such animals into the PCR+/IFA+ classification.  
Sample size adequacy should be considered.  Inferences based on the MLE method 
require a large sample size assumption for valid confidence interval estimates.  Enøe et. al. 
(2000) validated confidence intervals  by adding ± 3 S.E. to a parameter estimate and 
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checking for containment within the range 0 to 1 (Johnson, 1991).  When this performance 
check was applied to our parameter estimates resulting from MLE, the majority of our 
intervals generated fell outside of this target range suggesting that a larger sample size would 
be necessary to have valid 95% confidence intervals.  In most instances, the 95% confidence 
intervals from MLE were wider than the 95% credible intervals from Bayesian estimation 
reflecting the uncertainty due to small sample size.  ML estimation was deemed unsuitable 
for this data and results are not reported. 
3.4.  Discussion  
Our results clearly showed the potential for infected animals to be misclassified when 
IFA is used to determine BIV infection (sensitivity =  60%).   The nested-set PCR had better 
overall performance. Although the IFA used was a commercially available assay, the nested-
set PCR-based assay employed was in addition to at least five currently described (Suarez 
and Whetstone, 1997), each of which target different segments or combinations of segments 
of the BIV genome.   Suarez and Whetstone (1997) tested the ability of these other 5 PCR 
assays to detect BIV in 7 cell culture samples, white blood cell or lymph node preparations 
from 12 experimentally infected animals, and 16 lymph node or white blood cell preparations 
from 9 unrelated field submissions. Although their study demonstrated some differences 
between the assays’ performance in detecting positive BIV infection and were more 
consistent in predicting negative animals, this clearly was unsuitable for deducing the 
sensitivity and specificity of a BIV PCR for field use.   In a study more relative to natural 
infection, Jacobs et al., (1998) reported greater product amplification of the pol gene than the  
env gene in blood leukocyte samples from naturally infected bulls. Our estimations for 
sensitivity and specificity apply only to the pol-based methodology used and  reflect  actual 
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test conditions where infection status is unknown.  
  Sample size estimation for  Bayesian methods is complicated when misclassification 
is likely  and the distribution cannot be assumed  normal (Rahme et al, 2000).   Applying 
Rahme’s methods to each population and each diagnostic test separately resulted in average 
Credible Interval coverage probabilities ranging from 0.89 to 0.93 for the prevalence 
estimates.  This means we can be approximately 90% certain that the true value of the 
prevalence lies somewhere in the range of 0.15 ± 0.15 for Herd A and 0.73 ± 0.15 for Herd 
B.   A larger sample size would be necessary to increase our certainty to 95%. Or, by 
increasing the width of the credible interval around the prevalence interval we would achieve 
95% certainty with a loss of accuracy. In addition, one disconcerting effect of limited sample 
size is unstable point estimates and possibly even CI estimates. Estimate instability may 
occur when a moderate amount of misclassification produces a substantively different point 
estimate.  The apparent stability of our point estimates made after perturbing the cell 
frequencies of our source data do not demonstrate a great amount of sensitivity in our data to 
misclassification.  
  The similarity of the two tests’ sensitivity and specificity over the two populations 
suggests that the increased sample storage time for Herd B did not  affect test performance.  
We acknowledge the potential that both the increased storage time for Herd B and the use of 
dry cows from Herd A and lactating cows from Herd B are potential sources of error. 
However, we are not aware of any scientific literature supporting the hypothesis that either 
BIV antibodies or provirus are more or less likely to be detected in dry cows than lactating 
cows, or that false positives occur more frequently with either assay. One may speculate that 
detection of specific antibody or transcription of BIV may be influenced by lactation-cycle 
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related physiological events, so this issue is open to further study. 
This study is the most rigorous statistical evaluation of any available BIV assays to 
date. Use of two tests based on different physiological principles allowed for interpretation of 
data without the need for correction for conditional dependence; use of Bayesian techniques 
allowed for parameter estimation using available sample sizes.   If, in fact, nested-set PCR is 
only 80% sensitive and 85% specific, then misclassification will likely occur even if PCR is 
the sole diagnostic test applied.  This increases the sample sizes necessary for studies of 
animal health effects of BIV infection.  The decreased validity of the IFA among true 
positives might not necessarily reflect on the performance of other antibody-based assays as 
cross-reacting antibodies resulting in false positives can occur  (Suarez et al, 1994). In fact, 
differences in exposure/infection rates between herds might account for varying specificity 
estimates if Herd B had a larger number of false positives from a cross-reacting antibody 
producing disease. Enzyme immunoassays based on recombinant viral antigens should 
decrease the number of false positives from the reaction of serum with non-relevant proteins.  
However, PCR should still detect infection over a longer period than antibody-based assays, 
both before antibodies are present and after they are no longer detectable. 
3.5. Conclusions 
While nested-set PCR is slightly less specific than  IFA for determining BIV infection 
of adult dairy cattle it is considerably more sensitive.   Nevertheless, even a PCR assay of 
BIV infection can be expected to produce a potentially important amount of 
misclassification. Estimation of the average credible coverage interval of test prevalence 
estimates may be useful in evaluating the effect of small sample size on  test performance 
once estimated sensitivity and specificity have been determined. Techniques for reclassifying 
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misclassified data would be highly useful when small sample sizes and imprecise diagnostic 
assays must be evaluated. 
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CHAPTER FOUR 
EFFECT OF BOVINE IMMUNDEFICIENCY VIRUS ON HUMORAL RESPONSE 
TO BHV1 ANTIGEN IN BOVINE LEUKEMIA VIRUS INFECTED CATTLE 
 
4.1 Introduction 
4.1.1 Bovine Immunodeficiency Virus 
Bovine immunodeficiency virus (BIV), along with human immunodeficiency virus 
(HIV), is a lentiviral member of the family Retroviridae.  BIV has genetic and biochemical 
homology with HIV.  Both of these protein-encapsulated RNA viruses replicate within host 
white blood cells using a reverse-transcribed DNA form.  The DNA provirus form is 
transported to the host-cell nucleus where it integrates into host chromosomes and can persist 
for the life of the cell (Gonda, 1992).  Unlike HIV, BIV has not been associated with a severe 
acquired immunodeficiency syndrome.  BIV was first isolated in 1970 from an 8-year-old 
Holstein cow with persistent lymphocytosis, lymphadenopathy, central nervous system 
lesions, and wasting.  BIV infection is sporadic throughout the world. The early pathogenic 
effects of bovine immunodeficiency- like virus (BIV) were studied by (Carpenter et al., 
1992) in calves experimentally inoculated with BIV. All animals inoculated with BIV R29- 
infected cells seroconverted by 6 weeks post inoculation (PI), and BIV was recoverable from 
each animal at 2 weeks PI.   Levels of BIV replication in vivo appeared to be low, since 
during peak periods of viral replication in vivo, less than 0. 03% of peripheral blood 
mononuclear cells (PBMC) expressed detectable levels of viral RNA.  Inoculated calves had 
significantly higher numbers of circulating lymphocytes, and follicular hyperplasia was 
observed. Calves developed transient fever and neutropenia. The histopathological changes 
occurred early and were similar to changes found after infection with  HIV-1 and FIV. 
Clinical changes could not completely be ascribed to BIV and   might have been due to 
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BVDV. A study of BIV seroepiemiology in Mississippi  revealed that BIV infection was 
found in both beef and dairy cattle (Coats et al., 1994).  One dairy herd had a 64% incidence 
of BIV with a high incidence of lymphosarcoma, lymphadenopathy, and persistent health 
problems, with 74% of this herd seropositive for BLV.  A 21% seroprevalence of BIV was 
reported in a Colorado dairy herd, 40% in beef herds and 64% in dairy herds from Louisiana 
(Coats et al., 1994). 
In a study of BIV infection in two Mississippi dairy herds, a cumulative BIV 
seroprevalence of 50% was found. No significant differences were found in total leukocyte 
populations or subpopulations between BIV seropositives and negatives. BLV serostatus was 
not reported.  Clinical disease in BIV infected cattle is often associated with BLV 
coinfection, but dual infection does not appear to augment PL in BLV infection. Viral 
cofactors such as bovine herpesvirus type I infection may enhance BIV replication (Coats et 
al., 1994).  Activation of BIV expression was detected as increased BIV reverse transcriptase 
activity, increased number of syncytia induced by BIV, and increased in the steady state level 
of BIV-specific RNA upon BHV-1 super-infection (Geng et al., 1992).  
In 1993, a new isolate of BIV were taken from buffy coat cells cultivated in vitro 
from a seropositive cow in Florida. Two new isolates (FL112, FL191) were derived from 
buffy coat cells cocultivated in vitro with fetal bovine lung cell cultures(Suarez et al., 1993).  
The new isolates had higher cocultivation rates, longer incubation times between passage, 
decreased number of nuclei per syncytium and greater granularity and slower lysis of 
syncytia. Examination of pol gene product showed a 92.6 and 93.6% homology to published 
nucleotide sequence of BIV R29-127, a molecular clone derived from BIV R29. The Florida 
isolates cause transient mononuclear cell increase early in infection and induce mild to 
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significant follicular hyperplasisa and non-supparative pervascular cuffing in the cerebrum 
(Munro et al., 1998). 
Cellular tropism and transcription of bovine leukemia virus (BLV) and bovine 
immunodeficiency-like virus (BIV) were investigated using PBMC collected from a cow 
infected with both viruses (Wu et al., 2003). Each PBMC subset, purified by magnetic cell 
sorting, was subjected to PCR and RT-PCR for detection of integrated proviruses and 
transcript mRNAs. Both BLV and BIV genomes were detected by nested PCR in CD3+, 
CD4+, CD8+, and γδT cells, B cells and monocytes.  BLV tax transcription was only detected 
in B cells.  BIV transcript was detected in each subpopulation of PBMC. These results 
indicated that BLV can infect T cells and monocytes as well as B cells, but can be expressed 
by transcription only in B cells. In contrast, BIV can express its transcripts in all infected 
cells. 
4.1.2 Bovine Type 1 and Type 2 Cytokine Responses 
Cytokines play a central role in immunological, physiological, and pathological 
processes in animals.  The T Helper1  (TH1) response is dominated by lymphocyte cytokines 
IL-2, interferon gamma (IFN-γ), tumor necrosis factor alpha (TNF-α), and the macrophage 
cytokine  IL-12.  In mice, TH1 cytokines generate predominantly IgG2a antibody responses 
and the TH2 response is dominated by cytokines IL-4, IL-5, IL-6, and IL-10. TH2 cytokines 
generate IgG1 and IgE responses.  In the bovine, cytokine responses with some 
characteristics of murine TH1 and TH2 response have been called type 1 and type 2 (Brown et 
al., 1998).  Division of immune response type by cytokine profile is not fully described in the 
bovine. There does appear to be differential IgG isotype responses in IgG1 and IgG2 
equivalent to the association between TH2 and TH1 response types. In the bovine, cytokines 
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associated with the murine TH1 response support IgG2 production and cytokines associated 
with the murine TH2 response support IgG1 production. IL-12 activates type 1 cytokine 
production and is antagonistic to type 2 cytokines. IL-12 affects T cells natural killer (NK) 
cells, and B cells. With proinflammatory and immunoregulatory effects on T helper 
responses, IL-12 induces T-cell differentiation, cytokine production in T helper 1 cells, and 
inhibits type 2 cytokines (Pyeon and Splitter, 1998). If BIV does indeed act similarly to HIV, 
a shift in immune response from a type 1 cytokine response to a type 2 cytokine response 
might be seen.   A predominant TH1 response in vivo would be expected to upregulate IgG2 
as IFN-γ likely controls IgG2 production at the transcriptional level.   In the mouse, TH1 cells 
encourage IgG2a production in vivo (Estes, 1996).  TH0, TH1, TH2, cell subsets exist in the 
bovine. Cattle have cytokine mediated regulation of TH cell responses differing from those 
observed in mice (Brown et al., 1998).  In their study, a majority of over 60 parasite antigen-
specific TH cell clones coexpressed IL-4 and IFN-γ.  Polarized cytokine profiles were rarely 
observed.  IL-2 expression was not restricted to IFN-γ producing cells nor was IL-10 
restricted to  IL-4 producing cells. Bovine type 1 and type 2 responses, do not appear 
coordinated; TH1 and TH2 responses may not typify the immune response to most pathogens.  
Major regulatory cytokines (IL-4, IL-10, IL-12) do not selectively exert negative (IL-4, IL-
10) or positive IL-12) effects on TH1-like cells in the bovine. In the bovine, IL-10 is 
produced by TH1 and TH2 CD4+ cells similarly to humans and unlike mice. Polarization of 
an immune response towards a type 1 or type 2 response can occur in vivo against a specific 
antigen, particularly by intra-macrophage pathogens that induce IL-12 and then IFN-γ as in a 
type 1 response. A polarized type 2 response is seen with IL-4 and IL-5 induction by 
allergens. Cytokine response to BIV as not been fully explored.   
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Limited studies on the clinical effects of BIV natural infection have been performed. 
To date, none have specifically examined cytokine response.  Cytokine responses in BLV 
have direct bearing on this study. IL-10 produced by TH2 helper T cells, B cells, and 
macrophages inhibits cytokine production by TH1 cells and enhances B-cell proliferation and 
differentiation.   PBMC from BLV-infected animals in the late stages of disease expressed 
considerably more IL-10 mRNA than animals not infected or in the early stages of disease 
(Pyeon et al., 1996). In contrast, TH1 cytokines IL-2 and IFN-γ decreased with disease 
progression. BIV serostatus was not reported.  IL-10 was observed to be expressed 
principally by monocytes/macrophages in persistently lymphocytotic animals, indicating that 
B cell proliferation does not cause the IL-10 expression seen in BLV disease progression.  
BLV infection can thus result in B-cell differentiation and Ig class switching. An additional 
study by (Pyeon and Splitter, 1998) measured the IL-12 p40 mRNA  expression in BLV 
infection. IL-12 is known to activate type 1 cytokine production and antagonize type 2 
cytokines.  Cytokine profiles differed between BLV disease stages. In AL animals, the type 1 
cytokines IL-2 and IFN-γ were expressed in high amounts, with IL-10 (type 2 cytokine) 
increased in PL animals. IL-12 p40 decreased in PL animals and was only produced by 
monocytes and macrophages. Low antigen levels (as in AL) may trigger type 1 cytokines, 
while high antigen levels (PL) may trigger type 2 cytokines. IL-12 p40 mRNA was also 
expressed in PBMC of tumor-bearing animals. High expression of IL-10 was also present in 
tumor-bearing animals.  
4.1.3 Coinfection with BIV and BLV 
The role of cytokines in the disease process of BLV is potentially important due to 
the similarity of BLV with other retroviruses in which cytokines play a role, such as HTLV-I 
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and -II. In humans, the Human T-cell Leukemia virus type 1 (HTLV-1), an Oncovirus, is the 
etiological agent of two diverse diseases: Adult T-cell leukemia/lymphoma and the 
neurological disorder tropical spastic paraparesis/HTLV-1-associated myelopathy 
(HAM/TSP).  A genetically related virus, HTLV-2, has also been identified and isolated. 
There has been no demonstration of a definitive etiological role for HTLV-2 in human 
disease to date, although neurologic disorders are observed resembling HAM/TSP (Vrielink 
and Reesink, 2004).  Bovine leukaemia virus (BLV) has also been classified in the same 
group, Oncoviridae (Johnson et al., 2001).  BLV is closely related to HLTV-I and II and 
shares nearly identical genomic organization and disease progression (Keefe et al., 1997).  
It has been theorized that coinfection with BIV and BLV may act in a similar fashion 
to HIV and HLTV coinfection. As all cows in this study were co-infected with BLV, the 
effects of BLV infection must be considered.  A study to determine the effects of bovine 
leukemia virus (BLV) infection on production, reproduction and longevity in dairy cattle was 
undertaken (Pollari et al., 1992). Their study population was a commercial Holstein dairy 
herd of approximately 400 milking cows, with cattle tested for antibodies to BLV at least 
annually for three years and at culling. Four groups of culled cows were compared: 
seronegative cows (n = 79), seropositive cows without lymphocytosis (n = 176), seropositive 
cows with lymphocytosis (> or = 9,000 lymphocytes/µl) (n = 74), and seropositive cows with 
lymphosarcoma (n = 29). Seropositive groups of cows required more breedings and had 
longer calving intervals than seronegative cows. The seropositive groups had greater 305-day 
ME (mature equivalent) FCM (3.5% fat-corrected milk) per lactation and were older when 
culled than seronegative cows. However, the percent fat per lactation was greater in 
seronegative cows. In the last complete lactation, differences in 305-day ME FCM, days 
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open and cull age between groups were non-significant. In the cull lactation, only cows with 
lymphocytosis had a non-significant reduced milk production relative to seronegative cows.  
BLV infected cows had greater milk production on average than uninfected cows due to 
increased time in the herd. Adverse effects of BLV infection were primarily limited to 
lymphocytotic cows that were culled earlier and had reduced milk production in the cull 
lactation. 
 Environmental and genetic factors affecting the prevalence of antibodies to bovine 
leukosis virus and bovine immunodeficiency- like virus were studied on 137 periparturient 
Holstein cows selected for milk production (Detilleux et al., 1995). Cows selected for high 
predicted transmitting ability (PTA) for kilograms of milk fat plus protein had the highest 
prevalence of antibodies to bovine immunodeficiency- like virus and the lowest prevalence 
of antibodies to bovine leukosis virus. Approximately 30-70% of BLV infected cows 
developed persistent lymphocytosis attributable to proliferation of virus-infected B cells.   
Prevalence of antibodies to BIV was 10.2% and to BLV was 11.3%. Only one cow had a 
dual infection.  BLV prevalence tended to increase with parity, but decreasing numbers of 
cows with advanced parity did not allow for statistical significance.  BLV seropositivity was 
8.41 times lower in the line selected for high PTA for fat plus protein than for the genetic line 
selected for average PTA for milk.  Cows from high PTA lines were 9.02 times more likely 
to be BIV positive and BIV positive cows were more productive. 
In a study of BIV and BLV co-infection   cattle were infected for over 3 years with 
either BIV R29 (4), BLV (5) both BIV R29 and BLV(5),  or neither (3) (Isaacson et al., 
1995).   Immune reactivity to soluble antigen was determined following primary and 
secondary immunization with tetanus toxoid.  BIV infection caused only a slight decrease in 
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response to tetanus toxoid.  Significantly increased serum anti-tetanus titers were found in 
both BLV-infected groups for samples taken between 22-135 days following second 
vaccination.  BLV infection also tended to increase tetanus antigen-specific lymphocyte 
proliferation. 
BIV infection has been reported in Costa Rica, with most BLV-infected animals 
seropositive for BIV. Experiments were designed to evaluate the effect of BLV on mitogen-
stimulated   PBMC from naturally infected cattle.  (Hidalgo and Bonilla, 1996)  showed that 
dually-infected cattle (BIV-BLV) had reduced lymphoproliferative responses to the mitogen 
Con A with  leukocytosis and lymphocytosis.  Cows with lymphosarcomas were severely 
affected.   Due to the high rate of dual infections observed in Costa Rica, these results were 
not seen as sufficient to clarify if BLV or BIV was responsible for the suppressive activity or 
if they act synergistically. 
In a study from Hokkaido, Japan, approximately half of 120 cattle tested were 
seropositive for BLV, while 7.5% of the cattle were seropositive for BIV. Though increased 
numbers of leukocytes were frequently observed in BLV-seropositive cows, no such changes 
were observed in BIV-positive but BLV-negative cows. No correlation was demonstrated 
between BIV- and BLV-seroprevalence  (Hirai et al., 1996). 
Prevalence of single versus dual infection with BIV and BLV was examined when a 
dairy cattle herd was tested for anti-BIV and anti- BLV antibodies by ELISA (Cockerell et 
al., 1992).  Twenty-one percent (20/95) were BIV-seropositive, while  52% (49/95) of the 
same samples were seropositive for BLV.  Five cattle had persistent lymphocytosis; two of 
these were co-infected with BIV.  The mean anti-BLV titer was significantly higher in PL 
cattle, but no difference was found in anti-BIV titers in PL animals. BLV does occur in U.S. 
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dairy cattle (10-40%) and results in subclinical infections with or without lymphocyte 
eleveation or a fatal lymphoproliferation.    
 Flaming et al., (1997) found BIV infected cattle had significantly lower neutrophil antibody-
dependent cell-mediated cytotoxicity during 2 of 4 years post infection.  BIV infection was 
not associated with any long-term significant changes in lymphocyte blastogenesis or 
mononuclear cell. Trends did indicate BIV infection could be associated with decreased  
neutrophil iodination and lymphocyte blastogenesis to mitrogens. Co-infection with BIV and 
BLV did not consistently cause a different response than either virus considered separately. 
BLV infection caused an increase in lymphocytes. 
Isaacson et al., (1998) examined immune responses in cattle 3-5 years after 
experimental inoculation with BIV R29 and/or BLV.  Lymphocyte proliferative responses to 
Con A or to allogenic lymphocytes with foreign MHC were determined.   Antigen specific 
antibody and lymphocyte proliferative response were measured following vaccination with 
tetanus toxiod (TT) and BHV-1.  Lymphocytes from BIV-infected cattle had significantly 
reduced proliferative responses to Con A, but did not differ in responses to allo-MHC and TT 
from uninfected controls.  BIV infection had little effect on TT-specific antibody responses 
in vivo.  In contrast, BLV-infected cattle had increased secondary antibody responses to 
vaccination with TT as well as enhancement of antibody responses to BHV-1.  No significant 
interaction between the two viruses was seen in vivo and coinfection with BIV did not alter 
response to BLV.   Lymphocytes from BLV-infected cattle had slightly increased 
proliferative responses to Con A but no consistent alterations in response to allo-MHC, TT, 
or BHV-1.  The observed increased in antibody response to non-BLV antigens suggested that 
in clinically normal cattle, BLV infection might cause a non-specific B cell activation. 
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  By using quantitative competitive PCR, (Pyeon and Splitter, 1998) showed that 
PMBC from AL BLV-infected animals  expressed an increased amount of IL-12 p40 mRNA. 
However, IL- 12 p40 mRNA expression by cells from PL animals was significantly 
decreased compared to that by normal and AL animals. Interestingly, IL-12 p40 mRNA was 
also detected in tumor-bearing animals. IL-12 p40 expression occurred only in 
monocytes/macrophages, not B or T lymphocytes. IL-12 in bovine leukemia virus-infected 
animals may regulate production of other cytokines such as IFN-γ and IL-10 and may 
regulate the progression of bovine leukosis in animals that develop PL or B-cell 
lymphosarcoma.    Most positive animals are in the AL stage (65%). The type 2 cytokine IL-
10 is increased in PL animals. 
The purpose of this study was to determine if an alteration in IgG isotype exists  
between BIV positive and BIV negative animals, all co-infected with BLV. The humoral 
response to specific stimuli were measured by modifying a commercially available ELISA 
(IDEXX  Laboratories, Inc., Westbrook, ME,  04092) test kit for BHV1 to detect IgG1 and 
IgG2 optical densities specific for BHV1.    
4.1.4 Anti-BHV1 IgG1 to IgG2 Ratio as a Measure of Cytokine Response 
Several studies have evaluated the effects of BHV-1 on bovine immune responses. To 
study the development and persistence of circulating antibodies directed against bovine 
herpesvirus-1 (BHV-1) induced by vaccination, approximately 80% of the seronegative cows 
in four partly BHV-1 seronegative dairy herds were vaccinated once with a temperature-
sensitive live virus vaccine (Van der Poel et al., 1995). Most (83%) of the vaccinated animals 
developed antibodies to BHV-1 within two months after the vaccination. In the same period, 
21% of the unvaccinated control cattle also seroconverted, suggesting that the vaccine virus 
 130
had been transmitted to them. Thirty months after they had been vaccinated 91% of the 
vaccinated animals that initially responded still had detectable antibodies.  
 Mena et al., (2002) used real-time PCR to measure bovine IFN-γ(bIFN-γ) and bovine 
IL-4 (bIL-4) gene expression by antigen stimulated PBMC, isolated from BHV-1 infected 
animals. BHV-1-infected animals were either non-vaccinated or vaccinated using one of two 
adjuvants prior to infection. With non-vaccinated infected animals, a type 1 bias occurred, 
based on IFN-γ expression exceeding IL-4 expression.   
A study by Geng et al., (1992) demonstrated that BIV is activated by bovine 
herpesvirus type 1 (BHV-1).  Activation of BIV expression was detected as increased BIV 
reverse transcriptase activity, increase in syncytia  number, and increased  steady state level 
of BIV-specific RNA upon BHV-1 super-infection. Additional transactivation studies using 
the BIV-LTR (long terminal repeat) were conducted by linking the BIV-LTR to the 
chloramphenicol acetyl transferase gene (CAT) and transfecting into bovine cell cultures.    
Infection with BHV-1 increased CAT expression in  transfected cells.   
  4.2 Materials and Methods 
4.2.1 Population Sampled 
The herd sampled was the Louisiana State University (LSU) Dairy herd located on 
the LSU Dairy Research and Teaching Farm, Baton Rouge, Louisiana, USA.  Two to nine 
sequential sera samples were collected from each member of a cohort of 88 BLV-positive 
lactating dairy cows from one herd, followed over 14 months starting in 1994, and  examined 
for BIV serostatus. IgG1 and IgG2 specific antibody response to BHV1 antigen challenge 
was measured. Whole blood was collected by ventral coccygeal venipuncture into sterile 
vacutainer tubes,cooled on ice during transit and stored in  Sarstedt 1.7 ml tubes at –70° C.  
4.2.2 Serological Tests 
The IDEXX (IDEXX Laboratories, Inc., Westbrook, ME, 04092, USA) Bovine 
Leukemia Virus (BLV) Antibody Verification Test Kit was used to detect antibody to BLV. 
Indirect fluorescent antibody (IFA) was used to detect anti-BIV antibodies in serum samples. 
IFA slides were prepared in-house from BIV R29 (passage 20) grown in FBL-Z cells 
(passage 9) in confluent 75 cm2 flasks.  Cells were grown overnight in 5 ml of media.  
Infected cells were grown to 4.6 ± 3.4 syncytia/field when viewed at 100x.  Each flask was 
washed with 10 ml warm phosphate buffered saline (PBS), pH 7.2, and treated with 2.5 ml of 
0.5% trypsin at 37oC for 5 minutes.  After adding 2.5 ml warm media to each flask, 2.5 ml 
uninfected cells was combined with 5 ml infected cells in a 50 ml conical tube and the 
concentration diluted with 35 ml media to a final concentration of 8x104 cells/ml. Fifty µl of 
infected media was incubated on each well of 44-6mm, 12 well hydrophobic coated slides 
from Erie Scientific (Portsmouth, NH, 03801, USA).  Slides were incubated in a humidified 
chamber with 5%CO2 at 37oC for 16 hours.  After removing remaining media, slides were 
rinsed with PBX and immersed in ice cold acetone:methanol (1:1, v/v) for 60 seconds and air 
dried.  Slides were frozen prior to use.   
For IFA testing, serum was diluted 1:20 in 0.01M  PBS with 10% goat serum.  Slides 
were equilibrated to room temperature, and 30 µl of diluted test sample was placed on each 
well.  Positive and negative controls (VMRD, Inc., Pullman, WA 91163, USA) were used on 
each slide.  After incubation in a humidified chamber at 37oC for 30 minutes, the slides were 
flushed, then soaked 10 minutes in PBS and the surface blotted.  One drop (30 µl) of goat-
anti bovine IgG FITC conjugate (VRMD) was placed in each well and the slides reincubated 
under humidification for 25 minutes.  After incubation, the slides were again flushed, soaked 
 131
and read immediately at 100x using a reverse microscope.  Positive fluorescence brighter 
than the negative control and centered around synctia indicated the presence of BIV antibody 
in the test serum (Orr et al., 1999). 
4.2.3 Determination of Anti-BHV1 IgG1 to IgG2 Ratio 
For determination of IgG1 to IgG2 ratio, a modified IDEXX Bovine Rhinotracheitis 
Virus Antibody Screening Test Kit was used.  The test was performed according to the 
manufacturer’s instructions except where noted.  Each plate was divided into IgG1 and IgG2 
assays and each animal’s sequential samples were assayed on the sample plate. Rather than 
using the IBR Anti-Bovine IgG:Horseradish Peroxidase Conjugate, anti-bovine IgG1 and 
IgG2:Horseradish Peroxidase Conjugate (Bethyl Laboratories, Inc., Montgomery, Texas, 
77356, USA) were diluted in NET with 1% BSA w/v at 1:2500 and 1:500 respectively.  
Serum samples were diluted 1:25 with IBR Sample Diluent (IDEXX). The test kit negative 
control was used.  For a positive control, serum from a fetal calf exposed to IBR and having a 
strong IgG1 and IgG2 response was used.  The reaction was stopped with 100 µl 1M H2SO4 
and the absorbance at 450 nm was measured by spectrophotometer. The IgG1 and IgG2 
absorbance values were determined by dividing the absorbance of each sample by the 
absorbance of the positive control.  The final IgG1/IgG2 ratio was the result of dividing the 
standardized IgG1 value by the standardized IgG2 value.  
4.2.4 Univariate ANOVA for Repeated Measures of Anti-BHV1 IgG1:IgG2 Ratio   
 
Our study was a longitudinal study of a cohort of lactating dairy cows in which antibody 
specific to BHV1 in the form of IgG1 to IgG2 ratio was measured.  The BHV1 response was 
the humoral response to routine BHV1 vaccination administered at a single timepoint. One 
vaccination was administered during the 14 months of this study, approximately three 
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months after the first cows were enrolled.  Data collected prior to vaccination served as a 
baseline value. All animals were seropositive for BLV.  Animals were segregated into two 
groups by BIV serostatus and the IgG isotype ratio compared between the two groups. 
Calving was the point of entrance in the cohort and dry-off was the exit point.  Serum 
samples were collected from all members at 60 days intervals while they were in the cohort.  
Any animal experiencing a  ≥10% drop in the daily milk production (3 day moving average) 
was sampled at the midpoint between the two set sample times.  The number of sequential 
sera samples from each member of the cohort ranged from 2 to 9.  SAS 8.0 (SAS Institute 
Inc., Cary, North Carolina, 27513, USA) was used for data analysis. Data was analyzed using 
a univariate ANOVA with repeated measures with factorial arrangement of treatments 
analyzed as a split-plot. The main split was on BIV serostatus, with a secondary split by 
individual animal.  Because animals entered and left the cohort at different times and since 
only sick animals had blood drawn at 30 day intervals compared to the normal 60 day 
interval, there was missing data.  The amount of missing data forced the use of ANOVA 
instead of the newer repeated measure techniques. The ranked ratio of anti-BHV1 IgG ratios 
was used, as the isotype ratios were tested by Kolmogorov-Smirnov method and found to be 
nonnormal and skewed to the right.  Distribution fitting was attempted with BestFit (Palisade 
Corporation, Newfield, NY 14867, USA). No distribution was fitted at the 0.05 level, thus 
the use of ranked ratios. The response variable was the ranked ratio of anti-BHV1 IgG1 to 
IgG2, the explanatory variable was the BIV serostatus based on IFA. Difference in ranked 
ratios by timepoint were significant (p< 0.05). This model accounted for the random effect of 
the individual cow by nesting IgG1/IgG2 ratios by cow Parity, as a substitute for age. was a 
significant interaction term (p<0.05). The effects of pregnancy were insignificant.   
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4.3 Results 
4.3.1 BIV Effect on IgG1/IgG2 Ratio 
The BIV seroprevalence for animals included in this study was 77.5% (69/89),and the 
prevalence of BLV infection was 100%.  The mean value of the isotype ratio for dual 
positives was 0.473 +/- 0.306 and 0.451 +/- 0.253 for BLV positive, BIV negatives (not 
significant). Using StatXact-3®For Windows (CYTEL Software corporation, Cambridge 
MA, 02139, USA) a difference in dispersions was detected using the Conover test (p<0.05) 
with increased variance seen in the isotype ratios of dually infected animals. 
4.3.2 Response to BHV1 Vaccination 
  BIV negative animals appeared to have an appropriate immune response to 
vaccination with increasing levels of IgG2 relative to IgG1 after vaccination. Response to 
BHV1 vaccination was measured prevaccination, postvaccination day 1-35, Postvaccination 
day 35-90, and  > 90 days postvaccination.  Multiple measurements for one animal within 
one time period were averaged. BIV positive cow showed a shift toward type 2 responses 
with an increased IgG1/IgG2 ratio (Figure 4.1). BIV negative cows appeared to have an 
appropriate immune response with increasing levels of IgG2 relative to IgG1 as time past 
vaccination increased. A diminished IgG1 response (Figure 4.2) and failure to develop an 
appropriate IgG2 response among BIV positives (Figure 4.3) accounted for the relatively 
greater IgG1 to IgG2 response ratio seen with BIV positive animals. BIV negative animals 
demonstrated an expected early increase in IgG1 (Figure 4.2). The failure of an expected 
Type 1 humoral immune response among animals infected with BIV led to an apparent shift 
toward a Type 2 dominant response. 
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Figure 4.1. IgG1/ IgG2 Response to BHV1 vaccination in BLV infected dairy cattle 
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Figure 4.2. IgG1 Response to BHV1 vaccination in BLV infected dairy cattle 
4.4.  Discussion 
4.4.1. BIV Effect and Staging of Infection 
This study explored the effect of BIV infection on anti-BHV1 response to vaccination. The 
hypothesis was that the response of cows infected with both BIV and BLV to a specific 
antigen (BHV1) would be an altered cytokine expression leading toward IgG1 production 
and away from IgG2 production when compared with cows infected solely with BLV. An 
increase in IgG1/IgG2 ratio was seen in dually infected animals, but appeared to be due to a 
diminished IgG1 response. 
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Figure 4.3. IgG2 Response to BHV1 vaccination in BLV infected dairy cattle 
When prevaccination IgG2 levels were examined, dually infected animals had 
elevated baseline IgG2 when compared to animals only infected with BLV.  BIV infection 
was associated with an overall diminished immune response. The clinical importance of this 
altered specific humoral response is unknown. 
When this study was planned, it was hoped to evaluate the effect of BIV infection on 
baseline anti-BHV1 IgG1/IgG2 ratio and to evaluate the effect of length of BIV infection 
infection of anti-BHV1 IgG1/IgG2 ratio. These questions dealt with the response to BIV 
infection during the 14 months of the study and not as a specific response to BHV1 
vaccination. The answer to both of these questions was hampered by an inability to stage 
infection. We know animals were positive at their point of entry into the study, but not how 
long they had been positive.   The inability to accurately stage infection made measurement 
of baseline and time associated differences in anti-BHV1 difficult.  Indeed, no differences 
were found in baseline levels. This could be due to a preponderance of new BIV infections 
where differences in cytokine response have not manifested.  To evaluate response over time, 
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staging of infection as well as any seasonal connected antibody response changes must be 
evaluated.  The solution to this problem could be approached in two ways; following a larger 
cohort over a longer time with enrollment earlier in infection and knowledge of when BIV 
seroconversion occurred, or identifying some assayable marker of stage or duration of 
infection.   
4.4.2 BLV Effect 
It is important to note that all animals evaluated here for response to BHV1 
vaccination were BLV positive. BLV is known to effect cytokine expression with elevated 
levels of Il-10 and decreased IL-12 in animals with persistent lymphocytosis resulting in a 
shift toward a type 2 immune response and increased IgG1 relative to IgG2. Also, BLV's 
genome is homologous to Human T-cell Leukemia Virus, a human retrovirus which may 
increase HIV pathogenesis. The shift toward a type 2 response in dually infected animals was 
mainly a result of appropriate increase in IgG2 in BIV negative animals and a diminished 
IgG2 response in BIV positives. Staging of BLV infection was not possible, but should be a 
component of any further research, and the effect of length of BLV and BIV infection could 
be evaluated for interaction. 
4.4.3 Possible Misclassification of BIV Serostatus and Its Effect 
BIV infection status was determined by the known imperfect IFA test. Based on IFA 
results, 69 animals were classified BIV positive, and 20 were classified BIV negative. When 
IFA performance was estimated (Orr et al., 2003), test sensitivity was estimated at 60%, and 
specificity at 88%.  Misclassification of the explanatory variable (BIV serostatus) is likely.  
In fact, estimation of the true number of positive animals (Greenland, 1998) resulted in a 
number greater than the total number of animals (121). Recalculation using the high end 95% 
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credible interval values (Orr et al., 2003) of IFA sensitivity (72%), specificity (94%,)  still 
results in a number greater than the total number of animals (94).  Sample size estimation for  
Bayesian methods is complicated when misclassification is likely  and the distribution cannot 
be assumed  normal (Rahme et al, 2000).   Applying Rahme’s methods resulted in an average 
Credible Interval coverage probabilities ranging of 0.95 for the prevalence estimates.  This 
was generated by using estimated values of IFA sensitivity and specificity from Orr et al. 
(2003). This means we can be approximately 95% certain that the true value of the 
prevalence lies somewhere in the range of 0.75 ± 0.05.  Perhaps the amount of false 
negatives which might have been expected with a test sensitivity point estimate of 60%  did 
not actually occur.  Estimates of prevalence in any follow up research should use PCR or 
ELISA (if available, preferably dual assays) for BIV infection classification to offset the 
known misclassification likely to occur with IFA.  
4.4.4 Other Approaches to Data Analysis 
 Proc Mixed (SAS 8.0) is designed for the evaluation of repeated measures data. 
However, in the case of non-random missing data, robustness is lost. Here, the number of 
samples ranged from 2 to 9 per animal at varying time intervals, and Proc Mixed does not 
work well with unequally spaced time points. Proc GLM is also used for the evaluation of 
repeated measures written as multivariate responses. Proc GLM assumes all model effects 
are fixed and tries to find estimable linear combination over all the effects, as compared to 
Proc Mixed, which correctly sets coefficients for random effects to zero.(Littel et al., 1996). 
For this data set, the best choice for data analysis was univariate ANOVA for repeated 
measures, as all data could be evaluated. With set sample intervals and number, statistical 
methods allowing greater estimation power could have been used. 
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4.5 Conclusions 
 A more complete study, with accurate staging of BLV infection, more accurate 
diagnostic testing for BIV, BLV negative controls, and standardized time intervals and 
number of samples per cow might confirm and further elucidate the findings of a type 2 
cytokine shift in response to BHV1 vaccination in BIV positive animals.  Estimates of the 
average coverage credible interval of population prevalence using IFA test performance data 
suggests that misclassification might not have been as severe as expected, but still does not 
allow for data reclassification.  
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CHAPTER FIVE 
DISCUSSION AND CONCLUSIONS 
5.1 Overview 
 This dissertation started as a study of the effect of bovine immunodeficiency virus 
(BIV) on bovine health and production. Because of the nature of available testing for BIV, I 
became interested in data misclassification and examining methods to determine better 
estimations of diagnostic test performance when no gold standard was available. Over time, 
the focus of my dissertation shifted into a more statistical direction with estimation of 
diagnostic test performance in two persistent bovine viral infections, BIV and bovine viral 
diarrhea virus (BVDV). As part of my Fulbright Fellowship to Denmark I was able to use the 
large Danish Cattle Health Laboratory (DAHL) database to evaluate diagnostic tests for and 
prevalence of BVDV as part of their eradication program, My Fulbright experience at the 
Royal Veterinary and Agricultural University was invaluable to me for the insight I gained 
into European approaches to veterinary medicine and graduate epidemiological education.  
 In addition to a Fulbright Fellowship, I was fortunate enough to receive a David L. 
Boren National Security Education Program Fellowship to conduct research at the Graduate 
School of Veterinary Medicine, Hokkaido University, Sapporo, Japan. Dr. Misao Onuma and 
the Laboratory of Infectious Diseases have conducted numerous studies into the prevalence 
of BIV in Japan and southeast Asia.  In addition, the wealth of information on BIV I was 
given access to contributed greatly to this dissertation. Unfortunately, I developed a serious 
health condition that required my early return to the United States and delayed the 
completion of this dissertation. Nevertheless, I am extremely fortunate to have such a diverse 
international component to my dissertation. 
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5.2 Results 
Data provided by the DAHL allowed testing of several methods of estimation of 
diagnostic test performance. Firstly, data from the development of the antigen ELISA and its 
comparison to the tissue culture isolation technique (TCIT) and from the development of the 
antibody ELISA and its comparison to the viral neutralization technique (VNT) were used to 
estimate actual performance of the new tests. Since the data could be broken down into two 
tests and two populations, Maximum Likelihood Estimation (MLE), Bayesian estimation, 
and Bayesian Conditional Independence models could be used to estimate sensitivity and 
specificity of each new test. Both ML and Bayesian estimation suggested that the specificity 
of both antibody and antigen ELISA were higher than the original estimation when VNT and 
TCIT were considered gold standards. Because conditional independence was not present, 
and because MLE generated 95% confidence interval with upper limits > than 1.0, Bayesian 
estimates were used. Final estimates of antibody ELISA sensitivity was 0.970 and 0.990 for 
specificity. Antigen ELISA estimates were 0.980 and 0.998 respectively. These precise 
estimates were then used to evaluate individual test performance by quarter using Bayesian 
one test one population methods. Test performance of the antibody ELISA in small sample 
sizes (random 1/100 sub-sample and herds < 100 head), in sentinel population, and by herd 
type (beef versus dairy) were evaluated. The antibody performed at consistently high levels 
of sensitivity and specificity. 
Because the Danish database was so large, an opportunity was present to examine the 
effect of sample size on the Bayesian estimation of population prevalence. Using the one-
population one-test estimates of antibody sensitivity and specificity and relaxed priors, the 
adequacy of small sample sizes was evaluated by estimating the coverage probabilities for 
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prevalence; a coverage probability of 95% or higher would indicate an adequate sample size. 
Sample sizes of the 1/100 quarter sub-sample ranged from 8-642. Samples of 180 or greater 
consistently generated coverage probabilities of 95% or higher. This indicated a 95% chance 
that the true prevalence actually fell within  ± 0.05 of the estimated prevalence, since a 0.1 
credible interval width for the prevalence was fixed.  Smaller sample sizes were found 
towards the end of eradication, with five samples smaller than 100. The worst case scenario 
found was a sample size of eight that generated a 52% credible interval, or an approximate ½ 
chance that the prevalence estimated would actually be found within ± 0.05 of the prevalence 
point estimate.  This is not surprising, as actual Bayesian estimate of prevalence for this 
sample generated a very large 95% CI of width 0.48. Linear regression was used to evaluate 
the relationship of sample size to average credible coverage. Although there was a significant 
relationship (p<0.02), an r2 of 0.3695 suggests that other factors contributed to the 
relationship. 
Another approach to validate test performance in small samples was to examine test 
performance in herds of less than 100 head with test based antibody prevalence of 0-98%. 
Despite the wide variation in prevalence, sensitivity and specificity were consistent with the 
entire population relaxed samples. Mean sensitivity of the small herd sample for antibody 
ELISA was 97.73±0.12 with credible interval width 4.68±0.34. Mean specificity was 
97.73±0.15 with credible interval width 4.71±0.33. Point estimates and credible intervals 
differed from whole population estimates by less than 1%. 
Bayesian estimation was also used to evaluate the performance of two tests for BIV, 
IFA and nested set PCR. Two populations were available; a commercial dairy herd and a 
university dairy herd. Statistical examination revealed no conditional dependence. Again 
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MLE resulted in 95% confidence intervals with upper limits > 1.0. Prevalence of BIV 
infection in each herd was also estimated, with the commercial herd estimated to have a 0.20 
infection rate and the university herd to have a 0.71 infection rate. IFA sensitivity was 
estimated at 0.6 and specificity 0.88, PCR sensitivity at 0.8 and specificity at 0.85. 
Misclassification was thus almost certain to occur with IFA, and likely to been seen with 
PCR. The adequacy of the sample size evaluated by estimating the coverage probabilities for 
prevalence; a coverage probability of 95% or higher would indicate an adequate sample size. 
IFA performance was of significant interest, as IFA was the only test available for 
determination of infection in the humoral response to BIV infection study. The average 
coverage probability for the IFA estimate of prevalence was 92%. This indicated a 92% 
chance that the true prevalence actually fell within  ± 0.05 of the estimated prevalence, and 
could indicate that the test performance was more accurate than the point estimate of 60%.as 
using Bayesian derived estimates of IFA sensitivity and specificity resulted in a prevalence 
range estimate with a 92% chance of  containing the true prevalence. 
 A further study was a longitudinal study of a cohort of lactating dairy cows in which 
antibody specific to BHV1 in the form of IgG1 to IgG2 ratio was measured. A routine BHV1 
vaccination was administered at a single timepoint, approximately 3 months after the first 
cows were enrolled.  Data collected prior to vaccination served as a baseline value. All 
animals were seropositive for bovine leukemia virus.  Animals were segregated into two 
groups by BIV serostatus and the IgG isotype ratio compared between the two groups. 
Calving was the point of entrance in the cohort and dry-off was the exit point.  All members 
were serum sampled at 60 days intervals while they were in the cohort.  Any animal 
experiencing a 10% drop or greater in the daily milk production (3 day moving average) was 
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sampled at the midpoint between the two set sample times.  The number of sequential sera 
samples from each member of the cohort ranged from 2 to 9.    Data was analyzed using a 
univariate ANOVA with repeated measures with factorial arrangement of treatments 
analyzed as a split-plot, with a main split on BIV serostatus, and a secondary split by 
individual animal.   A ranked ratio of anti-BHV1 IgG ratios was used, as the isotype ratios 
were tested by Kolmogorov-Smirnov method and found to be nonnormal and skewed to the 
right. Increased variance seen in the isotype ratios of dually infected animals. Ranked ratios 
were used rather than true ratio. The response variable was the ranked ratio of anti-BHV1 
IgG1 to IgG2, and the explanatory variable was the BIV serostatus based on IFA.  IgG1/IgG2 
ratios were then nested by cow, with parity used as a substitute for age. Parity was a 
significant interaction term (p<0.05). The effects of pregnancy were examined and found 
insignificant. The BIV seroprevalence of animals included in this study was 77.5% (69/89), 
BLV infection rate was 100%.   BIV negative animals appeared to have an appropriate 
immune response to vaccination with increasing levels of IgG2 relative to IgG1 after 
vaccination. Response to BHV1 vaccination was measured prevaccination, postvaccination 
day 1 to 35, Postvaccination day 35-90, and over 90 days postvaccination.  Multiple 
measurements for one animal within one time period were averaged. BIV positive animals 
showed a shift toward type 2 responses with an increased IgG1/IgG2 ratio. BIV negative 
appeared to have an appropriate immune response with increasing levels of IgG2 relative to 
IgG1 as time past vaccination increased. A diminished IgG1 response and failure to develop 
an appropriate IgG2 response among BIV positives accounted for the relatively greater IgG1 
to IgG2 response ratio seen with BIV positive animals. BIV negative animals demonstrated 
an expected early increase in IgG1. The failure of an expected Type 1 humoral immune 
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response among animals infected with BIV led to an apparent shift toward a Type 2 
dominant response.   
To evaluate misclassification due to the use of IFA to evaluate infection, average 
credible interval coverage probabilities were generated and resulted in an average credible 
interval coverage probability of 0.95 for the prevalence estimate.  This was generated by 
using estimated values of IFA sensitivity and specificity from as reported in Chapter 3. This 
means we can be approximately 95% certain that the true value of the prevalence lies 
somewhere in the range of 0.75 ± 0.05.  Perhaps the amount of false negatives which might 
have been expected with a test sensitivity point estimate of 60% did not actually occur. Of 
course, with a test specificity of 88%, false positives would be expected as well.  
5.3 Conclusions 
Misclassification of diagnostic test results is likely to occur if sensitivity and 
specificity of diagnostic tests are assumed 100%. Evaluation of new diagnostic test 
performance will be inaccurate if reference tests that are not gold standards are assumed to 
have 100% sensitivity and specificity. Techniques exist to evaluate diagnostic test true 
sensitivity and specificity, and to evaluate the conditional dependence of two tests used 
simultaneously for infection detection. Both tests developed by the Danish Cattle Health 
Laboratory were highly sensitive and specific and performed well in large and small sample 
sizes. Examination of test performance in small sample sizes generated a method to roughly 
evaluate roughly adequacy of sample size. Estimates of the average coverage credible 
interval of population prevalence using IFA test performance data suggested that 
misclassification might not have been as severe as expected, but still did not allow for data 
reclassification into likely positive and negative.  
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5.4 Proposed Future Studies 
 If a BIV ELISA becomes available, its correlation with IFA and performance should 
be evaluated and samples classified solely on basis of IFA retested. For the effect of BIV 
infection on cytokines, a more complete study, with accurate staging of BLV infection, more 
accurate diagnostic testing for BIV, BLV negative controls, and standardized time intervals 
and number of samples per cow might confirm and further elucidate the findings of a type 2 
cytokine shift in response to BHV1 vaccination in BIV positive animals. 
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